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ABSTRACT 
 
Nonsense-mediated mRNA decay (NMD) is a mechanism to post-transcriptionally 
regulate gene expression in eukaryotes. Beside quantity control, NMD also serves as 
quality control for transcripts. The latter function comprises the degradation of aberrant 
RNAs with a so-called premature termination codon (PTC). Otherwise, these RNAs 
would give rise to truncated proteins with potentially deleterious functions which is 
often the case in diseases like cancer.  
In my diploma thesis, potential NMD components were investigated for their role in 
NMD. For this purpose, I especially established an assay in different HeLa cell lines. 
NMD is impaired, if an essential NMD component, like Barentsz (Btz) or the eukaryotic 
initiation factor 4A isoform 3 (eIF4AIII), is missing. This leads to accumulation of 
aberrant PTC-containing transcripts, because they are no longer degraded by NMD. 
Therefore, these two proteins served as positive controls for the establishment of the 
assay. As a next step, the impact of five putative protein-protein interactors of the RNA-
binding protein Btz on NMD was analysed: Nucleophosmin 1 (NPM1), DEAD-box 
polypeptide 5 (DDX5), U5-116 kDa, RNA-binding motif protein - X-linked (RBMX) 
and RNA-binding motif protein 4 (RBM4). I generated short hairpin RNA (shRNA) 
plasmids directed against these proteins and tested them. Subsequently, I investigated 
whether the depletion of the respective proteins using shRNAs caused accumulation of 
PTC-containing NMD reporter constructs, as it is the case in the Btz knockdown. Upon 
depletion, the expression levels and the decay of exogenously provided T-cell receptor ß 
(TCR-ß) and ß-Globin NMD reporter constructs with and without PTC were compared 
and measured using semiquantitative PCR and real-time PCR. In addition, 
neomycin/G418 selection was performed to enrich for successfully transfected, 
candidate-depleted cells. Finally, the obtained real-time PCR data indicated a crucial 
role of DDX5 and U5-116 kDa in NMD, because their knockdowns caused 
accumulation of aberrant transcripts. No firm conclusion was possible regarding NPM1, 
RBMX and RBM4, because their shRNA plasmids did not reduce the corresponding 
protein levels in the used stable HeLa cell lines. Further experiments for the analysis of 
these proteins are necessary. In this diploma thesis, I was able to identify two additional 
proteins which play a role in NMD: the potential Btz interactors DDX5 and U5-116 
kDa.
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INTRODUCTION 
1. RNA DECAY 
 
Eukaryotic gene expression is a complex and highly regulated process. It consists of 
many subsequent and interconnected steps: transcription, 5’-cap formation, messenger 
RNA (mRNA) splicing, polyadenylation, mRNA export and transport, mRNA storage 
or translation, translational control and mRNA degradation. These different stages of 
gene expression assure that genes and their products are only expressed when needed. 
Differential gene expression is crucial to provide the cell with the necessary transcripts 
and proteins in various situations. This enables the cell to react to its environment, to 
develop and to promote its own survival. 
 
For a cell, it is very important to keep its metabolism under tight control in order to 
minimise its energy requirement and conversion. Therefore, it is necessary to create 
different functional spaces, called compartments, for distinct reactions within a cell. 
One efficient way to achieve this is by tightly controlling local protein synthesis. In 
addition, it is very important for the cell to get rid of abnormal or no longer needed 
RNAs via RNA decay. Different kinds and forms of RNA decay have evolved within 
cells to adapt to the different requirements.  
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1.1. Nonsense-mediated mRNA decay (NMD) 
Nonsense-mediated mRNA decay (NMD) is a post-transcriptional quality-control 
mechanism for gene expression in eukaryotes (for an overview see (Chang, Y. F. et al. 
2007)). It is a highly conserved pathway present in all eukaryotes examined up to now. 
mRNAs that have premature-termination codons (PTCs) are degraded by this process. 
In higher eukaryotes, PTCs are defined by the “50 - 55 nucleotides“ rule saying that a 
stop codon residing more than 50 - 55 nt upstream of the 3‘-most exon-exon junction is 
a premature termination codon. 
If mRNAs containing PTCs were translated, they would result in truncated proteins with 
dominant-negative or deleterious gain-of-function activities. In case the NMD process is 
impaired, which is often the case in diseases (e.g. cancer), harmful and non-functional 
mRNAs with PTCs accumulate in the cell leading to further derailing of the cell’s 
metabolism. Approximately 3 -10% of the expression of the transcriptome are regulated 
via NMD in different species (reviewed in (Behm-Ansmant, I., Kashima, I. et al. 
2007)). 
 
 
Figure 1-1: The “50 - 55 nucleotides” rule for the definition of premature-termination codons 
(PTCs). (Figure 1B from (Schell, T. et al. 2002)). 
If a stop codon is located more than 50 - 55 nt upstream of the 3‘-most exon-exon junction and 
respectively exon-junction complex (EJC), it is a premature termination codon. 
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1.1.1. NMD in human diseases 
NMD is an important RNA surveillance mechanism. Interestingly, derailing of NMD 
can cause or aggravate human illnesses as well as NMD can modulate or ease the 
phenotype and the symptoms of genetic diseases through inhibition of the synthesis of 
harmful or non-functional proteins (reviewed in (Holbrook, J. A. et al. 2004)). 
Approximately, 10 - 30% of PTC-containing transcripts escape NMD and produce 
physiological levels of truncated proteins that can mediate certain effects (reviewed in 
(Neu-Yilik, G. et al. 2004)). Current studies find that ~20.3% of the ~43,000 disease-
associated single base pair mutations in coding genome sequences are nonsense 
mutations (according to the Human Gene Mutation Database in November 2007) (Mort, 
M. et al. 2008).  
1.1.2. Sources and definition of PTCs  
In principle, there are three major ways how PTCs are introduced (for an overview see 
(Chang, Y. F. et al. 2007)). First, random nonsense and frameshift mutations emerge in 
the DNA. These mutated DNA sequences are then subsequently transcribed into 
mRNA. The second source of PTCs is programmed DNA rearrangement. This is a very 
useful mechanism to create big diversity with little genomic space. In mammals, for 
example the T-cell receptor (TCR) and the immunoglobulin (Ig) genes use DNA 
rearrangement to increase their repertoire of antigen receptors. The third possibility to 
generate PTCs is via errors in RNA splicing, including aberrant alternative splicing. 
 
1.1.3. Distinction between a normal stop codon and a PTC 
For understanding the observed differences in NMD and its importance in various 
species, it is necessary to note that the NMD targets are not conserved and that the 
NMD effectors underwent functional diversification, at least in mammals (reviewed in 
(Behm-Ansmant, I., Kashima, I. et al. 2007)). Thus, NMD effectors can have slightly 
different or additional functions in NMD or other cellular processes in distinct species. 
Furthermore, a factor required for NMD in one organism might not even be necessary 
for decay in another organism. 
 
Ingrid Kieweg Introduction 
__________________________________________________________________________________________________________________________________________________________________________ 
 6 / 148 
In mammals 
 
An intron downstream of the PTC is a strong indication and signal for the cell that the 
mRNA might be aberrant. If the stop codon is normal, representing a so-called bona 
fide stop codon, it is usually localised in the last exon and therefore no intron follows. 
There are, however, exceptions from this rule. There is recent evidence that mammalian 
transcripts lacking introns are usually not targeted by NMD (Maquat, L. E. and Li, X. 
2001; Brocke, K. S. et al. 2002). But how can an intron which is already removed in the 
nucleus play a role for NMD that depends on the cytoplasmic translation apparatus? 
Interestingly, introns downstream of the PTC have to be spliceable to trigger NMD 
(Carter, M. S. et al. 1996). This indicates that the spliceosome leaves an imprint on the 
mRNA which is recognised by ribosomes: the exon-junction complex (EJC) (for an 
overview see (Chang, Y. F. et al. 2007)). 
 
In invertebrates 
 
In S. cerevisiae, D. melanogaster and C. elegans, PTC recognition to elicit NMD occurs 
independent of splicing and therefore of the EJC (reviewed in (Behm-Ansmant, I., 
Kashima, I. et al. 2007)). Three different triggers for NMD were observed in 
invertebrates (for an overview see (Behm-Ansmant, I., Kashima, I. et al. 2007)). First, 
loosely defined downstream elements (DSEs) can elicit NMD. Second, the poly(A)-tail 
or another mark generated during splicing contains positional information to recognise 
the PTC. Third, the so-called “faux 3’-UTR model” is involved in the activation of 
NMD. In this model, the “faux 3’-UTRs” have an altered protein composition compared 
to normal 3’-UTRs. These modified 3’-UTRs are recognised by ribosomes during 
translation. For example, the cytoplasmic poly(A)-binding protein PABPC1 (in 
metazoan) is a marker of normal 3’-UTRs (for an overview see (Amrani, N. et al. 2004; 
Behm-Ansmant, I., Gatfield, D. et al. 2007)). Interestingly, the binding of PABPC1 
downstream of a PTC converts the PTC into a normal stop codon and therefore 
suppresses NMD. This indicates that an increased distance between the poly(A)-tail and 
the stop codon is crucial for PTC recognition. Therefore, long 3’-UTRs seem to trigger 
NMD under certain conditions. This PABPC1-dependent form of NMD also exists in 
mammals (reviewed in (Behm-Ansmant, I., Kashima, I. et al. 2007)). 
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1.1.4. The core NMD machinery 
The core of the NMD machinery consists of the up-frameshift (UPF) proteins, UPF1, 
UPF2 and UPF3 (reviewed in (Chang, Y. F. et al. 2007)). They serve as a platform for 
the attachment and interaction of additional NMD factors like EJC components. 
UPF 1 is a phosphoprotein as well as a helicase of the group I family. The protein has 
an ATP-dependent 5’-to-3’ helicase activity and an RNA-dependent ATPase activity 
(reviewed in (Chang, Y. F. et al. 2007)). UPF1 plays an important role in DNA and 
RNA stability pathways (reviewed in (Azzalin, C. M. et al. 2006)). It is predominantly 
localised in the cytoplasm, but shuttles also between the cytoplasm and the nucleus 
(reviewed in (Chang, Y. F. et al. 2007)). This factor plays a crucial role in NMD and 
other cellular processes (reviewed in (Azzalin, C. M. et al. 2006)). Beside NMD, UPF1 
is also required in Staufen1-mediated RNA decay (SMD) (Kim, Y. K. et al. 2005) and 
mediates the decay of replication-dependent histone mRNAs together with Stem-Loop 
Binding Protein (SLBP) (reviewed in (Azzalin, C. M. et al. 2006; Behm-Ansmant, I., 
Kashima, I. et al. 2007)). Experiments showed that UPF1 is essential for survival in 
mammals, but is not absolutely necessary in lower eukaryotes (reviewed in (Chang, Y. 
F. et al. 2007)).  
When translation is terminated, UPF1 is recruited to the mRNA. Its activities in NMD 
are driven and regulated by cycles of de-/phosphorylation of its serine residues (for an 
overview see (Chang, Y. F. et al. 2007)). UPF1 is de-/phosphorylated by the 
Suppressors with Morphogenetic effect on Genitalia (SMG) proteins which where first 
identified in C. elegans. SMG-1 is a kinase which is responsible for the 
phosphorylation, whereas the SMG-5/SMG-7 heterodimer and the SMG-6 protein 
promote dephosphorylation. None of the SMG proteins is a phosphatase. Instead, they 
mediate their action for example via recruitment of protein phosphatase 2A (PP2A) to 
UPF1 (e.g. (Anders, K. R. et al. 2003)). The SMG factors play also a role in the 
recruitment of UPF1 to processing bodies (P-bodies) (Unterholzner, L. et al. 2004; 
Fukuhara, N. et al. 2005). Experiments in C. elegans proved the importance of the SMG 
proteins for NMD (Pulak, R. et al. 1993). If their corresponding genes are mutated and 
the proteins are no longer functional, NMD is completely abolished. 
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UPF 3 has no known biochemical function to date (reviewed in (Chang, Y. F. et al. 
2007)). Whereas mammals have two UPF3 genes, coding for UPF3a (also known as 
UPF3) and UPF3b (also UPF3X), lower eukaryotes possess only one UPF3 gene. In 
higher eukaryotes, UPF3a and UPF3b are recruited to the mRNA in the nucleus during 
splicing. They stay associated with the RNA-protein complex, also when the complex is 
exported into the cytoplasm. There they serve as a trigger for NMD as part of the EJC 
(for an overview see (Chang, Y. F. et al. 2007)).  
 
UPF2 serves as an adaptor molecule to bring UPF1 and UPF3 together to start NMD. It 
is still unclear whether UPF2 is recruited to mRNAs in the nucleus or later to the 
perinuclear region in the cytoplasm (reviewed in (Chang, Y. F. et al. 2007)). UPF2 is 
like UPF3 part of the EJC and therefore elicits NMD (reviewed in (Chang, Y. F. et al. 
2007)). 
 
Interestingly, some of these NMD factors play also a role in telomere maintenance (for 
an overview see (Holbrook, J. A. et al. 2004)). Studies in yeast showed that if NMD is 
impaired, 35.9% of all open reading frames (ORFs) of the telomeric region are 
upregulated implicating a function of NMD in telomeric gene regulation (He, F. et al. 
2003). 
 
Figure 1-2: Interactions of the core NMD machinery. (Figure 1 from (Behm-Ansmant, I., Kashima, I. 
et al. 2007)). 
The core of the NMD machinery consists of the three UPF proteins. UPF1, a conserved RNA helicase, is 
a key player in NMD. UPF1 is phosphorylated by the SMG-1 kinase at serine residues followed by 
association of UPF2 and UPF3. SMG-6 and the heterodimer SMG-5/SMG-7 bind phosphorylated UPF1 
via 14-3-3 domains and recruit protein phosphatase 2A (PP2A) for dephosphorylation. The de- and 
phosphorylated state of UPF1 allow the binding and interaction of different factors which mediate and 
regulate NMD. 
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1.1.5. The mammalian exon-junction complex 
This dynamic, multi-protein complex is deposited at the mRNA 20 -24 nt upstream of 
exon-exon junctions upon RNA splicing and serves as signal to trigger NMD. The core 
of the EJC consists of four proteins: Barentsz (Btz) or MLN51, the heterodimer 
MAGOH/Y14 and eIF4AIII (Tange, T. O. et al. 2005; Bono, F. et al. 2006). This 
protein core serves as a platform (Le Hir, H. et al. 2001) where transient EJC factors can 
associate and interact. For example, UPF2 and UPF 3b also associate to and are part of 
the EJC (reviewed in (Chang, Y. F. et al. 2007)). 
The EJC stays attached to the messenger ribonucleoprotein particle (mRNP), a complex 
of mRNA and proteins, when they enter the cytoplasm. Thus, the EJC marks previous 
locations of introns relative to stop codons (reviewed in (Chang, Y. F. et al. 2007)). This 
information is still present in the cytoplasm - as long as translation has not yet 
occurred - and dictates whether an mRNA is an NMD target. 
The main function of the EJC is to mediate NMD (reviewed in (Chang, Y. F. et al. 
2007)). In addition, the complex mediates the export of mature, normally spliced 
mRNAs, their subcellular localisation and translational stimulation (reviewed in 
(Chang, Y. F. et al. 2007; Le Hir, H. et al. 2008)). 
Two recent studies link the EJC’s translation control activities with translation 
activation via the mTOR signalling pathway (Ma, X. M. et al. 2008) as well as with 
translation repression (repression of bulk translation after the first pioneer round of 
translation) during NMD (Isken, O. et al. 2008). This is not contradictory, but 
emphasises the central role of the EJC.  
 
In normal transcripts, all EJCs are found upstream of the stop codon, so they can be 
displaced by the ribosomes. NMD mRNA targets have a stop codon in a premature 
position. This also results in the deposition of at least one EJC downstream of the PTC 
which is a clear signal that triggers NMD (reviewed in (Chang, Y. F. et al. 2007)). 
Furthermore, there is recent data indicating that EJC-independent NMD is possible in 
rare cases (for an overview see (Chang, Y. F. et al. 2007)).  
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Figure 1-3: The structure and composition of the exon-junction complex. (Figure 1 from (Chang, Y. 
F. et al. 2007)). 
The RNA-binding exon-junction complex (EJC) core consists of the four proteins: Y14, MAGOH, 
eIF4AIII and Barentsz (BTZ; also MLN51). In general, the EJC serves as a platform where other EJC and 
NMD factors (illustrated in dark green) can transiently associate and interact with the mRNP during its 
transportation from the nucleus into the cytoplasm. Possible and confirmed interactions of the core NMD 
machinery - consisting of the three UPF proteins – with the RNA and the EJC are also depicted. The N-
terminal binding domains of the proteins are coloured darker compared to the lighter C-terminal binding 
domains. Interaction and relation of the proteins to each other are explained by the caption on the right. 
 
The four essential protein core components of the EJC (with their synonyms in 
parentheses): 
 
1. Y14 (Y14: RBM8 – RNA-binding motif protein 8, tsu – tsunagi) &  
2. MAGOH (MAGOH: mago-nashi homolog) 
 
The proteins Y14 and MAGOH form a stable heterodimer via an RNA-binding domain 
(RBD). Both Y14 as well as MAGOH also directly bind to eIF4AIII (Shibuya, T. et al. 
2004; Bono, F. et al. 2006). 
 
3. eIF4AIII (eukaryotic initiation factor 4A isoform 3; DDX48 - DEAD (Asp-Glu-Ala-
Asp) box polypeptide 48) 
 
The ATP-dependent DEAD-box RNA helicase encloses one ATP molecule, directly 
binds Y14/MAGOH as well as spliced mRNA and anchors the EJC to its RNA substrate 
(Shibuya, T. et al. 2004). Thus, eIF4AIII serves as a clamp between the mRNA and the 
EJC and plays a central role in NMD (Palacios, I. M. et al. 2004).  
eIF4AIII represents one of three eukaryotic translation initiation factors of the eIF4A 
family which are encoded by different genes and have distinct functions (Li, Q. et al. 
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1999). eIF4A, eIF4E and eIF4G form the trimeric eIF4F pre-initiation complex for 
eukaryotic translation (Svitkin, Y. V. et al. 2005).  
 
4. Btz (Barentsz; MLN51 - Metastatic lymph node protein 51, CASC3 - cancer 
susceptibility candidate 3 protein) 
 
Btz is an RNA-binding protein (Degot, S. et al. 2004). In D. melanogaster Btz (van 
Eeden, F. J. et al. 2001), Y14/MAGOH, eIF4AIII and Staufen proteins orchestrate the 
localisation of oskar mRNA to the posterior pole of the oocyte (for an overview see 
(Chang, Y. F. et al. 2007)). In humans, Btz is overexpressed in breast cancer cells 
(Degot, S. et al. 2002). The protein was also shown to bind spliced mRNA in vitro and 
to localise to nuclear speckles - subnuclear structures enriched in pre-mRNA splicing 
factors – in vivo (Degot, S. et al. 2004; Ballut, L. et al. 2005). Btz directly interacts with 
the RNA through a single conserved residue, a phenylalanine, as well as with the 
proteins MAGOH and eIF4AIII (Chan, W. K. et al. 2007) via its speckle localiser and 
RNA-binding module (called SELOR domain; residues 137-283) (Ballut, L. et al. 2005; 
Bono, F. et al. 2006). The crucial role of Btz in NMD is already confirmed (Palacios, I. 
M. et al. 2004). 
 
 
 
 
 
 
Figure 1-4: The protein structure and different consensus motifs of Barentsz (Btz). (Figure 3A from 
(Degot, S. et al. 2004)). 
Btz protein is 703 amino acids and respectively 76 kDa in size. For its transportation und shuttling, the 
Btz protein has two nuclear localisation signals (NLS) - NLS1 and NLS2 – within the N-terminal half as 
well as one nuclear export signal (NES) within the C-terminal half. These sequences are conserved in 
miscellaneous species making Btz a nucleocytoplasmic protein. RNA binding is mediated by the speckle 
localiser and RNA binding module motif (SELOR domain; residues 137-283) which localises around the 
two NLSs in the N-terminal half. In addition, Btz has different potential protein-protein interaction 
domains: one coiled-coil domain, one SH2 domain binding site and four SH3 domain binding sites. Btz 
has a glycine-rich and a glutamine-rich region at the N-terminus and a proline-rich region at the C-
terminus. 
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1.1.6. Initiation and mechanism of NMD 
In the following, the chain of events is highlighted that marks an mRNA for decay (for 
an overview see (Chang, Y. F. et al. 2007)). Three signals and triggers are necessary to 
elicit NMD.  
First, an mRNA must have a PTC to be marked for decay. Second, the EJC is deposited 
20 – 24 nt before a splice donor site at the mammalian RNA during splicing. In S. 
cerevisiae, for example, specific mRNA downstream sequence elements and/or 
abnormally long 3’-UTRs serve as a second signal for NMD (Ruiz-Echevarria, M. J. et 
al. 1998). Third, the attachment of the NMD core machinery consisting of the UPF 
proteins is crucial for NMD. The activity of this complex is fine-tuned via 
de-/phosphorylation by the SMG proteins. The whole NMD process is then mediated by 
the binding and activity of additional protein interactors to both the EJC and the NMD 
core complex. Both complexes then in turn interact and communicate with each other. 
In general, NMD is only elicited, if the EJC interacts with factors bound near or at the 
PTC. It is still unclear how the ribosome then orchestrates the dissociation of the EJC 
from the mRNA. 
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1.1.7. Recognition of NMD targets occurs during different 
rounds of translation in distinct species 
If a PTC-containing mRNA went through several rounds of translation before it was 
decayed by NMD, it would give rise to large amounts of harmful or not functional 
proteins. This would be a major disadvantage and cause a serious problem for a cell. 
Thus, it is important that mRNA NMD targets are already recognised during their first 
round of translation.  
Interestingly, biochemical data support this idea showing that most mammalian mRNAs 
are already downregulated and decayed via NMD in the nuclear fraction (e.g (Carter, M. 
S. et al. 1996)). This implies that mRNAs are scanned for decay via NMD when they 
are in the nucleus or in the cytoplasm, but still attached to the nuclear envelope. 
Furthermore, this finding is also contributing to the discussion whether translation is 
exclusively proceeding in the cytoplasm or also occurring in the nucleus to some extent. 
Additional evidence, however, documents that also newly synthesised mRNAs are 
targeted by NMD during a unique pioneer round of translation (for an overview see 
(Chang, Y. F. et al. 2007)). The cap-binding complex, a heterodimer of the cap-binding 
proteins 20 and 80 (CBP20 and CBP80), is deposited at the 5’ of pre-mRNAs during 
transcription (for an overview see (Izaurralde, E. et al. 1995; Chang, Y. F. et al. 2007)). 
Therefore, CBC is a valid marker for newly synthesised mRNAs. CBC promotes RNA 
splicing and stays attached to the mRNA target until translation. If an mRNA has no 
NMD signals, CBC is replaced by the eukaryotic elongation factor eIF4E (for an 
overview see (Chang, Y. F. et al. 2007)). Then the pioneer round of translation can be 
followed by additional rounds of translation like on the assembly line, a process called 
bulk translation. 
NMD is just executed on CBP80-marked mRNAs, but never on eIF4E-bound mRNAs 
(Ishigaki, Y. et al. 2001; Lejeune, F. et al. 2002). Additional findings and experiments 
support this data (reviewed in (Chang, Y. F. et al. 2007)). 
Some publications, however, indicate that NMD can also occur without CBC, if the 
mRNAs have so-called internal ribosomal entry sites (IRES) (Wang, J. et al. 2002; 
Holbrook, J. A. et al. 2006). An IRES mediates the binding of the mRNA to the 
ribosome, usually when the 5’-cap is missing, and thereby initiates translation. 
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In contrast to mammals, S. cerevisiae seems to activate NMD in any round of 
translation. In general, NMD in yeast is very inefficient (Keeling, K. M. et al. 2004). 
Interestingly, NMD in yeast is still functional without Cbc1p (the yeast ortholog of 
mammalian CBP80) (Gao, Q. et al. 2005). 
Taken together, the presented evidence indicates that higher and lower eukaryotes differ 
in the number of translational rounds which are necessary to recognise the signals and 
elicit NMD. 
 
1.1.8. Translational termination upon recognition of NMD 
targets 
Translational termination occurs when the eukaryotic release factors eRF1 and eRF3 
recognise a stop codon. These two factors probably recruit UPF1 followed by SMG-1 to 
the stop codon at the ribosome. The emerging complex is called SURF complex 
consisting of SMG-1, UPF1 and eRFs (Kashima, I. et al. 2006). Interaction between 
UPF1 in the SURF complex on one side and UPF2 in the EJC on the other side leads to 
the formation of a “super” complex consisting of SURF and EJC which mediates NMD 
(Kashima, I. et al. 2006). This probably stimulates SMG-1 to phosphorylate UPF1. 
Hence, this is considered to be the starting signal for NMD. 
 
UPF1 phosphorylation probably triggers the recruitment of new NMD factors like 
SMG-7, dissociation from the mRNPs and therefore recycling of the eRFs and the 
ribosomal subunits. Biochemical data shows that phosphorylated UPF1 is 
predominantly present in polysome fractions (Pal, M. et al. 2001). Concerning all 
evidence to date, UPF1 can be seen as the central key player in mediating and eliciting 
mRNA decay. 
 
Nevertheless, contradictory data to the SURF/EJC model exists. These data indicate 
UPF2- (Gehring, N. H. et al. 2003; Gehring, N. H. et al. 2005) and UPF3-independent 
(Chan, W. et al. 2005) NMD pathways. In addition, an NMD pathway independent of 
the EJC core, but dependent on the RNA-binding proteins RNPS1 (RNA-binding 
protein with serine-rich domain 1) and UPF2 was reported (Gehring, N. H. et al. 2005). 
These three alternative pathways are called non-classical NMD pathways.  
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Figure 1-5: NMD in invertebrates versus mammals. (Figure 2 from (Behm-Ansmant, I., Gatfield, D. et 
al. 2007)). 
The PTC is defined by its relative position to a cis-acting downstream signal. The signal varies across 
different species. In invertebrates like S. cerevisiae, D. melanogaster and C. elegans, the cis-acting signal 
is a so-called “faux 3’-UTR” where a different subset of proteins associates compared to normal 3’-
UTRs. For example, cytoplasmic poly(A)-binding protein PABPC1 is a marker of normal 3’-UTRs 
flanking correct stop codons. PABPC1 is missing near PTCs. These signals elicit NMD. In mammals, the 
cis-acting signal is the exon-junction complex which is deposited at exon-exon boundaries during 
splicing. Translation termination is followed by subsequent events resulting in mRNA decay via NMD. 
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1.1.9. Mechanism and location of the actual decay 
 
Phosphorylated UPF1 attracts SMG-7 for its dephosphorylation. SMG-7 is supposed to 
be the terminal effector in NMD.  
Interestingly, the ribonucleases degrading normal or PTC-containing RNA are the same 
(reviewed in (Chang, Y. F. et al. 2007)). The decapping-dependent 5’-to-3’ 
exoribonuclease pathway as well as the 3’-to-5’ exoribonuclease pathway are used for 
NMD (reviewed in (Chang, Y. F. et al. 2007)). 
It is still unclear, whether NMD is just a nuclear and/or a cytoplasmic process. Different 
data supporting both models exist (for an overview see (Chang, Y. F. et al. 2007)). But 
it seems that it is depending on the target itself where it is decayed. Therefore, NMD 
substrates can be divided into two classes, concerning whether they are already 
degraded in or associated with the nucleus or later on in the cytoplasm (for an overview 
see (Frischmeyer, P. A. et al. 1999; Maquat, L. E. and Carmichael, G. G. 2001; 
Wilkinson, M. F. et al. 2002)). 
One possible site for NMD to take place in the cytoplasm are P-bodies. The C-terminus 
of SMG-7 was identified to localise mRNPs containing mRNAs with PTCs to P-bodies 
where they can be decayed (Unterholzner, L. et al. 2004). 
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Figure 1-6: Decision between translation and NMD in mammals. (Figure from (Maquat, L. E. 2005)). 
Pre-mRNPs are processed in the nucleus. Introns are spliced out and the EJC assembles on exon-exon 
junctions. The 5’ of the pre-mRNAs is marked by the cap-binding complex (CBC = CBP20 and CBP80). 
Mature mRNPs are then exported into the cytoplasm. The PTC (= NC = nonsense codon) and other 
protein signals for NMD are then recognised by the ribosome either in a nucleus-associated or a 
cytoplasmic pioneer round of translation. PTCs are defined via the “50 - 55 nucleotides“ rule. The 
ribosome is stalled and mRNA decay involving decapping and/or deadenylation takes place. In contrast, 
if the mRNA contains no PTC and no NMD signals, the CBC is replaced by the eukaryotic elongation 
factor eIF4E and steady-state translation (also called bulk translation) occurs. 
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2. RNA INTERFERENCE  
 
The discovery of RNA interference (RNAi) has opened up a plethora of opportunities 
for its application and use. RNAi probably evolved as a protection mechanism against 
invading double-strand RNA (dsRNA) (reviewed in (Plasterk, R. H. 2002; Zamore, P. 
D. 2002; Wilkins, C. et al. 2005)) in fungi, plants and animals. It is an important 
mechanism to mediate gene regulation and silencing. Gene silencing was first 
discovered in plants by Napoli et al. in 1990 (Napoli, C. et al. 1990) and the mechanism 
was later confirmed by van Blokland (van Blokland, R., van der Geest, N., Mol, J., 
Kooter, J. 1994) who named it co-suppression, as transgene and endogenous gene were 
both repressed. 
Systemic silencing was first of all described in plants in 1997 (Palauqui, J. C. et al. 
1997; Voinnet, O. et al. 1997). In 1998, Fire et al. and Tabara et al. independently of 
each other identified siRNA-mediated suppression as an own intracellular mechanism 
via injection of dsRNA into C. elegans (Fire, A. et al. 1998; Tabara, H. et al. 1998). 
They found that dsRNA was more efficient in gene silencing than antisense RNA alone. 
Andrew Z. Fire and Craig C. Mello shared the Nobel Prize in Physiology or Medicine in 
2006 for their work on RNA interference in C. elegans from 1998.  
 
RNAi can be mediated by different RNA sources like RNA viruses, transposons, 
exogenously introduced dsRNAs called short interfering RNAs (siRNAs) and 
endogenous, small non-coding RNAs known as microRNAs (miRNAs) (for an 
overview see (Rana, T. M. 2007)). In general, two pathways trigger RNAi via 
introduction of dsRNA: siRNA and miRNA. In the case of siRNA, the outcome is 
predominantly target degradation, whereas translational suppression and enhancement 
of mRNA degradation are usually triggered by miRNAs. The specific actions of 
siRNAs or miRNAs are mediated via a multi-component complex called RNA-induced 
silencing complex (RISC) into which the small RNAs are incorporated. 
Crucial components of the human RISC complex are for example Dicer, Argonaute 
proteins, TRBP (HIV-1 transactivation responsive element (TAR) double-stranded 
RNA-binding protein), dsRNA-binding protein PACT as well as FMRP (Fragile X 
mental retardation protein) and related proteins (for an overview see (Filipowicz, W. 
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2005)). The homologues of the RISC components are highly conserved between species 
(for an overview see (Meister, G. et al. 2004)). 
An interesting finding is that miRISC components localise to P-bodies. P-bodies are 
storage and degradation sites of translational repressed RNAs in the cytoplasm. One 
such miRISC component is the general translation repressor protein RCK (also called 
p54 and DDX6). So the miRNA in the miRISC might provide the sequence specificity, 
whereas RCK could serve as an effector molecule that shuttles mRNA targets and 
therefore whole RNPs to P-bodies where they are either stored or degraded (for an 
overview see (Chu, C. Y. et al. 2006; Rana, T. M. 2007)). 
 
2.1. Summary of RNAi mechanisms 
To sum it up, RNAi is triggered by dsRNA that is cropped by Dicer (for an overview 
see (Matzke, M. A. et al. 2004)). The small RNAs are then incorporated into different 
silencing effector complexes (RISCs). These complexes recognise and bind the target 
mRNA or also DNA to mediate mRNA degradation, translational repression or genome 
modification in order to silence genes. RNA-mediated gene silencing pathways are 
essential for development, chromosome structure and virus resistance in fungi, plants 
and animals. 
For a global overview of RNAi, it shall also be mentioned that a third pathway of RNAi 
exists, regulating the heterochromatin silencing by small RNAs (Lippman, Z. et al. 
2004). But despite the importance and the permanent use of RNAi, the underlying 
mechanisms are not yet fully understood. 
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Figure 1-7: Biogenesis and post-transcriptional suppression of miRNAs and siRNAs. (Figure 2 from 
(He, L. et al. 2004)). 
Pri-miRNAs are processed by the enzyme Drosha into ~ 70 nt pre-miRNAs inside the nucleus. These 
precursors are exported into the cytoplasm via Exportin 5 using GTP-hydrolysis. There, the enzyme Dicer 
produces miRNA:miRNA* duplexes as well as it crops long dsRNAs into siRNA duplexes. Only one 
strand of the miRNA or siRNA duplex is then assembled into the RNA-induced silencing complex 
(RISC). The loaded RISC mediates translational repression when there are mismatches between the target 
and the small RNA. Upon perfect complementarity, mRNA cleavage is induced via the RISC. 
ORF, open reading frame. 
 
2.2. Differences and similarities between miRNA and 
siRNA 
An internal bulge is formed when miRISC binds to its target and this bulge makes 
miRISC unable to cleave its target. Interestingly, when the miRNA and the target 
mRNA sequence are perfectly complementary, miRISC can also cleave the mRNA 
target as siRISC usually does (e.g. (Hutvagner, G. et al. 2002)). Similarly, siRNAs can 
also act as miRNAs (e.g. (Saxena, S. et al. 2003)). 
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So as siRNAs and miRNAs seem to be functionally and chemically similar or maybe 
even identical, it is still unsolved, whether they consist of the same components and 
have the same enzymatic properties (reviewed in (Rana, T. M. 2007)). The so-called 
seed region from nucleotide number two till number eight on the siRNA or miRNA is 
crucial for the RNAi effect. Base paring between the seed region and the target mediates 
the action of the siRNA or miRNA (for an overview see (Wu, L. et al. 2008)). 
 
2.3. Short hairpin RNA plasmids 
Usually, silencing via siRNA is only transient. To overcome this limitation, siRNAs can 
be generated from cloned short hairpin RNAs (shRNAs) expressed from exogenously 
provided vectors (for an overview see (Kumar, L. D. et al. 2007)). The expressed 
shRNA is recognised and processed into the corresponding siRNA by the RNAi 
machinery (for an overview see (Kumar, L. D. et al. 2007)). 
Different strategies with varied advantages can be used to finally obtain the desired 
siRNA. Sense and antisense siRNA sequence are hybridised and cloned into an 
expression vector with an RNA Polymerase III (Pol III) promoter (e.g. the 
pSUPERIOR.neo+gfp vector from OligoEngine used in this thesis, see also 
(Brummelkamp, T. R. et al. 2002)). For the design of the shRNA sequence which is 
inserted into this kind of vector, it is crucial to avoid strong secondary structures that 
would otherwise prematurely terminate the transcription by RNA Polymerase III 
(reviewed in (Kumar, L. D. et al. 2007)). This problem can be overcome by the use of 
vectors with dual Pol III promoters where the premature siRNA duplex is directly 
created form the selected 19 bp DNA sequence (for an overview see (Kumar, L. D. et 
al. 2007)). Inducible promoters can also be used and allow tight control of the 
expression of the shRNA and therefore of the knockdown of the investigated protein.  
Thus, short-hairpin-activated gene silencing (SHAGging) is a good alternative to 
normal siRNAs to study gene function in mammalian cells (Paddison, P. J. et al. 2002). 
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3. IDEAS, AIMS AND WORKING HYPOTHESIS 
 
3.1. The idea behind the NMD assay 
An NMD assay for HeLa cells was designed and developed by Miles Wilkinson and 
coworkers (Carter, M. S. et al. 1995; Li, S. et al. 1997; Muhlemann, O. et al. 2001). 
They transiently transfected HeLa cells with an NMD reporter construct (TCR-ß or ß-
globin) for the expression of either a wild type (wt) or a premature termination codon 
(PTC)-containing mRNA (Carter, M. S. et al. 1995; Li, S. et al. 1997). The role of 
possible NMD factors for decay was then investigated via the expression and 
degradation of the reporter constructs. 
With an NMD assay, new putative candidates can be investigated for their role in NMD. 
HeLa cells are a fast and convenient experimental model system. Therefore, HeLa cells 
are optimal to establish and set up an NMD assay which can later be used in more 
demanding primary cells or cell lines. 
 
The RNA-binding protein Btz and eIF4AIII are core components of the EJC and play a 
major role in NMD (Palacios, I. M. et al. 2004). In Btz-depleted HeLa cells, the NMD 
process is no longer functional and mRNAs with PTCs accumulate, giving rise to 
truncated proteins (Palacios, I. M. et al. 2004). The same effect was also shown for 
UPF1 (Sun, X. et al. 1998) and eIF4AIII (Ferraiuolo, M. A. et al. 2004). Thus Btz and 
eIF4AIII were chosen as positive controls for the establishment of the NMD assay in 
this diploma thesis.  
 
The candidates for the NMD assay were selected by Dr. Daniela Karra based on her 
work in our laboratory (Daniela Karra, PhD thesis 2008). In her PhD thesis, she isolated 
endogenous Btz-ribonucleoprotein particles (RNPs) from rat brain and identified the 
protein components via mass spectrometry in cooperation with Dr. Keiryn Bennett and 
Dr. Giulio Superti-Furga (CeMM, Vienna). In addition, she adopted a procedure that 
made it possible to distinguish between RNA-mediated and possible protein-protein 
interactors. In a first round of experiments, five putative protein-protein interactors were 
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chosen as candidates for the NMD assay: Nucleophosmin 1 (NPM1), DEAD(Asp-Glu-
Ala-Asp)-box polypeptide 5 (DDX5), U5-116 kDa, RNA-binding motif protein - X-
linked (RBMX) and RNA-binding motif protein 4 (RBM4). The proteins are described 
below with important synonyms in parentheses.  
 
NPM1 (Nucleophosmin 1; Nucleolar phosphoprotein B23; Nucleolar protein 
NO38; Numatrin) 
 
NPM1 was first identified as a multifunctional, predominantly nucleolar protein and 
chaperone (Feuerstein, N. et al. 1987; Schmidt-Zachmann, M. S. et al. 1987). Its cellular 
activities include cell proliferation, cytoplasmic/nuclear shuttle transportation, binding 
of single-stranded nucleic acids, ribonucleic cleavage and molecular chaperoning 
(reviewed in (Ye, K. 2005)). NPM1 is also involved in the assembly and transport of 
ribosomes (Nozawa, Y. et al. 1996). The protein is upregulated in cancer cells compared 
to normal cells (Nozawa, Y. et al. 1996). NPM1 is supposed to be crucial for the 
regulation of cancer growth via the p53/p14ARF/mdm2 stress response pathway (for an 
overview see (Ye, K. 2005; Gjerset, R. A. 2006)) and can therefore contribute to 
tumorigenesis (reviewed in (Yung, B. Y. 2007)). Therefore, the protein serves as a 
tumor marker acting through binding and suppressing various tumour suppressors.  
Interestingly, NPM1 is reported to have both oncogenic and tumour suppressive 
functions (Grisendi, S. et al. 2005).  
Overexpression of NPM1 was shown to counteract apoptosis (reviewed in (Ye, K. 
2005)). The importance of NPM1 for proliferation, apoptosis and differentiation was 
also recently confirmed in neural stem cells (Qing, Y. et al. 2008). In addition, previous 
data in yeast indicates a possible function of NPM1 in NMD (Palaniswamy, V. et al. 
2006). 
 
DDX5 (DEAD-box polypeptide 5; p68 - probable ATP-dependent RNA helicase 
DDX5) 
 
DDX5 is a multifunctional ATP-dependent RNA helicase which belongs to the DEAD-
box (Asp-Glu-Ala-Asp) (DDX) family. The members of this protein family are highly 
conserved (reviewed in (Luking, A. et al. 1998; Fuller-Pace, F. V. 2006; Linder, P. 
2006)) and have important roles in RNA metabolism (for an overview see (Fuller-Pace, 
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F. V. 2006)). Thus, DDX3 or DDX17 are highly related to DDX5 (Luking, A. et al. 
1998; Ogilvie, V. C. et al. 2003; Abdelhaleem, M. 2005; Barbosa-Morais, N. L. et al. 
2006; Fuller-Pace, F. V. 2006). The latter two RNA helicases even share 90% amino 
acid identity across the conserved core (Ogilvie, V. C. et al. 2003) and exist as a 
heterodimer in the cell (Lamm, G. M. et al. 1996). 
DDX5 protein shows ATP-dependent RNA helicase and RNA-dependent ATPase 
activities in vitro (Ogilvie, V. C. et al. 2003). It functions in translational repression as 
well as activation via interaction with different cofactors (e.g. CBP/p300 or RNA Pol II 
for activation; histone deacetylase 1 (HDAC1) for repression) (reviewed in (Fuller-
Pace, F. V. 2006)). In addition, DDX5 also mediates pre-mRNA and pre-rRNA 
processing, alternative splicing, mRNA decay and RNA interference (for an overview 
see (Fuller-Pace, F. V. 2006)). DDX5 expression is regulated during growth and 
development and correlates with organ differentiation (Stevenson, R. J. et al. 1998). 
A previous publication also indicates that DDX5 plays a role in the regulation of 
incorrect transcripts and therefore NMD in yeast (Bond, A. T. et al. 2001). 
 
U5-116 kDa (U5 snRNP-specific protein - 116 kD; EFTUD2 - elongation factor Tu 
GTP-binding domain containing 2) 
 
The best-characterised components of the spliceosome are the four small nuclear 
ribonucleoprotein particles (snRNPs) U1, U2, U4/U6, and U5 (Behrens, S. E. et al. 
1991). These four snRNPs differ in their composition and therefore consist of distinct 
snRNAs and proteins (Behrens, S. E. et al. 1991). U5-116 kDa is a small nuclear RNP 
(Fabrizio, P. et al. 1997). Little is known about this protein. The U snRNPs are splicing 
factors and helicases (Fabrizio, P. et al. 1997). The spliceosome forms via orchestrated 
assembly of both snRNPs and other splicing factors on the pre-mRNA (Fabrizio, P. et 
al. 1997). U5-116 kDa is supposed to play a role in rearrangement steps during 
spliceosome assembly or the splicing process (Achsel, T. et al. 1998). The protein is a 
component of the 20S U5 snRNP (Behrens, S. E. et al. 1991). U5-116 kDa shows a high 
degree of homology with the ribosomal elongation factor EF-2, a ribosomal translocase 
and GTPase (Fabrizio, P. et al. 1997). Like EF-2, U5-116 kDa binds and hydrolyses 
GTP and might therefore play a crucial role either in splicing or the recycling of 
spliceosomal snRNPs (Fabrizio, P. et al. 1997). There is only one publication showing a 
predominantly nuclear localisation of U5-116 kDa where it colocalises with nuclear 
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speckles in HeLa cells (Fabrizio, P. et al. 1997). 
Altogether, the role of U5-116 kDa in the splicing process makes it a promising 
candidate for NMD. 
 
RBMX (RNA-binding motif protein - X-linked; hnRNP G - heterogeneous nuclear 
ribonucleoprotein G) 
 
RBMX is a heterogeneous, nuclear ribonucleoprotein of the RNA-binding motif (RBM) 
or RBMY family (Delbridge, M. L. et al. 1999; Elliott, D. J. 2004). It is localised on the 
X chromosome (Delbridge, M. L. et al. 1999). Very little is known about this protein so 
far. RBMX has an RNP-consensus RNA-binding domain (RBD) at the amino terminus 
and is rich in serines, arginines and glycines at the carboxyl terminus (Soulard, M. et al. 
1993). Knockdown experiments were performed in zebrafish where the depletion of 
RBMX led to underdevelopment of the head and eyes as well as to a reduced body size 
compared to wt zebrafish (Tsend-Ayush, E. et al. 2005). Due to the study in zebrafish 
and a recently published study in Xenopus laevis (Dichmann, D. S. et al. 2008), RBMX 
plays an essential role in the development of the brain. 
RBMX and RBMY are homologues which evolved from a common ancestor 
(Delbridge, M. L. et al. 1999). RBMY is located on the Y chromosome and displays a 
male-specific function in testis for spermatogenesis (Delbridge, M. L. et al. 1999).  
There are publications indicating a role of the RBMY family proteins and therefore 
RBMX in pre-mRNA splicing (e.g. (Venables, J. P. et al. 2000)). In addition, RBMX is 
also considered to be a transcriptional regulator (Takemoto, T. et al. 2007). This role of 
RBMX in RNA processing and regulation might provide a link of the protein to NMD. 
 
RBM4 (RNA-binding motif protein 4; LARK). 
 
RBM4 is an RNA-binding protein of the RNA recognition motif (RRM) class and a 
splicing factor (Markus, M. A. and Morris, B. J. 2006). RBM4 localizes in nuclear 
speckles and nucleoli and can be redistributed to perinucleolar clusters (Markus, M. A. 
and Morris, B. J. 2006). These findings indicate a potential role of RBM4 in RNA 
processing and/or splicing. Actually, RBM4 is also involved in alternative splicing (e.g. 
(Markus, M. A., Heinrich, B. et al. 2006; Lin, J. C. et al. 2007)). In addition, the protein 
acts as a suppressor of cap-dependent as well as an enhancer of IRES-mediated 
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translation in response to stress signals (Lin, J. C. et al. 2007). These RBM4 activities 
are regulated via phosphorylation (Lin, J. C. et al. 2007). Moreover, RBM4 is required 
for miRNA-guided gene regulation and therefore incorporated into a complex with 
Argonaute proteins (Hock, J. et al. 2007). 
These facts are good indicators for a possible role of RBM4 in the NMD process. 
 
3.2. The experimental approach 
The shRNA plasmids for the five candidates targeting both human (for use in HeLa 
cells) and rat (for use in primary hippocampal neurons) were designed and generated. 
First, these shRNA sequences were tested for their efficiency of downregulation of the 
corresponding protein in HeLa cells via Western Blot and immunofluorescence. 
Working shRNA plasmids were cotransfected together with a TCR-ß NMD reporter 
construct (either with or without a PTC). Total RNA was isolated and reverse 
transcribed into cDNA. Semiquantitative PCR was then performed to monitor 
differences in the expression level of the TCR-ß NMD reporters.  
Subsequently, I also investigated the effects of the selected candidates on NMD using 
two cell lines stably expressing ß-globin reporter constructs (again with or without 
PTC) and real-time PCR. Again the expression levels of the ß-globin constructs were 
used to monitor the impact on and the integrity of NMD in cells depleted for an NMD 
candidate. 
 
3.3. Aim & working hypothesis 
The aim of this diploma thesis was to investigate the role of the five selected putative 
Btz interactors - NPM1, DDX5, U5-116 kDa, RBMX and RBM4 - in NMD. Therefore, 
an NMD assay was established in the laboratory. Once the assay is set up, it is quick 
and easy to investigate the function of new, putative NMD components in different cell 
types and lines. 
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In theory, if an essential NMD component is missing, NMD is impaired and aberrant 
transcripts accumulate, because they are no longer degraded by NMD. This was already 
shown for Btz and eIF4AIII (Ferraiuolo, M. A. et al. 2004; Palacios, I. M. et al. 2004). 
As Btz and eIF4AIII are established NMD markers, they were chosen as positive 
controls for the establishment of the NMD assay in this diploma thesis. Since the five 
chosen NMD candidates (NPM1, DDX5, U5-116 kDa, RBMX and RBM4) are putative 
protein-protein interactors of Btz, the idea of this study was to test whether their 
depletion has a similar effect on NMD like Btz and therefore cause accumulation of 
PTC-containing reporter constructs. This effect would then indicate a role of the 
candidate in NMD. Thus, shRNAs were generated to downregulate those protein 
candidates first in HeLa cells and later on in rat hippocampal neurons in order to 
investigate their role in NMD. 
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MATERIAL & METHODS 
1. MATERIAL 
1.1. Reagents & consumables  
Reagents: 
 
Acetic acid Roth 
Acrylamide mix, 30% Roth 
Agar  Sigma 
Agarose  Roth 
Ammonium peroxodisulfate (APS)  Roth 
Ampicillin Roth 
β-Mercaptoethanol Sigma 
Bio-Rad Protein Assay  Bio-Rad 
Bovine serum albumin (BSA) Calbiochem 
Bromphenol blue  Serva 
Complete, Mini, EDTA-free - protease inhibitor cocktail 
tablets 
Roche 
dATP, 100 mM Fermentas 
dCTP, 100 mM Fermentas 
Detector Block, 5x  KPL 
dGTP, 100 mM Fermentas 
4',6-Diamidino-2-phenylindole dihydrochlorid (DAPI) Roth 
1,4-Diazabicyclo[2.2.2]octane (DABCO)  Sigma 
Diethylpyrocarbonate (DEPC) Sigma 
Dithiothreitol (DTT) Sigma 
DMEM Invitrogen 
dTTP, 100 mM Fermentas 
Ethanol, absolute Merck 
Ethidium bromide solution (1% in H2O) Fluka 
Ethylendiamine tetraacetate (EDTA), Na-salt Sigma 
Fetal Calf Serum (FCS) PAA 
FuGENE® HD Transfection Reagent  Roche 
Gelatin from cold water fish skin, ~ 45% in H2O Sigma 
GeneRulerTM 1 kb DNA Ladder (0.5 µg/µl) Fermentas 
GeneRulerTM 100 bp DNA Ladder (0.5 µg/µl) Fermentas 
Geneticin® G-418 Sulphate Gibco 
Glycerol Sigma 
Glycine Biomol 
Guanidine hydrochloride Sigma 
Hydrochloric acid Roth 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES) 
Sigma 
iQTM SYBR® Green Supermix Bio-Rad 
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Isopropanol (2-Propanol) Roth 
Loading Dye Solution, 6x Fermentas 
Magnesium chloride (MgCl2), 25 mM  Fermentas 
MLV Reverse Transcriptase 5X Reaction Buffer Promega 
MOWIOL® 4-88 Reagent Calbiochem 
N,N,N’,N’-Tetramethylethylendiamin (TEMED) Roth 
PageRulerTM Prestained Protein Ladder Fermentas 
Paraformaldehyde (PFA) Merck 
10x PBS Dulbecco, w/o Ca2+ Mg2+ Biochrom AG 
Polyethylenimine (PEI), 50% Sigma 
Ponceau S Merck 
PROTRAN®-Nitrocellulose transfer membrane, 0.2 µm pore 
size 
Schleicher & Schuell 
Sodium chloride Merck 
Sodium dodecylsulfate (SDS) Serva 
Sodium hydroxide Merck 
Trichloric acid (TCA) Merck 
Tris(hydroxymethyl)-aminomethan (Tris) Roth 
Triton X-100 Roth 
Tryptone Roth 
Tween 20 Roth 
Whatman chromatography paper Multimed 
Yeast extract Roth 
 
RNA grade reagents: 
 
Chloroform Fluka 
Ethanol, absolute Merck 
Glycogen, (20 mg/ml) Fermentas 
MLV Reverse Transcriptase 5x Reaction Buffer Promega 
2-Propananol (isopropanol), for molecular biology, min 99% Sigma 
RNaseZAP® Sigma 
Trizol® Reagent  Invitrogen 
Random Primers, (0.5 µg/µl) Promega 
RiboLockTM Ribonuclease Inhibitor (40 u/µl) Fermentas 
 
 
Consumables: 
 
DNA, RNA and protein handling 
 
Microtubes - PLASTIBRAND® 
Biopur® Safe-Lock micro test tubes (DNase and RNase-free) - Eppendorf 
15 ml and 50 ml PP Tubes, sterile - Greiner  
Rotilabo®- Expendable Cuvettes, PS - Roth 
8-strip 0.2 ml PCR tubes, colorless, thin walled - Eppendorf 
Syringe Filter, 0.45 µm - Schleicher & Schuell 
Rotilabo®-Petri dishes, Ø 90 mm, sterile, PS - Roth 
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Cell culture 
 
Dishes Nunclon™Δ 60 x 15 - NuncTM 
Multidishes 12, non-treated - NuncTM 
Rotilabo®-Syringe filter sterile; 0.22 µm; PVDF - Roth 
 
Immunofluorescence 
 
Ø 10 mm glass coverslips, 0.13 – 0.16 mm - Marienfeld 
Microscope Slides, cut edges, ca. 76 x 26 mm - Roth 
 
Real-time PCR 
 
Thin-Wall PCR Plates, 96-well, 0.2ml - Bio-Rad 
Microseal® 'B' Film, optically clear - Bio-Rad 
Flat Cap Stripes, optical - Bio-Rad 
 
 
Kits: 
 
Agarose gel purification 
 
QIAquick Gel Extraction Kit - Qiagen 
 
Cloning 
 
LigaFastTM Rapid DNA Ligation System - Promega 
 
DNA isolation (Maxiprep) 
 
EndoFree Plasmid Purification Kit - Qiagen 
PureYieldTM Plasmid Maxiprep System - Promega 
 
RNA isolation 
 
RNeasy Midi Kit - Qiagen 
mirVanaTM miRNA Isolation Kit - Ambion 
 
DNase digestion  
 
Deoxyribonuclease I - Sigma 
 
Reverse transcription PCR (RT-PCR) 
 
Moloney Murine Leukemia Virus Reverse Transcriptase, RNase H Minus, Point 
Mutant (M-MLV RT (H-) - Promega 
First Strand cDNA Synthesis Kit - Fermentas 
iScriptTM cDNA Synthesis Kit - Bio-Rad 
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Real-time PCR 
 
iQTM SYBR® Green Supermix (100mM KCl; 40 mM Tris-HCl; pH 8.4; 0.4 mM 
of each dNTP; dATP, dCTP, dGTP, dTTP; iTaq DNA polymerase; 50 u/ml; 
6mM MgCl2; SYBR Green I; 20 nM fluorescein; and stabilisers) - Bio-Rad 
1.2. Enzymes 
BglII (10 u/µl) - Fermentas 
HindIII (10 u/µl) - Fermentas 
T4 DNA Ligase (3 u/µl) - Promega 
Deoxyribonuclease I - Sigma 
Moloney Murine Leukemia Virus Reverse Transcriptase, RNase H Minus, Point Mutant 
(M-MLV RT (H-)) (200 u/µl) - Promega 
Taq DNA Polymerase (recombinant; 5 u/µl) - Fermentas 
 
1.3. Antibodies 
Western Blot: 
 
All antibody dilutions for Western Blots were made in 1x Detector Block (KPL). 
 
Primary antibodies: 
 
Antigen  Size [kDa] Species Dilution  Company 
U5-116 kDa 116 rabbit 1:1,000 Dr. Lührmann 
Btz 115 rabbit (#8) 1:500 D. Karra, PhD 
thesis 2008 
DDX5 68 rabbit 1:1,000 Aviva Systems 
Biology 
α-Tubulin 55 mouse 1:5,000 Sigma 
 
eIF4AIII 48 rabbit 1:1,000 Abcam 
 
RBMX 43 goat 1:500 Santa Cruz 
Biotechnologies 
RBM4 43 goat 1:500 Abcam 
NPM1 38 (double band) mouse, 
monoclonal 
1:500 Abnova 
EGFP 26 rabbit ≥ 1:1,000 P. Altrichter 
 
Ingrid Kieweg Material & Methods 
__________________________________________________________________________________________________________________________________________________________________________ 
 32 / 148 
Secondary antiodies: 
 
Fluorophores: 
 
IRDye 800 – green 
IRDye 700 – red 
 
Specificity IRDye Dilution Company 
donkey α rabbit 800 1:10,000 LI-COR Biosciences 
donkey α rabbit 700 1:10,000 Rockland 
goat α mouse 800 1:10,000 Rockland 
donkey α mouse 700 1:10,000 LI-COR Biosciences 
donkey α goat 700 1:10,000 Molecular Probes 
 
 
Immunocytochemistry: 
 
All antibody dilutions for immunofluorescence were made in 10% Blocking Solution. 
 
Primary antibodies: 
 
Antigen Size [kDa] Species Dilution  Company 
U5-116 kDa 116 rabbit 1:500 Dr. Lührmann 
Btz  115 rabbit (#8) 1:500 D. Karra, PhD 
thesis 2008 
DDX5 68 rabbit 1:500 Aviva Systems 
Biology 
RBMX 43 goat 1:100 Santa Cruz 
Biotechnologies 
NPM1 38  mouse, 
monoclonal 
1:500 Abnova 
 
Secondary antibodies: 
 
Specificity Fluorophore Dilution Company 
goat α mouse CY3 (red) 1:1,000 Dianova 
goat α rabbit CY3 (red) 1:1,000 Dianova 
donkey α goat CY3 (red) 1:2,000 Dianova 
 
Ingrid Kieweg Material & Methods 
__________________________________________________________________________________________________________________________________________________________________________ 
 33 / 148 
1.4. Plasmids & primers 
Plasmid: 
 
 
 
 
Figure 2-1: Picture of the pSUPERIOR.neo+gfp vector map taken from http://www.oligoengine.com. 
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Colony PCR primers 
 
Notation Orientation Sequence 
pSUPER2101f forward ACACAGGAAACAGCTATGAC 
pSUPER-2390rv reverse GCGCCCTGGCAGGAAGATGG 
 
Primers for semiquantitative PCR of TCR-ß pre- and mRNA: 
 
Notation Orientation Sequence Reference 
TCR-ß-
mRNA for 
forward GACTGACTGTTCTCGAGG 
TCR-ß-pre-
mRNA 
forward GTACCTGATCCAGACAGTTA 
TCR-ß-REV  reverse GTCAAGGTGTCAACGAGGAA
C. Giorgi, 
personal 
communication 
 
Primers for semiquantitative PCR used as internal standards for normalisation of TCR-
ß PCR products: 
 
Notation Orientation Sequence 
GAPDHfor forward GAGCTGAACGGGAAGCTCAC 
GAPDHrev reverse GGAGAGTGCTCAGTGTTGGG 
ßtubulin for forward AGACCGCATCATGAACACCT 
ßtubulin rev reverse TCTTGGAGTCGAACATCTGC 
 
Primes for real-time PCR: 
 
Target & 
notation 
Orienta
tion 
Sequence Resulting 
fragment 
size 
Reference 
ß-Globin  
ß-globin-
Morris-
for 
forward TTGGGGATCTGTCCACTCC (Morris, 
C. et al. 
2007) 
ß-globin-
Morris-
rev 
reverse CACACCAGCCACCACTTTC 
277 bp 
(Morris, 
C. et al. 
2007) 
GAPDH  
Gap-F-2   forward ATTCTTCCACCTTTGATGC 
Gap-R-2   reverse GTCCACCACCCTGTTGCTGTA 
104 bp Y. Xie 
Tubulin  
Tub-F-2   forward TGTCTTCCATCACTGCTTCC 
Tub-R-2   reverse TGTTCATGGTAGGCTTTCTCAG
150 bp Y. Xie 
 
 
Primers were in any case order from Sigma with exception of the Random Primers 
(0.5 µg/µl; Promega) for the RT-PCR. 
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1.5. Markers & ladders 
Agarose gels: 
 
• GeneRulerTM 1 kb DNA Ladder (0.5 µg/µl) – Fermentas 
 
   
Figure 2-2: Picture taken from http://www.fermentas.com. 
 
 
• GeneRulerTM 100 bp DNA Ladder (0.5 µg/µl) – Fermentas 
  
  
 
 Figure 2-3: Picture taken from www.fermentas.com. 
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SDS-PA gels: 
 
• PageRulerTM Prestained Protein Ladder - Fermentas 
 
 
  
 Figure 2-4: Picture taken from http://www.fermentas.com. 
 
1.6. Cells 
• Top 10 E. coli - Invitrogen 
 
• Conventional HeLa cells – DSMZ Heidelberg 
 
• Stable HeLa cell lines for real-time PCR experiments (from Dr. Oliver 
Mühlemann (Institute of Cell Biology, University of Bern, Switzerland)) 
 
ß-Globin cell lines: 
Notation Construct Reference 
HeLa wt ß-Globin PTC- (Thermann, R. et al. 1998) 
HeLa NS39 ß-Globin PTC+ (Thermann, R. et al. 1998) 
 
TCR-ß cell lines: 
Notation Construct Reference 
HeLa 290F PTC- (Muhlemann, O. et al. 2001) 
HeLa 593C PTC+ (Muhlemann, O. et al. 2001) 
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1.7. Buffers & solutions 
Cloning & transfection:  
 
Ampicillin stock  100 mg ampicillin in 1 ml sterile water 
? The stock is sterile-filtrated with a syringe 
through a 0.45 µm filter unit, aliquoted and stored at 
-20°C for further use. 
 
Annealing Buffer  100 mM NaCl 
50 mM HEPES pH 7.4 
 
LB (for 1 l) 10 g Tryptone 
 5 g Yeast extract 
10 g NaCl  
 ? fill up with ddH2O and autoclave 
 
LB plates   400 ml LB medium 
6 g agar 
? heat in microwave until agar is completely solved  
? cool down to ~ 50°C  
? add 400 ml of ampicillin stock and pour plates 
 
Polyethylenimine (PEI) PEI is dissolved in pre-heated ddH20 at 80°C to a 
final concentration of 1 mg/ml 
? cool to RT       
? carefully adjust to pH 7.0 with HCl 
 ? filter sterilise (0.45 µm pore size) 
 ? aliquots stored at -80°C 
+ 150 mM NaCl (autoclaved + filter-sterilised (0.45 
µm pore size)) 
TE Buffer (Qiagen) 10 mM Tris (to pH 8.0 with HCl) 
 1 mM EDTA 
 
 
Cell culture: 
 
HeLa medium   DMEM + 10% (v/v) FCS 
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HeLa lysate & Western Blot: 
 
Blocking solution (Western Blot) 1x DetectorTM Block, KPL 
 
10x Blotting Buffer (Towbin) 250 mM Tris 
1.92 M Glycine 
 
1x Blotting Buffer ? dilute from 10x Blotting Buffer 
 
4x Laemmli Buffer (SDS-PAGE)  200 mM Tris HCl pH 6.8 
200 mM DTT 
8% SDS 
0.04% bromphenol blue 
40% glycerol 
 
2x Laemmli Buffer (SDS-PAGE)  400 µl ddH2O 
100 µl 1 M Tris HCl pH 8.5 
500 µl 4x Laemmli Buffer 
 
Lysis Buffer for HeLa cells  50 mM Tris pH 7.5 
150 mM NaCl 
1 mM EDTA 
1% (v/v) Triton X-100 
      
1x PBS Dulbecco, w/o Ca2+ Mg2+, from Biochrom AG 
? dilute from 10x PBS Dulbecco, w/o Ca2+ Mg2+, 
from Biochrom with ddH2O 
140 mM NaCl 
2.7 mM KCl 
16 mM disodium hydrogen phosphate 
1.8 mM potassium dihydrogen phosphate 
? adjust pH to 7.1 with HCl    
  
Ponceau-S solution  0.2% (w/v) Ponceau S 
3% TCA (w/v) in ddH2O 
 
10% SDS (for 1l)  100g SDS 
? fill up with ddH2O 
 
10x SDS Running Buffer 0.25 M Tris 
1.92 M Glycine 
1% SDS 
 
1x SDS Running Buffer ? dilute from 10x SDS Running Buffer with ddH2O 
 
10x TBS  150 mM Tris pH to 7.5 
1.5 M NaCl 
 
1x TBS ? dilute from 10x Blotting Buffer 
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TBS-T 1x TBS with 0.1% (v/v) Tween 20 
 
 
RNA & protein isolation: 
 
DEPC water  ddH2O including 0.1% of DEPC is constantly stirred 
for 6 h and subsequently autoclaved 
 
75% ethanol (v/v) (for 50 ml)     37.5 ml ethanol absolute 
 12.5 ml DEPC H2O 
 
6 M guanidine hydrochloride  28.7 g guanidine hydrochloride 
 ? fill up with DEPC H2O to 50 ml 
 
0.3 M guanidine hydrochloride 2.5 ml 6 M guanidine hydrochloride 
(for 50 ml)  47.5 ml ethanol absolute 
 
 
PCR: 
 
dNTPs (10 mM each) 10 µl of each dNTP (dATP, dCTP, dGTP, dTTP, 
100 mM, Fermentas)  
 60 µl ddH2O or DEPC H2O (for RT-PCR) 
 
 
Agarose gel: 
 
Ethidium bromide working solution – 0.2 mg/ml ? final concentration in gel – 0.02 
µg/ml 
1 ml Ethidium bromide solution (1% in H2O) 
 50 ml ddH2O 
 
50x TAE (2 l) 484 g Tris  
114.2 ml Acetic acid 
200 ml EDTA (0.5 M, pH 8.0) 
? adjust pH to 7.5 to 7.8 with HCl 
 
1x TAE ? dilute from 50x TAE with ddH2O 
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Immunocytochemistry: 
 
Blocking Solution  2% (v/v) FCS 
2% (v/v) BSA 
0.2% (v/v) Gelatin from cold water fish skin, ~ 45% 
in H2O   
10x PBS (10ml for 100 ml) 
? make aliquots and store them at  -20°C 
 
10% Blocking Solution  ? dilute from Blocking Solution with 1x PBS 
 
DAPI  500µl DAPI (2mg/ml) in 500 ml 1x PBS  
? mix and protect from light with tin foil 
 
Mowiol  2.4 g MOWIOL® 4-88 Reagent  
6 g glycerol 
? stir to mix for 5 – 10 min 
+ 6 ml ddH2O 
? leave at RT o/n 
+ 12 ml 0.2 M Tris pH 8.5 – 8.8 
? heat to 50°C with occasional stirring 
+ 2.5% DABCO (w/v) in ddH2O (12 mg/ 500 µl 
Mowiol) when at 37°C and dissolve 
? centrifuge 15 min at 5,000 g 
? make aliquots and store them at  -20°C 
16% PFA  16 g PFA 
70 ml ddH2O 
? heat to 60°C while stirring  
? add 1 -2 pellets NaOH 
+10 ml 10x PBS 
? adjust at RT to pH 7.4 with HCl 
? fill up with ddH2O to 100 ml 
? make aliquots and store them at  -20°C 
 
4% PFA  ? dilute from 16% PFA with 1x PBS 
 
1% Triton X-100  ? dilute in 1x PBS 
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Gels: 
 
2% agarose gel: 
 
For 1 gel                         2 g agarose  
100 ml 1x TAE 
? heat in microwave 
? stir until cooled down to hand-hot 
? clean and prepare gel chamber 
+ 10 µl ethidium bromide working solution – 0.2 
mg/ml ? final concentration in gel - 0.02 µg/ml 
? pour gel 
? gel is run in 1x TAE at 100 V 
 
 
1.5 mm 10% PA gel: 
 
? gel is run in 1x SDS Running Buffer at 130 V for 1 h and 20 min 
 
 10% Separation gel (8 ml/gel) 
 for 10 ml [ml] 
H2O 4.0 
30% Acrylamide 3.3 
1.5 M Tris pH 8.8 2.5 
10% SDS 0.1 
 mix well 
10% APS 0.1 
TEMED 0.004 
 
 5% Stacking gel (3 ml/gel) 
 for 3 ml [ml] 
H2O 2.1 
30% Acrylamide 0.5 
1.0 M Tris pH 6.8 0.38 
10% SDS 0.03 
 mix well 
10% APS 0.03 
TEMED 0.003 
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1.8. Equipment  
Thermomixer  
Eppendorf Thermomixer comfort - Eppendorf 
 
Vortexer 
Vibrofix VF1 - Janke & Kunkel IKA 
 
pH Meter  
MP225 - Mettler Toledo 
 
Shaker  
GFL 3015 - GFL® 
 
Waterbath 
GFL® 
 
Incubator 
Unitron - INFORS HT® 
 
Balances 
KERN ABS - KERN® 
KERN 440-49N - KERN® 
 
Spectrophotometer  
GeneQuant Pro spectrophotometer - Amersham Pharmacia 
 Cuvette Suprasil, 10 mm - Hellma 
 
Power supplies 
Power Pac 300 power supply for electrophoresis - Bio-Rad 
Power Pac HC power supply for electrophoresis - Bio-Rad 
 
Western Blot 
Mini-Protean® 3 Cell SDS-PAGE-System - Bio-Rad 
Trans-Blot Cell blotting chamber - Bio-Rad 
 
Scanner for WB membranes 
Odyssey® Infrared Imaging System - LI-COR® Biosciences;  
software: Odyssey® Application Software 2.1  
 
Agarose gels 
Horizontal DNA Electrophoresis Gel Boxes - Bio-Rad 
 
UV/IR imaging system 
Peqlab imaging system with UV/IR interference filter type F590 - Peqlab 
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Microcentrifuges 
Eppendorf Centrifuge 5417 C - Eppendorf 
Eppendorf Centrifuge 5417 R - Eppendorf  
 
Centrifuge Avanti J-25TM, Beckman Coulter 
 Rotor JLA10.500 - Beckman 
 Rotor JA-25.50 - Beckman 
 
Microscopes 
Leica MZ 16F - Leica; software: Leica Application Suite Version 2.6.0 R1 
[Build 1192] - Leica 
Axioplan - Zeiss; software: analySISB - Olympus 
 
-80°C freezer 
Herafreeze - Heraeus Instruments  
 
PCR cycler 
PTC-200 Peltier DNA Engine Thermal Cycler - MJ Research 
 
Real-time PCR machine 
MyiQTM Single Color Real-Time PCR Detection System - Bio-Rad;  
software: iQ5 Optical System Software (Version 2.0) - Bio-Rad 
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2. METHODS 
2.1. Design, creation and testing of shRNA plasmids 
2.1.1. Design 
The sequences for new shRNAs were either designed using the “Target Design Option: 
Stealth™ RNAi“ of the “BLOCK-iT™ RNAi Designer” from Invitrogen 
(http://rnaidesigner.invitrogen.com/rnaiexpress/) or by alignment of the sequences 
found in the NCBI (http://www.ncbi.nlm.nih.gov/) and Ensembl 
(http://www.ensembl.org/index.html) data bases with the computer program Lasergene 
from DNASTAR (Version 7.1.0 (44)).  
 
Criteria for the design of shRNA sequences (Johanna Barbara Munding, PhD thesis 
2006): 
 
• Avoid the third quarter of the whole target gene 
• shRNA sequences targeting the 3’-UTR (3’ - untranslated region) are as 
efficient for knockdown as sequences from the coding region (CDR) of the 
target gene (Hsieh, A. C. et al. 2004)  
• Choose optimal guanine/ cytosine content of 30 – 52% 
• Adenine/ uracil base pairs at the 5’-UTR have a low internal stability for the 
binding and directed incorporation into the RNA-induced Silencing Complex 
(RISC)  
• A high melting temperature (Tm) facilitates the folding of the hairpin structure 
• Avoid internal repeats and palindromes which would interfere with the hairpin 
structure 
• Analysis of shRNA sequences with high silencing efficiencies lead to the 
following structural similarities: Adenine at position 3 and 19, Uracil at position 
10, no Guanine at position 13 and neither Guanine nor Cytosine at position 19 
(Reynolds, A. et al. 2004)  
 
For a table of all used and tested shRNA sequences see 1.4 Plasmids & primers in the 
Material section. 
 
2.1.1.1.Manual design of shRNAs using Lasergene  
Sequences found in the NCBI (http://www.ncbi.nlm.nih.gov) and Ensembl 
(http://www.ensembl.org/index.html) databases of the desired genes were aligned with 
the computer program Lasergene (DNASTAR, Version 7.1.0 (44)). After alignment, 19 
nucleotides were selected manually and blasted for their specificity using the NCBI 
database. The blast hits on the query sequence were identified using the NCBI, the 
iHOP (Information Hyperlinked over Proteins) (http://www.ihop-net.org) and the 
ExPASy (http://www.expasy.org) database, checking for the different nomenclatures of 
the identified genes and proteins. 
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When the specificity of the sequence was confirmed, the fragment was inserted into the 
following primer structures: 
 
 
 
Figure 2-5: Transcription of a 60 nt oligo to a hairpin RNA which is processed to a functional siRNA 
(picture taken from http://www.oligoengine.com). 
 
These two 60 nt primers per each new shRNA plasmid were then ordered from Sigma-
Aldrich. 
 
2.1.1.2. “BLOCK-iT™ RNAi Designer” from Invitrogen 
In addition to the manually designed target sequences, shRNAs were designed using the 
“Target Design Option: Stealth™ RNAi” of the “BLOCK-iT™ RNAi Designer” from 
Invitrogen (http://rnaidesigner.invitrogen.com/rnaiexpress/). The nucleotide sequences 
or the gene accession number was filled into the form of the search engine and possible 
shRNA sequences were detected by a highly effective, proprietary algorithm. 
19 nt were picked from the received sequences and blasted with the NCBI database for 
their specificity. 
 
 
2.1.2. Cloning 
Chosen sequences were cloned into the pSUPERIOR RNAi SystemTM from 
OligoEngine (Brummelkamp, T. R. et al. 2002; Brummelkamp, T. R. et al. 2002). The 
two 60 nt primer constructs contain a BglII and a HindIII restriction site that allowed 
cloning them into the pSUPERIOR.neo+gfp expression vector according to the 
manufacturer’s protocol. 
This mammalian expression vector has a Polymerase-III H1-RNA gene promoter. The 
recombinant vector gives rise to a 19 base pair stem-loop structure which is cleaved into 
a functional siRNA inside the cell. The produced short RNAs have no polyadenosine 
tail, but a prominent transcription and termination signal of 5 consecutive thymidines. 
So cleavage at the termination site occurs after the second uridine, leading to a 3’ 
overhang of 2 U or T as in synthetic siRNAs (Brummelkamp, T. R. et al. 2002).   
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It was shown that even a single mismatch in the 19 nt targeting sequence restores the 
expression of the targeted gene (Brummelkamp, T. R. et al. 2002). 
The EGFP of the expression vector allows an easy monitoring of transfection and the 
transfection efficiency. The ampicillin and the neomycin resistance genes of the plasmid 
can be used for selection of transfected cells. 
 
2.1.2.1.Primer annealing 
3 µg of each primer pair (forward and reverse; diluted in sterile, nuclease-free H2O) 
were incubated in 48 µl Annealing Buffer (100 mM NaCl, 50 mM HEPES pH 7.4) at 
90°C for 4 min in the PCR cycler. The annealing mix was then cooled down in 10°C 
steps for 4 min each (except for a 10 min step at 70°C) until 40°C were reached. Then 
two further steps, one with 37°C for 10 min and one with 10°C for 4 min were added, 
until the mix was cooled down to 4°C. Either the annealed primers were immediately 
used in a ligation reaction or put at -20°C for longer storage. 
 
2.1.2.2.Ligation  
2 µl of the mix of annealed primers (see 2.1.2.1 Primer annealing) were then inserted 
into the pSUPERIOR.neo+gfp vector linearised with HindIII and BglII (the same 
restriction sites as for the primers).The digested vector was purified from a 1% agarose 
gel using the QIAquick Gel Extraction Kit (Qiagen). Ligation was done using the 
LigaFastTM Rapid DNA Ligation System (Promega). 
 
1x ligation reaction mix: 
 
Annealed primers 2 µl 
pSUPERIOR.neo+gfp (linearised with HindIII and BglII; 0.2 – 0.5 µg/µl)  1 µl 
2x Rapid Ligation Buffer (Promega)  5 µl 
ddH2O  1 µl 
T4 DNA Ligase (3 u/µl; Promega)  1 µl 
 
Σ   10 µl 
 
Ligation reaction was either performed for 2 h at RT or at 4°C o/n. 
 
2.1.2.3.Digestion with BglII restriction enzyme 
If the primers were cloned into the vector correctly, the BglII restriction sites are 
destroyed. In order to get rid of false-positive bacterial clones, BglII digestion was 
performed, because the enzyme can just cut self-ligated pSUPERIOR.neo+gfp plasmids 
without the inserted primers. 
 
1 µl BglII enzyme (Fermentas) was added to the ligation reaction and incubated for 30 
min at 37°C. 
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2.1.2.4.Transformation into Top10 E. coli  
A 100 µl aliquot of Top10 E. coli competent cells (Invitrogen) was thawn on ice. 2 µl of 
the ligation were then added to the bacteria and gently mixed with the pipette tip. This 
mixture was kept on ice for 30 min. A heat shock in a water bath at 42°C for 1 min was 
performed to infiltrate the cells with the DNA. Cells were again cooled on ice for 2 min, 
before 700 µl LB medium were added to the bacteria. The bacterial suspension was now 
incubated for 1h at 37°C on the shaker at 400 rpm to allow the bacteria to recover and to 
develop the antibiotic resistance. To increase the concentration and density of the 
bacterial suspension, cells were spun down at 4,000 g (Eppendorf Centrifuge 5417 C or 
Eppendorf Centrifuge 5417 R - Eppendorf). 600 µl of the supernatant were removed 
and the bacterial pellet was resuspended in the remaining 200 µl of medium. This cell 
suspension was then sterilely plated onto LB-Amp (ampicillin; 100 µg/ml) agar plates. 
The dishes were incubated at 37°C o/n to facilitate bacterial growth. 
 
 
2.1.3. Selection and colony PCR 
2.1.3.1.Selection 
Only bacteria containing the desired plasmids for the shRNA have antibiotic resistances 
(ampicillin and neomycin) and can therefore be selected using LB-Amp agar plates. 
 
2.1.3.2.Colony PCR 
Colony PCR is a special and quick form of PCR to screen bacterial colonies for the 
desired genetic background. Positive bacterial clones are those containing the desired 
plasmid construct. The reaction volume is 25 µl. Single bacterial colonies were taken 
from the original plate with a tip, partially transferred to another, marked LB-Amp plate 
and afterwards the tip was dumped into a PCR tube containing 25 µl of the PCR mix 
(see below). The bacterial colonies were released into the PCR tube by gently blowing 
remaining liquid out of the tips with a pipette. During the initial denaturation step of the 
PCR, bacteria break open and their DNA content is released. The PCR was performed 
according to the listed cycle scheme below. 
 
The primers used for colony PCR are binding outside the insert in the vector’s 
sequence: 
 
Notation Orientation Sequence 
pSUPER2101f forward ACACAGGAAACAGCTATGAC 
pSUPER-2390rv reverse GCGCCCTGGCAGGAAGATGG 
 
These primers give a 317 bp fragment for vectors with the insert and a 261 bp fragment 
for vectors without insert. 
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1x reaction volume: 
 
10x Taq buffer (Fermentas) 2.5 µl  
MgCl2 (25mM; Fermentas) 1.5 µl  
dNTPs (10 mM for dATP, dCTP, dGTP, dTTP; Fermentas) 0.5 µl  
pSUPER2101f (10 µM; Sigma) 0.7 µl  
pSUPER-2390rv (10 µM; Sigma) 0.7 µl  
Taq DNA Polymerase (5 u/µl; Fermentas) 0.2 µl  
ddH2O 18.85 µl  
+ bacterial colony   
 
Σ 25 µl 
 
For screening of several colonies a mastermix was prepared. 
 
PCR cycle scheme: 
 
- 94°C 30 sec 1 cycle 
 
- 94°C 30 sec 
- 58°C 30 sec 30 cycles 
- 72°C 1 min 20 sec 
 
- 4°C for ever 
 
Vectors containing the desired inserts were larger and therefore running above the 
empty vectors on the gel. 5 μl 6x Loading Dye (Fermentas) were added to each PCR 
tube and 18 µl were loaded onto a 2% agarose gel. To identify positive clones 12 µl of 
the GeneRulerTM 100 bp DNA Ladder (Fermentas) were loaded in parallel. 100 V were 
applied for 30 min. Afterwards pictures of the gel were taken using an UV/IR imaging 
system (Peqlab imaging system with UV/IR interference filter type F590 – Peqlab). 
 
 
2.1.4. Large-scale DNA isolation (Maxiprep) 
Positive bacterial clones, containing the shRNA sequence insert, were inoculated o/n in 
200 ml LB medium with ampicillin (100 µg/ml) for plasmid DNA amplification. As a 
backup for further use a glycerol stock with 1 ml bacterial culture and 0.5 ml glycerol 
was prepared before each maxiprep for every new positive clone. Two different 
Maxiprep kits were used for plasmid DNA isolation during this diploma thesis. 
 
2.1.4.1.EndoFree Plasmid Purification Kit - Qiagen 
This kit was mainly used in the course of this diploma thesis, because it yields very pure 
DNA of high concentration which guarantees high transfection efficiency (Weber, M. et 
al. 1995; Zeitelhofer, M. et al. 2008). 
Cells were harvested at 6,000 g and 4°C for 15 min (Avanti J-25TM Centrifuge - 
Beckman Coulter, rotor JLA10.500). Meanwhile, two 50 ml Falcon tubes were prepared 
per sample and Buffer P1 and P3 were cooled on ice. The bacterial pellet was 
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resuspended in 10 ml P1 (with RNase A) and transferred to one of the 50 ml tubes. 10 
ml Buffer P2 were added and mixed by inverting 4-6x. This mixture was the incubated 
at RT for 5 min. Lysis was stopped with 10 ml Buffer P3, again inverted 4-6x and then 
immediately poured into a QIAfilter Cartridge.  An incubation for 10 min at RT should 
allow the bacterial debris as well as the genomic DNA and the proteins to separate from 
the aqueous phase. The screwtop of the cartridge was removed and the lysate was 
filtrated via plunger into the second 50 ml tube. 2.5 ml ER were added, mix was 
inverted 10x and cooled on ice for 30 min for removal of endotoxins.  
A QIAGEN-tip 500 was equilibrated by flow-through of 10 ml Buffer QBT. Then the 
lysate was loaded onto the QIAGEN-tip 500. 50 ml centrifugation tubes were sterilised 
with 10 ml isopropanol and QIAGEN-tip 500 was washed twice with 30 ml Buffer QC. 
Now the DNA was eluted into the sterile centrifugation tubes with 15 ml Buffer QN. 
First the DNA in the tube was precipitated by addition of 10 ml isopropanol and mixed 
carefully. Second the DNA precipitate was pelleted by centrifugation at 14,000 g and 
4°C for 35 min (Avanti J-25TM Centrifuge - Beckman Coulter, rotor JA-25.50). After 
centrifugation the supernatant was discarded and the white DNA pellet was resuspended 
in 500 µl 70% ethanol to remove salts and transferred into a sterile 1.5 ml tube. The 
suspension was then spun down at 20,000 g and 4°C for 5 min (Eppendorf Centrifuge 
5417 C or R - Eppendorf). After centrifugation the supernatant was discarded again and 
the DNA pellet was washed with 200 µl 70% ethanol. Again the DNA was precipitated 
by centrifugation at 20,000 g and 4°C for 5 min (Eppendorf Centrifuge). The residual 
pellet was then dried on air for 5 - 10 min and dissolved in 180-200 µl TE or nuclease-
free water. DNA concentration was measured by UV spectrophotometry at 260 nm and 
DNA purity was also monitored by using the 260 nm:280 nm ratio, where the optimum 
is a value of 1.8. Finally, the purified DNA was aliquoted for further use and stored at -
20°C. 
 
2.1.4.2.PureYieldTM Plasmid Maxiprep System – Promega  
Cells were harvested at 6,000 g and 4°C for 15 min (Avanti J-25TM Centrifuge - 
Beckman Coulter, rotor JLA10.500). The pellet was then resuspended in 12 ml 
Resuspension Solution and transferred into a sterile 50 ml centrifugation tube. 12 ml 
Cell Lysis Solution were added to start the lysis of the bacteria. The suspension was 
gently inverted 3 - 5x and incubated at RT for 3 min. Lysis was stopped by addition of 
12 ml Neutralisation Solution inverting the mixture for 10 – 15x. Sufficient mixing is 
essential in this step to ensure precipitation of the cellular debris. The mixture was then 
centrifuged at 14,000 g and RT for 20 min (Avanti J-25TM Centrifuge - Beckman 
Coulter, rotor JA-25.50) to deposit the debris. Now a blue PureYieldTM Clearing 
Column was placed on the top of a white, silica-membrane PureYieldTM Maxi Binding 
Column. This column stack was fixed onto a special vacuum manifold (Vac-Man® 
Laboratory Vacuum Manifold - Promega). Approximately half of the lysate was poured 
into the blue clearing column and maximal vacuum was applied until the liquid passed 
both columns. Then the remainder of the lysate was also added to the columns. DNA 
should have bound to the binding membrane of the column by this procedure. Now the 
vacuum was slowly released to remove the clearing column, the binding column 
remained on the vacuum manifold. The binding column was then washed by addition of 
5 ml Endotoxin Removal Wash to get rid of endotoxins, RNA and protein, and 
appliance of the vacuum. 20 ml of Column Wash were added and passed through the 
membrane. The membrane was dried for 10 or more min by applying the vacuum onto 
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the empty binding column. Ethanol was removed from the tip and the outside of the 
column with a paper towel. Afterwards the binding column was inserted inside the 
elution device on the top of a sterile 1.5 ml tube. This construct was again placed on the 
vacuum manifold. 600 µl of sterile, nuclease-free water were added and DNA was 
eluted by applying the vacuum. 
DNA concentration was measured by UV spectrophotometry at 260 nm and DNA 
purity was also monitored by using the 260 nm:280 nm ratio, where the optimum is a 
value of 1.8. Finally the maxiprep was aliquoted for further use and stored at -20°C. 
 
 
2.1.5. Transfection of HeLa cells 
Transfections were usually performed using the FuGENE® HD Transfection Reagent 
from Roche. Polyethylenimine (PEI) was also tested for transfection (PEI:DNA ratio 
[µl:µg] of 3:1) (Boussif, O. et al. 1995). 
 
2.1.5.1.Transient transfection of HeLa cells using FuGENE® HD 
Transfection Reagent  
For lipofection, a FuGENE® HD Transfection Reagent (Roche):DNA [µl:µg] ratio of 
8:3 was used. The whole procedure was performed under a sterile hood.  
350,000 HeLa cells per Ø 6 cm dish were cultured with 5 ml of DMEM with 10% FCS 
for 24 h. Before starting the procedure, HeLa Medium and OPTI-MEM® (GIBCO) were 
pre-warmed in a water bath at 37°C for at least 30 min. Then the medium was changed 
(5 ml per dish) and cells were put back into the incubator (37°C, 5% CO2) to adjust 
them to the new medium for 30 – 60 min. In the meantime, 230 µl pre-warmed OPTI-
MEM® (serum-free medium) were put into a sterile 1.5 ml tube and 7.5 µg of purified 
plasmid DNA were added.  
For transfection of single plasmids, 7.5 µg plasmid DNA were used. Cotransfections 
were carried out with 7.5 µg of the plasmid DNA of interest together with 100 ng of 
plasmids either for wt TCR-ß mRNA (plasmid #333) or TCR-ß mRNA with a 
premature termination codon (PTC) (plasmid #337) (Li, S. et al. 1997)which serve as 
targets for NMD decay.  
The glass vial with the FuGENE® HD Transfection Reagent was vortexed. 20 µl of 
FuGENE® HD Transfection Reagent consisting of lipids and other components in 80% 
ethanol were then added to the OPTI-MEM® and the DNA. It is essential in this step to 
avoid contact with the plastic tube wall, because chemical residues can decrease the 
biological activity of the transfection reagent. The mix was carefully vortexed for 15 sec 
to mingle. Then the mixture was incubated for 15 min at RT to allow lipid vesicles to 
from around the DNA. The mixture was added drop by drop to the cells in the dish and 
evenly distributed. Cells were then put back into the incubator and 24 h after the 
procedure the transfection efficiency was evaluated according to the EGFP expression 
under the microscope (Leica MZ 16F Microscope).  
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2.1.6. Protein lysate of HeLa cells 
Protein lysates of HeLa cells were usually performed 3 days after transfection to allow 
downregulation by shRNAs to take place efficiently. Transfection efficiency was 
evaluated according to the EGFP expression under the microscope (Leica MZ 16F 
Microscope - Leica). Cells were also checked for morphology. The lysate was only 
made if the cells looked healthy. Pictures of the transfected cells were taken (Leica 
Application Suite Version 2.6.0 R1 [Build 1192]) to compare different samples and 
their transfection rates. Afterwards, pictures were assembled and arranged with Adobe 
Photoshop CS3 and/or Adobe InDesign CS2. Images were not modified other than 
adjustment of levels, brightness, contrast and magnification. 
 
First PBS was pre-warmed, 1 protease inhibitor tablet (Roche) was added to the 
prepared Lysis Buffer and a microcentrifuge (Eppendorf Centrifuge 5417 C or R - 
Eppendorf) was pre-cooled. Second, the medium was taken off and the cells were once 
washed with pre-warmed PBS. All following steps were then performed on ice or 
cooled to limit protease activities. 250 µl of the Lysis Buffer (50 mM Tris pH 7.5, 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100) where added per Ø 6 cm dish. Cells were 
scraped from the dish and lysis was promoted by pipetting up and down 10 times. The 
lysate was transferred into a 1.5 ml tube. Then a centrifugation step at 20,000 g and 4°C 
for 5 min separated the lysate from the cellular debris. The supernatant was transferred 
into a new 1.5 ml tube. Protein concentration was ascertained by the Bradford Assay 
(Bio-Rad Protein Assay - Bio-Rad). This assay is based on the binding of the sulfonate 
groups of the dye Coomassie Brilliant Blue G-250 to the positively charged groups of 
the protein at a low pH. Due to the binding, the absorption maximum of the dye shifts 
from 465 nm (anionic form) to 595 nm (ionic form). After protein measurement, 100 µl 
4x Laemmli Buffer were added to the lysate and the proteins were denatured at 95°C for 
10 min. Afterwards the lysate was either immediately used for a Western Blot or stored 
at -20°C for later use. 
 
 
2.1.7. Western Blot (WB) 
A Western Blot was then made to confirm the downregulation of a protein by the 
corresponding, designed shRNA. 
 
2.1.7.1.SDS (Sodium dodecyl sulphate)-polyacrylamid gel (SDS-PA gel) 
and SDS-polyacrylamid gel electrophoresis (SDS-PAGE) 
SDS binds proteins thereby yielding negatively charged complexes that now run 
according to their molecular size. Due to this fact, proteins can be separated under the 
term of their molecular weight by applying electric power. Protein samples move 
towards the anode through the gel pores as soon as the electric current is applied. 
Thereby small proteins are much faster than larger ones. These facts lead to a separation 
with the large proteins closer to the slots of the gel and the small proteins closer to the 
lower edge of the gel. 
Based on Laemmli, 1.5 mm thick 10% PA gels for SDS-PAGE were prepared as 
described in the Material section (Laemmli, U. K. 1970).  
Usually 75 ug of the HeLa lysates (see 2.1.6 Protein lysate of HeLa cells) and equal 
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volumes of proteins isolations with TRIzol® Reagent (see 2.3.1.1 Total RNA & protein 
isolation with TRIzol® Reagent (Invitrogen)) were denaturated at 95°C for 10 min 
before loading into the gel slots (always together with untreated, untransfected control 
samples). 3 µl of PageRulerTM Prestained Proteins Ladder (Fermentas) were used as 
molecular weight marker. Constant electric voltage of 130 V was applied for 1 h and 20 
min (Power Pac HC and Power Pac 300 power supply for electrophoresis - Bio-Rad) to 
separated the proteins. 
 
2.1.7.2.Western Blot 
Proteins separated by a SDS-PAGE were then transferred on a nitrocellulose membrane 
(0.2 µm pore size; Schleicher & Schuell) as Western Blot. For the transfer and Western 
blotting, the tank blotting system from Bio-Rad was used. First 2 sponges, the filter 
papers and the membrane were soaked and equilibrated in cold 1x Blotting Buffer. 
Second the sandwich was assembled in the following order starting from the cathode: 
sponge, 3 filter papers, gel, membrane, 3 filter papers and sponge. So the negatively 
charged proteins move towards the anode and thereby attach to the membrane. Proteins 
were blotted at constant amperage of 250 mA for 90 min (Power Pac HC or 300 power 
supplies, Bio-Rad) in the cold room at 4°C and additionally cooled with ice. To confirm 
the quality of the transfer and for later cutting of the membrane at the desired molecular 
sizes, the membrane was then stained with Ponceau S. Usually a photo (using the 
Peqlab imaging system with UV/IR interference filter type F590 – Peqlab) was taken to 
make sure that equal amount of the samples were loaded (also confirmed by an α-
Tubulin staining later on). The membrane was then cut according to the marker for the 
following probing of the proteins of interest. Blocking of the membrane was performed 
for at least 30 min at RT in Detector Block solution (KPL) while shaking (shaker GFL 
3015 – GFL®). Thereby, unspecific binding sides were saturated to reduce the 
background of the detection. Incubation with the specific primary antibody was either 
done for 2 h at RT (shaking) or o/n at 4°C (shaking). Afterwards the membrane stripes 
were washed 3x 5 min with TBS-T Buffer (see 1.7 Buffers & solutions). The secondary 
antibody was now added for 45 min at RT (shielded from light). Finally, the blot was 
washed as previously described and scanned using the Odyssey® Infrared Imaging 
System (LI-COR® Biosciences; software: Odyssey® Application Software 2.1). Pictures 
were then assembled and arranged with Adobe Photoshop CS3 and/or Adobe InDesign 
CS2. Images were not modified other than adjustment of levels, brightness, contrast and 
magnification. 
 
 
2.1.8. Quantification of downregulation of proteins via Western 
blotting 
Western Blot Quantifications were performed using the Odyssey® Infrared Imaging 
System (LI-COR® Biosciences) with the Odyssey® Application Software 2.1 (see 
manufacturer’s manual).  
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2.2. Immunocytochemistry 
Once the knockdown of the desired protein was confirmed by Western Blot, 
immunofluorescence was performed to look at the downregulation in situ.  
 
2.2.1. Transient transfection of HeLa cells on coverslips using 
FuGENE® HD Transfection Reagent  
For lipofection, a FuGENE® HD Transfection Reagent (Roche):DNA [µl:µg] ratio of 
8:3 was used. The whole procedure was performed under a sterile hood. 350,000 HeLa 
cells per Ø 6 cm dish containing 8 sterile Ø 10 mm glass coverslips (CSs) were cultured 
with DMEM and 10% FCS for 24 h. The CSs were transferred to a 12-well plate, 1 CS 
per well. 1 ml of fresh medium was added per well. The transfection procedure was then 
carried out as in 2.1.5 Transfection of HeLa cells using 50 µl pre-warmed OPTI-MEM® 
(serum-free medium), 1.5 µg of plasmid DNA from a maxiprep and 4 µl of FuGENE® 
HD Transfection Reagent per CS and well. 
 
2.2.2. Immunofluorescence  
3 days after transfection of normal HeLa cells and 5 days after transfection of the stable 
ß-Globin HeLa cell lines (see 1.6 Cells), cells were fixed and stained.  
First the medium was taken off and the CSs were washed with pre-warmed PBS (see 
1.7 Buffers & solutions). Cells were then fixed with 4% paraformaldehyde (PFA) in 
PBS for 15 min at RT. CSs were washed 3x for 5 min with PBS while shaking (shaker 
GFL 3015 – GFL). Permeabilisation was achieved using 1% Triton X-100 in PBS for 5 
min at RT. Again cells were washed as described. Blocking Solution was added for at 
least 30 min at RT. The following antibody solutions were always diluted in 10% 
Blocking Solution in PBS. Incubation with the primary antibody (see 1.3 Antibodies) 
was either done for 2 h at RT or o/n at 4°C. Cells were washed as previously. The 
secondary antibody (see 1.3 Antibodies) was applied for 45 min at RT and secured from 
light. CSs were washed again and incubated in DAPI solution in the dark for 3 min to 
visualise nuclei. Finally, the CSs were washed with PBS as previously and then once 
with ddH2O and mounted with 8 µl of Mowiol onto object glass slides (Roth). 
 
2.2.3. Microscopy of immunocytochemical preparations 
Stained CSs were then investigated using an Axioplan microscope (Zeiss). Pictures of 
the stained untransfected and transfected cells were taken using analySISB software 
(Olympus) and assembled with Adobe Photoshop CS3 and/or Adobe InDesign CS2. 
Images were not modified other than adjustment of levels, brightness, contrast and 
magnification. 
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2.3. Semiquantitative PCR  
Conventional HeLa cells were cotransfected (see 2.1.5.1 Transient transfection of HeLa 
cells using FuGENE® HD Transfection Reagent) with the respective shRNA plasmid 
and a plasmid coding for TCR-ß mRNA, either wt (plasmid #333) or with a PTC 
(plasmid #337)(Li, S. et al. 1997), to monitor NMD.  
 
2.3.1. RNA isolation 
72 h after cotransfection, HeLa cells were washed once with pre-warmed PBS. Total 
RNA and proteins were usually isolated using the TRIzol® Reagent (Invitrogen) 
according to the manufacturer’s protocol. Two other RNA isolation kits were also tested 
in order to fine-tune the quality and the amount of the isolated RNA: the RNeasy Midi 
Kit (Qiagen) and the mirVanaTM miRNA Isolation Kit (Ambion). These 2 kits were 
used according to the manufacturer. 
 
RNA handling in general: 
 
To avoid RNase contamination when working with RNA samples the following 
precautions were taken: 
 
• The working space was cleaned with ethanol and RNaseZAP® (Sigma®) 
• Gloves were worn and frequently cleaned with 75% ethanol or frequently 
disposed 
• Water was treated with 0.1% diethylpyrocarbonate (DEPC) 
• RNA grade chemicals were used to prepare solutions 
• Barrier tips and pipettes reserved for RNA work only were used for pipetting  
• RNase-free tubes were used for RNA experiments (Biopur® Safe-Lock micro 
test tubes – Eppendorf) 
• Total RNA was stored at -80°C in DEPC-treated water with RiboLockTM 
Ribonuclease Inhibitor (Fermentas) 
 
2.3.1.1.Total RNA and protein isolation with TRIzol® Reagent 
(Invitrogen) 
The TRIzol® Reagent is a mono-phasic solution of phenol and guanidine isothiocyanate 
and is an improvement of the single-step RNA isolation (Chomczynski, P. et al. 1987). 
Handling of samples containing TRIzol® Reagent, chloroform or guanidine 
hydrochloride was always done under a chemical fume hood. Using the TRIzol® 
Reagent allows to isolate total RNA and protein simultaneously from the same sample. 
 
72 h after transfection the viability, the morphology of the cells as well as the 
transfection efficiency according to their EGFP expression was analyzed using the 
Leica MZ 16F microscope (Leica). Pictures were taken using the Leica Application 
Suite Version 2.6.0 R1 [Build 1192] software (Leica) to record the state of the cells. 
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RNA isolation 
 
The medium was discarded and cells were 1x washed with pre-warmed PBS. 1.6 ml of 
TRIzol® Reagent were added. After 2 – 3 min of incubation cells were resuspended in 
TRIzol® Reagent by pipetting up and down. The suspension was transferred into a 
sterile, RNase-free 2 ml tube (Biopur® Safe-Lock micro test tubes - Eppendorf), 
vortexed for 15 sec and incubated at RT for 10 min. TRIzol® Reagent disrupts cells and 
dissolves cell components, but maintains the integrity of the RNA, DNA and the 
proteins. 320 µl of chloroform were added. The mixture was again vortexed for 15 sec 
and incubated at RT for 5 min before it was centrifuged in a microcentrifuge at 12,000 g 
and 4°C for 15 min to allow the pink organic phase, the interphase and the aqueous 
phase to separate. After centrifugation the upper, aqueous phase containing the RNA, 
which should be ~ 60% of the initial TRIzol® Reagent volume, was transferred into an 
RNase-free 1.5 ml tube (Biopur® Safe-Lock micro test tubes - Eppendorf). 1 µl of 
glycogen (20 µg/µl) diluted in diethylpyrocarbonate (DEPC)-treated H2O which 
facilitates the precipitation and 800 µl of isopropanol were added. This mix was 
incubated for 10 min at RT. The RNA was now precipitated by centrifugation at 12,000 
g and 4°C for 10 min. Afterwards the RNA pellet at the bottom of the tube was washed 
with 1.5 ml 75% ethanol. RNA was again pelleted by centrifugation at 7,600 g and 4°C 
for 7 min. The pellet was air-dried for 5 – 10 min. It is important that the RNA pellet 
does not dry out completely, otherwise it can hardly be re-dissolved in DEPC water 
afterwards. To facilitate this step, the DEPC water (15 µl each pellet) was pre-warmed 
at 50°C. RNA was completely solved at 50°C, shaking at the thermomixer (Eppendorf) 
at 350 rpm for 5 min.  
 
Protein isolation 
 
Proteins were isolated in parallel from the organic phase after the addition of 
chloroform according to the manufacturer’s protocol.  
The aqueous phase was removed completely. 500 µl of absolute ethanol were added to 
precipitate the DNA from the interphase. The mixture was 5x inverted and incubated for 
2 – 3 min at RT. DNA was pelleted in a microcentrifuge (Eppendorf Centrifuge 5417 C 
or R - Eppendorf) at 2,000 x g and 4°C for 5 min. The phenol-ethanol supernatant (~800 
µl) was then transferred into two 2 ml tubes and 1.5 ml isopropanol were added per 
tube. The mix was inverted 5x and incubated at RT for 10 min. Proteins were pelleted at 
12,000 g and 4°C for 10 min in a microcentrifuge. The pellet was washed with 2 ml 0.3 
M guanidine hydrochloride in 95% ethanol for 20 min at RT. After centrifugation at 
7,600 g and 4°C for 5 min the supernatant was discarded. This washing procedure was 
performed 3x in total. During the last guanidine hydrochloride washing step the 2 
protein pellets of the same sample were fused in one 2 ml tube. 2 ml absolute ethanol 
were added for the last washing step to remove salts, vortexed and incubated for 10 min 
at RT. Again the samples were centrifuged at 7,600 g and 4°C for 5 min. The protein 
pellet was air-dried until it started to get transparent. 4x Laemmli Buffer was now added 
according to the pellet size. The protein pellet was resuspended at the thermomixer 
(Eppendorf) at 95°C and 450 rpm for 10 min. Afterwards the protein suspension was 
either immediately used for a Western Blot (see 2.1.7 Western Blot) or stored at -20°C 
for later use. 
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2.3.1.2.DNase digestion 
Possible DNA contaminations of the RNA isolation were reduced using 
Deoxyribonuclease I (Sigma) according to the manufacturer. 
RNA concentration was measured using UV spectrophotometry at 260 nm and RNA 
purity was also monitored by using the 260 nm:280 nm ratio, where the optimum is a 
value of 2. 
 
 
2.3.2. Reverse transcription PCR (RT-PCR) 
Usually 1 – 3 µg of total RNA (see 2.3.1.1 Total RNA & protein isolation with TRIzol® 
Reagent (Invitrogen)) were transcribed using Moloney Murine Leukemia Virus Reverse 
Transcriptase, RNase H Minus, Point Mutant (M-MLV RT (H-); Promega) ((Roth, M. J. 
et al. 1985) and Sambrook J., Fritsch E. F., Maniatia T.; Molecular Cloning: A 
Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Habor; 1989). 
 
The First Strand cDNA Synthesis Kit (Fermentas) and the iScriptTM cDNA Synthesis 
Kit (Bio-Rad) were also used for some samples according to the manufacturer’s 
protocol. 
 
2.3.2.1.RT-PCR using random primers or TCR-ß reverse primers 
RNA solution (1 – 3 µg total RNA) 1 µl 
Random Primers (0.5 µg/µl; Promega) 1 µl 
DEPC H2O 15 µl 
 
Σ 17 µl 
 
These reactions were prepared in a 0.2 ml PCR tube (Eppendorf). To melt secondary 
structures within the template, the mix was heated at 70°C for 5 min using the PCR 
cycler. Afterwards the mix was cooled down to 4°C for 5 min to prevent reformation of 
secondary structures. 
In some experiments, specific TCR-ß reverse primers were used instead of the random 
primers in order to enrich the PCR products with the desired TCR-ß fragments. This 
mix was then also heated at 70°C for 5 min, but incubated afterwards at 58°C, which is 
the annealing temperature of the TCR-ß reverse primer, for 10 min. 
 
The following reagents were now added to each PCR tube: 
 
MLV Reverse Transcriptase 5X Reaction Buffer (Promega) 5 µl 
dNTPs (10 mM for dATP, dCTP, dGTP, dTTP; Fermentas) 1.5 µl 
RiboLockTM Ribonuclease Inhibitor (40 u/µl; Fermentas)  0.5 µl 
M-MLV RT (H-) (200 u/µl; Promega) 1 µl 
 
Σ 25 µl 
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PCR cycle scheme: 
 
- 25°C for 10 min 
- 40°C for 1 h 
- 70°C for 15 min 
- 4°C for ever 
 
The PCR scheme was modified for the specific TCR-ß reverse primer. 
 
Modified PCR cycle scheme: 
 
- 25°C for 10 min 
- 55°C for 1 h 
- 70°C for 15 min 
- 4°C for ever 
 
 
2.3.3. Semiquantitative PCR  
PCR was performed to amplify TCR-ß pre- and mRNA to monitor the efficiency and 
continuance of the NMD process. 
 
1x reaction volume: 
 
10x Taq buffer (Fermentas) 5 µl 
MgCl2 (25 mM; Fermentas) 3 µl 
dNTPs (10 mM for dATP, dCTP, dGTP, dTTP; Fermentas) 1 µl 
TCR-ß forward primer (10 µM; Sigma) 1 µl 
TCR-ß reverse primer (10 µM; Sigma) 1 µl 
ddH2O 38.5 – x µl 
cDNA x µl 
Taq DNA Polymerase (5 u/µl; Fermentas) 0.5 µl 
 
Σ 50 µl 
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Primers (5’-3’): 
 
Notation Orientation Sequence Reference 
TCR-ß-
mRNA for 
forward GACTGACTGTTCTCGAGG 
TCR-β-pre-
mRNA 
forward GTACCTGATCCAGACAGTTA 
TCR-β-
REV 
reverse GTCAAGGTGTCAACGAGGAA
C. Giorgi, 
personal 
communication 
 
The resulting PCR product for the TCR-ß pre-mRNA was ~200 nt and for the TCR-ß 
mRNA ~150 nt long. These fragments were analysed by agarose gel electrophoresis. 
 
In some experiments, GAPDH or tubulin primers were added as an internal standard in 
order to normalize PCR products. The GAPDH and tubulin PCR products have a size of 
~500 bp each. 
 
Notation Orientation Sequence 
GAPDHfor forward GAGCTGAACGGGAAGCTCAC 
GAPDHrev reverse GGAGAGTGCTCAGTGTTGGG 
ßtubulin for forward AGACCGCATCATGAACACCT 
ßtubulin rev reverse TCTTGGAGTCGAACATCTGC 
 
PCR cycle scheme: 
 
- 94°C for 40 sec 1 cycle 
 
- 94°C for 40 sec 
- 58°C/60°C for 40 sec 30 cycles 
- 72°C for 1 min  
 
 
- 72°C for 5 min  1 cycle 
- 4°C for ever 
 
Annealing temperatures for PCR: 
 
TCR-ß pre-mRNA ? 60°C 
TCR-ß mRNA ? 58°C 
 
After PCR 8 µl 6x Loading Dye (Fermentas) were added to each PCR reaction and 30 
µl of this PCR mixture were then loaded onto a 2% agarose gel. 15 µl of the 
GeneRulerTM 100 bp DNA Ladder (Fermentas) were loaded in parallel in order to 
determine the size. 100 V were applied for 50 min. Afterwards pictures of the gels were 
taken using an UV/IR imaging system (Peqlab imaging system with UV/IR interference 
filter type F590 – Peqlab). Pictures were then assembled and arranged with Adobe 
Photoshop CS3 and/or Adobe InDesign CS2. Images were not modified other than 
adjustment of levels, brightness, contrast and magnification. 
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2.4. Real-time PCR 
For the real-time PCR experiments, instead of the conventional HeLa cells 2 stable 
HeLa cell lines were used, which express NMD mRNA targets (ß-Globin or TCR-ß) 
with or without PTC. These stable cell lines were a generous gift from Dr. Oliver 
Mühlemann (Institute of Cell Biology, University of Bern, Switzerland). 
 
Stable HeLa cell lines: 
 
ß-Globin HeLa cell lines: 
Notation Construct Reference 
HeLa wt ß -Globin PTC- (Thermann, R. et al. 1998) 
HeLa NS39 ß-Globin PTC+ (Thermann, R. et al. 1998) 
 
TCR-ß HeLa cell lines: 
Notation Construct Reference 
HeLa 290F PTC- (Muhlemann, O. et al. 
2001) 
HeLa 593C PTC+ (Muhlemann, O. et al. 
2001) 
 
In order to increase the efficiency of the downregulation of the NMD assay candidates, 
cells were also selected with neomycin (see 2.4.4 Neomycin selection). 
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2.4.1. Temperature gradient PCR for optimisation of annealing 
temperature of primers 
Real-time primer (5’-3’): 
 
Target & 
notation 
Orientation Sequence Resulting 
fragment 
size 
Reference 
ß-Globin  
ß-globin-
Morris-
for 
forward TTGGGGATCTGTCCACTCC (Morris, C. 
et al. 2007)
ß-globin-
Morris-
rev 
reverse CACACCAGCCACCACTTTC 
277 bp 
(Morris, C. 
et al. 2007)
GAPDH  
Gap-F-2   forward ATTCTTCCACCTTTGATGC 
Gap-R-2   reverse GTCCACCACCCTGTTGCTGTA 
104 bp Y. Xie 
Tubulin  
Tub-F-2   forward TGTCTTCCATCACTGCTTCC 
Tub-R-2   reverse TGTTCATGGTAGGCTTTCTCAG
150 bp Y. Xie 
 
1x reaction volume: 
 
10x Taq buffer (Fermentas) 2.5 µl 
MgCl2 (25 mM; Fermentas) 1.5 µl 
dNTPs (10 mM for dATP, dCTP, dGTP, dTTP; Fermentas) 0.5 µl 
ß-globin-Morris-for (400 nM; Sigma) 2 µl 
ß-globin-Morris-rev (400 nM; Sigma) 2 µl 
ddH2O 38.5 – x µl 
cDNA (0.5 µg from wt ß-Globin cell line) x µl 
Taq (5 u/µl; Fermentas) 0.5 µl 
 
Σ 50 µl 
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PCR cycle scheme: 
 
- 95°C for 4 min 1 cycle 
 
- 95°C for 30 sec 
- Increasing temperature gradient with each cycle for 45 sec   30 cycles 
- 72°C for 45 sec  
 
 
- 72°C for 5 min 1 cycle 
- 4°C for ever 
 
After the PCR, 5 µl 6x Loading Dye (Fermentas) were added to each PCR tube and 18 
µl of the PCR mixture were loaded onto a 2% agarose gel in parallel with 15 µl of the 
GeneRulerTM 100 bp DNA Ladder (Fermentas). 100 V were applied for 50 min. 
Afterwards, pictures were taken, assembled and modified as described in 2.3.3 
Semiquantitative PCR. 
 
 
2.4.2. Optimisation of real-time PCR conditions 
The template amounts, primer concentrations, setup for the dilution series and the 
sealing method (Microseal® 'B' Film (optically clear) and Flat Cap Stripes (optical) – 
Bio-Rad) of the PCR plates were also optimised for real-time PCR. 
 
 
2.4.3. Optimised real-time PCR cycle scheme 
Template amount: 
 
200 ng cDNA (see 2.3.2 Reverse transcription PCR (RT-PCR)) of wt or NS39 ß-Globin 
HeLa cells were used for real-time PCR. 
 
1x reaction volume: 
 
iQTM SYBR® Green Supermix (Bio-Rad) 12.5 µl 
ß-globin-Morris-for (200 nM; Sigma) 1.5 µl 
ß-globin-Morris-rev (200 nM; Sigma) 1.5 µl 
ddH2O 9.5 - x µl 
cDNA (200 ng)  x µl 
 
Σ 25 µl 
 
Samples and dilution series were analysed in triplicates, therefore mastermixes were 
prepared. Dilution series were made by a dilution factor of 4. In total, 300 nM of each 
ß-globin primer and 400 nM of the GAPDH and tubulin primers were used on 200 ng 
cDNA template. The 96-well plates were sealed using Flat Cap Stripes (optical) (Bio-
Rad) preventing evaporation. 
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PCR cycle scheme: 
 
- 95°C for 3 min 1 cycle 
 
- 95°C for 15 sec 55 cycles 
- 55°C for 40 sec 
 
Melting curve 
 
- 55°C - 95°C (+0.5°C per cycle) for 30 sec for each temperature               81 cycles 
 
After the PCR, 5 µl 6x Loading Dye (Fermentas) were added to each PCR tube and 20 
µl of the PCR mixture were loaded onto a 2% agarose gel in parallel with 12 µl of the 
GeneRulerTM 100 bp DNA Ladder (Fermentas). 100 V were applied for 50 min. 
Afterwards, pictures were taken, assembled and modified as described in 2.3.3 
Semiquantitative PCR. 
 
 
2.4.4. Neomycin selection 
The reasons to pick neomycin (neo) for selection were the following: neo selection is a 
common used tool for the generation of stable cell lines and selection of the desired 
genotype. For example, the tested stable TCR-ß cell lines were also created via neo and 
respectively geneticin (G418) selection (Muhlemann, O. et al. 2001). Neo and geneticin 
were also suggested for selection in the manual of the pSUPERIOR.neo+gfp vector 
from OligoEngine.  
Neo is an aminoglycoside antibiotic. In pro- and eukaryotic cells, this antibiotic blocks 
the protein synthesis by binding ribosomal subunits and inhibiting the translocation of 
the peptidyl-tRNA from the A-site to the P-site. This also causes misreading of the 
mRNA hindering the cell to synthesise proteins vital to its survival and growth.  
G418 is also an aminoglycoside antibiotic which blocks protein synthesis more 
efficiently than neo in eukaryotic cells. Therefore, geneticin is used instead of neo for 
selection in eukaryotic cells.  
After transfection (see 2.1.5 Transfection of HeLa cells) of the ß-Globin HeLa cell lines, 
the cells were kept in medium (DMEM + 10% FCS) containing the transfection reagent 
(FuGENE® HD Transfection Reagent - Roche) and the plasmid DNA for 24 hours. 
Then selection was induced using Geneticin® G-418 Sulphate (Gibco®) diluted in 
ddH2O (sterile filtrated; Rotilabo®-Syringe filter sterile; 0.22 µm; PVDF - Roth) which 
was applied to the medium (600 µg/ml final concentration). The medium and the neo 
solution were exchanged every 24 h for 7 days in total. Untransfected control dishes 
were treated equally with G418 in parallel to monitor the occurrence of spontaneous or 
persistent antibiotic resistant cells. Transfected cell samples were incubated with G418 
until almost all cells in the controls were killed. 
Transfection efficiency was evaluated according to the EGFP expression under the 
microscope (Leica MZ 16F Microscope - Leica). In addition, the cells were checked for 
their morphology and their physiological status. Pictures of the transfected cells and 
controls were taken (Leica Application Suite Version 2.6.0 R1 [Build 1192]) and 
assembled with Adobe Photoshop CS3 and/or Adobe InDesign CS2. Images were not 
modified other than adjustment of levels, brightness, contrast and magnification. 
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2.5. Nucleofection of embryonic day 17 (E17) rat 
hippocampal neurons 
Nucleofection is a method of transfection with high efficiency, especially for post-
mitotic cells such as hippocampal neurons. In general, neurons are very sensitive to 
mechanical and physiological stress, so handling of the cultures should be quick and 
careful. The time span between the recovery of the neurons and the nucleofection 
should be as short as possible. In order to obtain high transfection efficiencies and to 
prohibit cellular stress or death, plasmid DNA preparations have to be very pure. The 
removal of endotoxins is also crucial for the survival of the neurons. Hence, the 
Endofree Plasmid Maxi Kit (Qiagen) was exclusively used for DNA preparation. Air 
bubbles in the culture suspension shall also be avoided during nucleofection, because 
they interfere with the flow of the electrical currents. To limit the stress after 
nucleofection, the neurons were transferred form the nucleofection cuvettes into poly-L-
lysine-coated culture dishes with equilibrated medium as fast as possible. The neurons 
were then incubated for 3 days at 37°C and 5% CO2. This incubation step allows the 
expression of the transgenes and the knockdown of the corresponding proteins. 
In these experiments, 10 and 20 µg plasmid DNA were tested for their transfection 
efficiencies, which were checked under the Leica MZ 16F Microscope (Leica). Pictures 
were taken to monitor the differences. Nucleofection was carried out with the O-003 
program in any case (included in Nucleofector II “S” software version S4-4 or above; 
Amaxa). 
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RESULTS 
1. CREATION AND TESTING OF shRNAS FOR 
NMD ASSAY CANDIDATES 
 
The aim of this diploma thesis was to establish a nonsense-mediated decay (NMD) 
assay in the laboratory. The design of the assay was based on the method and assay 
developed by Miles Wilkinson and coworkers (Carter, M. S. et al. 1995; Li, S. et al. 
1997; Muhlemann, O. et al. 2001). They transiently transfected HeLa cells with a NMD 
reporter construct (TCR-ß or ß-globin) for the expression of either a wild type (wt) or a 
premature termination codon (PTC)-containing mRNA (Carter, M. S. et al. 1995; Li, S. 
et al. 1997).  
With this NMD assay, I wanted to investigate the role of new putative candidates for the 
NMD process. In a first step, the NMD assay should be established in HeLa cells as 
shown by other groups (Miles Wilkinson and coworkers and (Carter, M. S. et al. 1995; 
Li, S. et al. 1997; Muhlemann, O. et al. 2001)). In addition this is cheaper, faster and 
experimentally easier to set up. In a second step, which is not part of this diploma thesis, 
the assay can then be adapted for hippocampal neurons, which are the main focus of the 
laboratory. 
Usually RNAs harbouring PTCs are recognised and degraded by the NMD machinery. 
This mechanism is essential to prohibit the translation of truncated proteins with 
dominant-negative or deleterious gain-of-function activities (for a summary and 
overview see (Chang, Y. F. et al. 2007)). So if the NMD process is impaired, which is 
often the case in diseases e.g. cancer, harmful and non-functional mRNAs with PTCs 
accumulate in the cell leading to further derailing of the cell’s metabolism. The so-
called up-frameshift (UPF) proteins are the core components of the NMD machinery 
(Lykke-Andersen, J. et al. 2000). These UPF proteins are recruited to the PTC-
containing mRNA via interactions with the exon junction complex (EJC) components 
(Lykke-Andersen, J. et al. 2000; Kashima, I. et al. 2006). The EJC plays a major role in 
the decay of incorrect transcripts and therefore in the NMD process (Palacios, I. M. et 
al. 2004). 
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The RNA-binding protein Btz is a core component of the EJC (Degot, S. et al. 2004; 
Palacios, I. M. et al. 2004; Tange, T. O. et al. 2005). As a component of the EJC, Btz 
plays a major role in NMD (Palacios, I. M. et al. 2004). In Btz-depleted HeLa cells, the 
NMD process is no longer functional and mRNAs with PTCs accumulate, giving rise to 
truncated proteins (Palacios, I. M. et al. 2004). The same effect was also shown for 
Upf1 (Sun, X. et al. 1998) and eIF4AIII (Ferraiuolo, M. A. et al. 2004). So if an 
essential component of the NMD machinery is missing, the process will be impaired. 
 
The candidates for the NMD assay were selected based on previous work in our 
laboratory by Dr. Daniela Karra (Daniela Karra, PhD thesis 2008). In her PhD thesis, 
she isolated endogenous Btz-ribonucleoprotein particles (RNPs) from rat brain and 
identified the protein components via mass spectrometry in cooperation with Dr. Keiryn 
Bennett (CeMM, Vienna). In addition, she adopted a procedure that made it possible to 
distinguish between RNA-mediated and possible protein-protein interactors. In a first 
round of experiments, only putative protein-protein interactors were chosen as 
candidates for the NMD assay.  
The candidates for the NMD assay were: NPM1, DDX5, U5-116 kDa, RBMX and 
RBM4. For NPM1 and the RNA helicase DDX5, previous data indicated a possible 
function in the regulation of incorrect transcripts (Bond, A. T. et al. 2001; Palaniswamy, 
V. et al. 2006).  
 
In order to investigate the role of those candidates in NMD, shRNA plasmids were 
designed. These plasmids express shRNAs, which selectively inactivate the 
corresponding proteins via RNA interference (RNAi) (Brummelkamp, T. R. et al. 2002; 
Brummelkamp, T. R. et al. 2002). I designed and cloned the shRNA plasmids for the 
selected candidates as described in the Methods section. Whenever possible, shRNAs 
were designed to target human and rat sequences, so that the assay could first be 
established in HeLa cells and later on also be used to knock down the respective protein 
in primary rat hippocampal neurons. The selected shRNA sequences were cloned into 
the pSUPERIOR.neo+gfp vector (OligoEngine) shown in Figure 3-1A. False positive 
clones were removed by BglII digestion, which only cuts the empty vector lacking any 
insert. Successful cloning of the desired shRNA sequence into the vector was then 
proven by colony PCR. The PCR products were loaded onto a 2% agarose gel. The little 
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shift in the size of the PCR product indicates the successful and accurate cloning 
(Figure 3-1B). The bands on the gel always had different intensities. So either the 
expression level of the shRNA construct varied from clone to clone and was for 
example especially low in clone 1 (CL1), or the differences were just due to different 
DNA amounts in the PCR reaction. 
According to the gel picture positive clones were chosen, the plasmid DNA was 
amplified in bacteria, isolated, concentration measured and the DNA was stored in 
small aliquots at-20°C for later use. 
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Figure 3-1: Generation of shRNA constructs. 
(A) pSUPERIOR.neo+gfp vector map. The pSUPERIOR.neo+gfp (OligoEngine) vector map was 
created using the computer program Lasergene (DNASTAR, Version 7.1.0 (44)). Oligos were designed, 
hybridised and cloned into this vector to get new shRNA plasmids. (B) Colony PCR. The picture shows 
an agarose gel from colony PCR, in this case for shNPM1 plasmid (#317). Clone 10 (CL10) was chosen 
further experiments. 18 µl of each PCR reaction including 6x Loading Dye (Fermentas) were separated 
on a 2% agarose gel in parallel with 12 µl of the GeneRuler™ 100 bp DNA Ladder (Fermentas). Primers 
were added in excess (* indicates the primer cloud). A vector containing the shRNA insert results in a 
317 bp PCR product (pos. clone). Without the insert, the PCR fragment is 261 bp long (neg. clone). The 
PCR product of an empty pSUPERIOR.neo+gfp vector was loaded as a control to detect the size shift of 
the fragments on the gel.  
AMP, ampicillin; H1 promoter, Polymerase-III H1-RNA gene promoter for expression of shRNAs; 
EGFP, Enhanced Green Fluorescent Protein; NEO, neomycin; f1(+) origin, origin for bacterial 
replication; CL, bacterial clone. 
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The purity and quantity of the plasmid DNA was crucial for the transfection efficiency, 
as previously shown (Zeitelhofer, M. et al. 2008).  
Usually, the quality of the plasmid DNA obtained with the maxiprep kit from Promega 
was not as convincing as the plasmid DNA from the maxiprep kit from Qiagen, 
although both kits include an endotoxin removal step. The purity and the concentration 
of the DNA were lower with the Promega kit, which resulted in lower transfection 
efficiencies (data not shown and (Zeitelhofer, M. et al. 2008)). So for all final and 
crucial experiments, exclusively the kit from Qiagen was used. 
 
The newly created shRNA plasmids were transiently transfected into conventional 
HeLa cells to test their potential to downregulate their corresponding proteins. Cells 
were lysed after 72 h and the knockdown of the corresponding protein was analysed via 
Western blotting. Quantification was performed using the Odyssey® Application 
Software 2.1 (see Methods section and the respective manual). ShRNA samples were 
always compared to an untransfected control lysate (=100% protein expression) and 
normalised to Tubulin. The EGFP signals on the Western Blots were also quantified and 
served as an indicator for the transfection efficiency.  
 
The subcellular localization of the candidate proteins in HeLa cells was analysed by 
immunostainings using commercially available antibodies against the respective 
protein. In order to visualize the effect of the shRNA plasmids in single cells and to 
overcome low transfection efficiencies immunocytochemistry experiments were 
performed. Therefore, HeLa cells on coverslips were transfected with the investigated 
shRNA plasmid and fixed 72 h after transfection. The staining procedure was performed 
as described in the Material section. 
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1.1. ShRNA plasmids targeting NPM1  
NPM1 was first identified as a multifunctional, predominately nucleolar protein and 
chaperone (Feuerstein, N. et al. 1987; Schmidt-Zachmann, M. S. et al. 1987). Its cellular 
activities include cell proliferation, nucleo-cytoplasmic shuttling, nucleic acid binding, 
ribonucleic cleavage and molecular chaperoning (Ye, K. 2005).  
 
Figures 3-2A and 3-3A show Western Blots for testing the effects of two distinct 
shRNA plasmids targeting NPM1 (shNPM1, plasmid #312 and #317). NPM1 proteins 
give a double band on the Western Blot, representing the unphosphorylated and 
phosphorylated NPM1, respectively. 
Using the shNPM1 plasmid #312, I observed a downregulation of NPM1 of 26.02% 
compared to the protein level in the untransfected control sample (UT=100%) 
(Figure 3-2B). This meant that the usual expression level of NPM1 was reduced by 
73.98%. Tubulin served as a loading control for the normalisation of the quantification. 
So the shNPM1 plasmid #312 had a strong effect on the expression of its corresponding 
protein. The EGFP signal normalised to the Tubulin signal indicated the high 
transfection efficiency of the shRNA shNPM1 plasmid #312.  
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Figure 3-2: Testing of one shNPM1 plasmid in HeLa cells. 
(A) Test of protein downregulation on Western Blot. Western Blot showing the downregulation of 
NPM1 protein upon transfection of HeLa cells with the shNPM1 plasmid (#312). NPM1 gives a double 
band on the Western Blot, representing the phosphorylated and unphosphorylated NPM1 (marked with ■). 
The corresponding molecular weights are indicated on the left side, the chosen antibodies for protein 
detection on the right side. (B) Quantification of downregulation. Quantification was done using the 
Odyssey® Application Software 2.1 (see manufacturer’s manual). Protein level of NPM1 are compared to 
the level of untransfected cells (=100%) and normalised to Tubulin. (C) Immunocytochemistry. 
Immunostainings to test for NPM1 downregulation in fixed cells. Transfection and staining procedure as 
described in the Methods section. (1) HeLa cells transfected with the shNPM1 plasmid (#312) strongly 
expressing EGFP are marked with *. Expression levels of EGFP differ from cell to cell. (2) DAPI 
staining of the DNA to visualise nuclei. (3) Antibody staining for NPM1 to visualise downregulation in 
transfected cells. Transfected HeLa cells are depleted for NPM1: the puncta of NPM1 in the nuclei are 
reduced or abolished. The inset on the left indicates a 2fold magnification of the selected cell area. (4) 
Phase contrast picture of the cells to check their morphology and their physiological status. 
UT, untransfected; #312, shNPM1 plasmid; α, anti. 
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The protein expression level of NPM1 upon transfection with the shNPM1 plasmid 
#317 was 17.94% on average (Figure 3-3B). According to the Western Blot data in 
Figure 3-3A the transfection efficiency of plasmid #317 was lower than those of #312. 
Both shNPM1 plasmids downregulated the corresponding protein, but the degree of 
downregulation was even a little stronger with plasmid #317.  
Subsequently, downregulation of NPM1 upon transfection with plasmids # 312 and 
#317 was also investigated by immunostaining using specific antibodies against NPM1  
(Figure 3-2C and Figure 3-3C).  
The specificity of the observed NPM1 antibody staining pattern was as previously 
reported (Yung, B. Y. et al. 1990; Iggo, R. D. et al. 1991; Bocker, T. et al. 1995; Wu, 
M. H. et al. 1995; Nozawa, Y. et al. 1996; Zatsepina, O. V. et al. 1997; Cordell, J. L. et 
al. 1999). NPM1 is preferentially found in the nucleolus and also in the nucleoplasm 
(Cordell, J. L. et al. 1999). The protein shuttles continuously between the cytoplasm and 
the nucleolus, thereby functioning as a carrier of newly synthesised ribosomal proteins 
into the nucleolus (Borer, R. A. et al. 1989; Cordell, J. L. et al. 1999). Nucleolar 
labelling is not always observed due to the fixation procedure (Cordell, J. L. et al. 
1999), but the cytoplasm is usually diffused stained (Cordell, J. L. et al. 1999). 
 
Based on the antibody staining, the transfected HeLa cells were clearly depleted for 
NPM1. Also the puncta of NPM1 in the nuclei were reduced or abolished which is 
especially visible in the magnified insets (Figures 3-2C and 3-3C). In the cell 
periphery, NPM1 seemed to be completely removed. The transfected cells are identified 
by their EGFP expression. The nuclei were intact as confirmed by DAPI staining. 
Moreover, the morphology was good, which was also a clear parameter whether the 
cells were stressed or even dead (see Figures 3-2C4 and 3-3C4, phase contrast images). 
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Figure 3-3: Testing of two different shNPM1 plasmids in HeLa cells. 
(A) Test of protein downregulation on Western Blot. Western Blot showing the downregulation of 
NPM1 protein upon transfection of HeLa cells with two different shNPM1 plasmids (#317 and #312, 
respectively) in comparison. Double band of NPM1 as described in Figure 3-2 marked with ■. The 
corresponding molecular weights are indicated on the left side, the chosen antibodies for protein detection 
on the right side. (B) Quantification of downregulation. Quantification was done using the Odyssey® 
Application Software 2.1 (see manufacturer’s manual). Protein levels of NPM1 are compared to the level 
of untransfected cells (=100%) and normalised to Tubulin. (C) Immunocytochemistry. Immunostainings 
to test for NPM1 downregulation in fixed cells. Transfection and staining procedure as described in the 
Methods section. For description of pictures see also Figure 3-2. (1) HeLa cells transfected with the 
shNPM1 plasmid (#317) expressing EGFP are marked with *. Expression levels of EGFP differ from cell 
to cell as can be seen from the 2 transfected cells shown. (2) DAPI staining. (3) Antibody staining for 
NPM1 to visualise downregulation in the transfected cells. Transfected HeLa cells are depleted of NPM1: 
the puncta of NPM1 in the nuclei are reduced or abolished. The inset on the left indicates a 1.5fold 
magnification of the selected cell area. (4) Phase contrast picture.  
UT, untransfected; #312, shNPM1 plasmid; #317, shNPM1 plasmid; α, anti. 
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1.2. ShRNA plasmid targeting DDX5  
DDX5 is a member of the DEAD-box (DDX) family and shows ATP-dependent RNA 
helicase and RNA-dependent ATPase activities in vitro (Ogilvie, V. C. et al. 2003). 
Previous data showed that DDX5 plays a role in the regulation of incorrect transcripts in 
yeast and therefore in the NMD process (Bond, A. T. et al. 2001). 
 
Figure 3-4A shows the analysis of the newly generated shRNA plasmid targeting 
DDX5 (plasmid #339) via Western Blot. The quantification in Figure 3-4B displays the 
efficiency of DDX5 downregulation with plasmid #339. The protein level of DDX5 was 
reduced to 79.71% compared to the UT sample.  
The observed DDX5 antibody staining pattern seemed to be not specific (Iggo, R. D. et 
al. 1991; Lamm, G. M. et al. 1996; Kahlina, K. et al. 2004) (see Discussion section). 
Published DDX5 staining patterns showed a predominantly nucleolar or nucleoplasmic 
localisation of the protein depending on the cell cycle stage (Iggo, R. D. et al. 1991; 
Lamm, G. M. et al. 1996; Ogilvie, V. C. et al. 2003; Kahlina, K. et al. 2004). In this 
diploma thesis, no obvious differences between the transfected and untransfected HeLa 
cells were observed in the immunocytochemistry experiment. Small puncta were evenly 
distributed across the cell areas and the downregulation of DDX5 was not visible in the 
transfected cells, although the same antibody has been used as for the Western Blots 
experiment (Figure 3-4C).The transfected cells shown in Figure 3-4C1 demonstrated 
the variability of the EGFP expression in single HeLa cells. The nuclei and the 
morphology of the cells were analysed as in Figure 3-2C.  
However, downregulation of DDX5 via the respective shRNA (plasmid #339) was 
confirmed on the Western Blots, but could not be visualised in the immunostaining (see 
Discussion section). 
In addition, other created shDDX5 plasmids (see 1.4 Plasmids & primers in the 
Material section) have been tested, but did not downregulate DDX5 (data not shown), 
before the working plasmid #339 was identified. 
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Figure 3-4: Testing of the shDDX5 plasmid in HeLa cells. 
(A) Test of protein downregulation on Western Blot. Western Blot showing the downregulation of 
DDX5 protein upon transfection of HeLa cells with the shDDX5 plasmid (#339). The corresponding 
molecular weights are indicated on the left side, the chosen antibodies for protein detection on the right 
side. (B) Quantification of downregulation. Quantification was done using the Odyssey® Application 
Software 2.1 (see manufacturer’s manual). DDX5 expression is compared to the expression level of an 
untransfected control (=100%) and normalised to Tubulin. (C) Immunocytochemistry. Immunostainings 
to visualise DDX5 downregulation in fixed cells. Transfection and staining procedure as described in the 
Methods section. For description of pictures see also Figure 3-2. (1) HeLa cells transfected with the 
shDDX5 plasmid (#339) expressing EGFP are marked with *. Expression levels of EGFP differ from cell 
to cell as can be seen here. (2) DAPI staining. (3) Antibody staining for DDX5 to visualise 
downregulation in the transfected cells. Depletion of DDX5 in the transfected HeLa cells is not obvious 
in this example. (4) Phase contrast picture.  
UT, untransfected; #339, shDDX5 plasmid; α, anti. 
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1.3. ShRNA plasmid targeting U5-116 kDa 
Very little is known about U5-116 kDa which is a small nuclear ribonucleoprotein 
(snRNP) (Fabrizio, P. et al. 1997). U5-116 kDa is supposed to play a role in 
rearrangement steps during spliceosome assembly or the splicing process (Achsel, T. et 
al. 1998). 
 
Figure 3-5A shows a representative Western Blot exploring the efficiency of shU5-116 
kDa to downregulate its corresponding protein. When quantified, a 54.33% reduction 
was observed compared to an untransfected sample (Figure 3-5B). 
Immunostaining experiments were also performed to show the shRNA mediated 
knockdown of U5-116 kDa in HeLa cells (Figure 3-5C). In this thesis, the antibody 
staining for U5-116 kDa showed a significant downregulation in the transfected cells. 
Depletion of U5-116 kDa was visible especially in the periphery of the cell (see the 2x 
magnification of the cell area).  
The EGFP signal was so strong that there was even bleed through in the DAPI channel. 
The transfected HeLa cell had an intact nucleus and morphology which were indicators 
for the cell’s liveliness.  
However, downregulation of U5-116 kDa upon transfection with its corresponding 
shRNA was visible on the Western Blots as well as in the immunofluorescence 
experiments. 
Literature search revealed only one publication indicating a different staining pattern for 
U5-116 kDa (Fabrizio, P. et al. 1997) with a predominantly nuclear localisation of the 
protein. So the observed antibody staining seems not specific, according to the 
previously published subcellular localisation pattern (see Discussion section). 
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Figure 3-5: Testing of the shU5-116 kDa plasmid in HeLa cells. 
(A) Test of protein downregulation on Western Blot. Western Blot showing the downregulation of U5-
116 kDa protein upon transfection of HeLa cells with the shU5-116 kDa plasmid (#342). The 
corresponding molecular weights are indicated on the left side, the chosen antibodies for protein detection 
on the right side. (B) Quantification of downregulation. Quantification was done using the Odyssey® 
Application Software 2.1 (see manufacturer’s manual). Protein levels of U5-116 kDa are compared to the 
level of untransfected cells (=100%) and normalised to Tubulin. (C) Immunocytochemistry. 
Immunostainings to visualise U5-116 kDa downregulation in fixed cells. Transfection and staining 
procedure as described in the Methods section. For description of pictures see also Figure 3-2. (1) HeLa 
cells transfected with the shU5-116 kDa plasmid (#342) expressing EGFP are marked with *. (2) DAPI 
staining. (3) Antibody staining for U5-116 kDa to visualise downregulation in transfected cells. Depletion 
of U5-116 kDa in the transfected HeLa cells is visible especially in the periphery of the cell. The inset on 
the left indicates a 2fold magnification of the selected cell area. (4) Phase contrast picture. 
UT, untransfected; #342, shU5-116 kDa plasmid; α, anti. 
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1.4. ShRNA plasmids targeting RBMX  
RBMX is a heterogeneous, nuclear ribonucleoprotein of the RNA-binding motif (RBM) 
family (Elliott, D. J. 2004). Very little is known about this protein so far. Knockdown 
experiments were performed in zebrafish, where the depletion of RBMX led to 
underdevelopment of the head and eyes as well as to a reduced body size compared to 
wt zebrafish (Tsend-Ayush, E. et al. 2005). Due to the study in zebrafish (Dichmann, D. 
S. et al. 2008) and a recently published study in Xenopus laevis (Dichmann, D. S. et al. 
2008), RBMX plays an essential role in the development of the brain. 
 
As RBMX was not detectable with the commercial antibody on the Western Blots to 
test the downregulation via corresponding shRNAs (data not shown), another Western 
Blot was made to investigate the protein expression level of RBMX in HeLa cells. To 
check whether in conventional HeLa cells the RBMX protein was maybe expressed in 
very low amounts, a Western Blot was made with 50 – 150 µg of an untreated HeLa cell 
lysate (UT). The protein was not detected under any condition, so its expression level in 
HeLa cells might simply be below the detection sensitivity of a Western Blot (see 
Discussion section). Therefore, the shRBMX plasmids could not be tested for their 
downregulation of RBMX in HeLa cells by Western blotting. The detection of RBMX 
(~43 kDa) on Western Blots was not possible with the used antibody (Figure 3-6A). 
But as RBMX is a nuclear ribonucleoprotein (Elliott, D. J. 2004), its concentration in 
the cell’s cytoplasm might simply be to low to be detected on a Western Blot. Most 
likely, the buffer used to lyse the cells in this diploma project was not strong enough to 
solubilise nuclei (see also Discussion section).  
The immunostaining experiment performed with the same antibody as used for the 
Western Blots is shown in Figure 3-6B. Transfection was confirmed by the expression 
of EGFP, the transfected HeLa cells had intact nuclei as confirmed by DAPI staining and the 
morphology was also normal as shown by the phase contrast image. 
The obtained RBMX staining pattern, however, seems rather diffuse and not very 
specific. Since there is no data published on RBMX in HeLa so far, there was no way to 
confirm the specificity of the antibody staining. If the staining pattern for RBMX was 
specific, it indicated that most RBMX protein is mainly concentrated in the nuclei and just to a 
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little extent cytoplasmic, which is a typical subcellular localisation pattern for hnRNPs (see 
Discussion section). With the antibody used for these experiments, there was no down 
regulation of RBMX detectable, neither on the Western Blot nor in the 
immunocytochemistry experiment. So it is unclear whether the shRBMX is working or 
not (Figure 3-6B). 
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Figure 3-6: Testing of the shRBMX plasmids in HeLa cells. 
(A) Detection of RBMX on Western Blot. Different protein amounts (50 - 150 µg) of an UT HeLa 
lysate were tested on a Western Blot to detect RBMX. The protein was not detected in any condition on 
the blot, whereas the RBMX immunostainings displayed fluorescent signals (see (B)). So the shRBMX 
plasmids could not be tested for their downregulation of RBMX. Blot was probed for RBMX, which 
should result in a ~43 kDa band. RBMX could also not be detected in the ß-Globin HeLa cell lines (see 
Figure 3-14). (B) Immunocytochemistry. Immunostainings to check whether RBMX downregulation 
could be made visible in fixed cells. Transfection and staining procedure as described in the Methods 
section. For description of pictures see also Figure 3-2. (1) HeLa cell transfected with the shRBMX 
plasmid (#308) strongly expressing EGFP is marked with *. (2) DAPI staining. (3) Antibody staining for 
RBMX to visualise downregulation in transfected cells. There is no apparent reduction or depletion of 
RBMX visible, if the observed staining pattern is specific. (4) Phase contrast picture. 
UT, untransfected; #308, shRBMX plasmid; α, anti. 
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1.5. ShRNA plasmids targeting RBM4  
RBM4 is an RNA-binding protein of the RNA recognition motif (RRM) class and a 
splicing factor. RBM4 localizes in nuclear speckles and nucleoli, which supports its 
potential role in splicing or RNA processing (Markus, M. A. and Morris, B. J. 2006). 
These facts are also good indicators for a possible role of RBM4 in the NMD process. 
 
The created shRBM4 plasmids were tested for their capacity of protein downregulation 
via Western Blot. Figure 3-7A and B show Western Blots displaying no 
downregulation of RBM4 protein (~43 kDa) upon transfection of conventional HeLa 
cells with the shRBM4 plasmids #320, #321, #343 and #344. According to the EGFP 
signals, transfections worked for all four plasmids. In the case of the shRNA constructs 
#343 and #344, the EGFP signals were quite low compared to those of plasmids #320 
and #321. This indicated a lower transfection rate and EGFP expression upon 
transfection with #343 and #344. No RBM4 signal was detected on the Western Blot in 
Figure 3-7B (see Discussion section).  
The shRNA sequences for plasmid #343 and #344 were chosen according to a recent 
study (Hock, J. et al. 2007), but did not downregulate RBM4 in our experiments. In this 
publication, the siRNA constructs were pre-transfected as 2’-O-methyl 
oligoribonucleotides into HeLa cells using EscortV (Sigma), according to the 
manufacturer’s instructions.  
Taken together, none of the designed and tested shRNA plasmids was able to reduce 
RBM4 expression and also inconsistencies with the RBM4 detection on the Western 
Blots occurred (see Discussion section). 
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Figure 3-7: Testing of the shRBM4 plasmids in HeLa cells. 
The Western Blots for testing RBM4 downregulation were quantified using the Odyssey® Application 
Software 2.1 (see manufacturer’s manual). The protein levels of the transfected samples were compared 
to the levels of an UT control (=100%) and normalised to Tubulin. The corresponding molecular weights 
are indicated on the left side, the chosen antibodies for protein detection on the right side. 
(A) Test of protein downregulation on Western Blot. Western Blot showing no downregulation of 
RBM4 protein (~43 kDa) upon transfection of HeLa cells with two different shRBM4 plasmids (#320 and 
#321).  
(B) Test of protein downregulation on Western Blot. Western Blot showing no downregulation of 
RBM4 protein (~43 kDa) upon transfection of HeLa cells with two additional shRBM4 plasmids (#343 
and #344). The RBM4 protein was not even detected on the Blot.  
UT, untransfected; #320, shRBM4 plasmid; #321, shRBM4 plasmid; #343, shRBM4 plasmid; #344, 
shRBM4 plasmid; α, anti. 
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2. ESTABLISHMENT OF AN NMD ASSAY 
 
To investigate the role of the selected candidate proteins in NMD, I set out in 
collaboration with Dr. Daniela Karra to establish an NMD assay (Daniela Karra, PhD 
thesis 2008) based on the method developed by Miles Wilkinson and coworkers (Carter, 
M. S. et al. 1995; Li, S. et al. 1997; Muhlemann, O. et al. 2001). For this assay, they 
transiently transfected HeLa cells with either a wild type (wt) or a PTC-containing 
NMD reporter construct (TCR-ß or ß-Globin) to monitor the efficiency of the decay by 
NMD (Carter, M. S. et al. 1995; Li, S. et al. 1997).  
 
2.1. Essential controls for the NMD assay 
Since it was already shown that the RNA-binding proteins Btz and eIF4AIII play a role 
in NMD, those proteins were chosen to serve as positive controls for the NMD assay 
(Ferraiuolo, M. A. et al. 2004; Palacios, I. M. et al. 2004). The corresponding shRNA 
plasmids were designed and tested for the NMD assay by Dr. Daniela Karra (Daniela 
Karra, PhD thesis 2008 and data not shown). The following shRNA plasmids served as 
positive controls in the NMD assay: shBtz (plasmid #283) and sheIF4AIII (plasmid 
#291); the empty pSUPERIOR vector (plasmid #100) as negative control. The shRNA 
plasmids, which should serve as NMD assay controls, were tested in HeLa cells. Dr. 
Daniela Karra also investigated their effect in hippocampal neurons during her PhD 
thesis.  
Figure 3-8A shows a typical NMD assay experiment where HeLa cells were 
cotransfected with the controls and the WT or PTC TCR-ß constructs and the samples 
were compared to an untransfected, untreated control (UT). Downregulation of Btz 
(plasmid #283) and eIF4AIII (plasmid #291) protein upon transfection of conventional 
HeLa cells was clearly visible on the Western Blot. The shBtz usually showed a 
reduction of protein expression of ~ 50 – 60% upon transfection (Daniela Karra, PhD 
thesis 2008). The effect of the sheIF4AIII was found to be strongly dependent on the 
quality of the maxiprep, which is a crucial criterion for the obtained transfection 
efficiency, as was observed before for all transfections (Zeitelhofer, M. et al. 2008).  
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The control plasmid #100 had no effect on the Btz or eIF4AIII expression as expected. 
Some of the #100 + WT sample diffused into the UT slot. Therefore, the UT sample 
showed a residual EGFP signal. All transfections worked well according to the EGFP 
signal. Only the #100 control samples had weaker EGFP signals than the other samples.  
The immunofluorescence pictures in Figure 3-8B show a typical example of a high 
transfection efficiency obtained for the control plasmids. Conventional HeLa cells were 
cotransfected with shBtz (plasmid #283) and the wt TCR-ß construct (WT). Since 
EGFP is coexpressed together with the respective shRNA from the same plasmid, EGFP 
expression in cells is just a verification of the transfection with the shRNA plasmids and 
does not tell whether the TCR-ß plasmids are successfully transfected into the same cell 
as well. Obviously the expression levels of EGFP differ from cell to cell as can be seen 
in this picture. The phase contrast picture of the cells was used to check the cells’ 
morphology and if they are alive. 
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Figure 3-8: Test of NMD assay controls and setup in conventional HeLa cells. 
(A) Protein downregulation of NMD assay controls Btz and eIF4AIII. Western Blot showing the 
downregulation of Btz (plasmid #283) and eIF4AIII (plasmid #291) protein upon cotransfection of 
conventional HeLa cells with the control shRNA plasmid and the WT or PTC TCR-ß construct. The 
TCR-ß constructs are used to monitor the effect on NMD, when a protein is depleted. The corresponding 
molecular weights are indicated on the left side, the chosen antibodies for protein detection on the right 
side. Levels of protein expression are compared to the protein levels of an untransfected control (=100%) 
and normalised to Tubulin. Some of the negative control (#100 + WT) sample diffused into the UT slot. 
Therefore, the UT sample shows a little EGFP signal. Control (#100) samples have weaker EGFP signals 
than the other samples. (B) Pictures of transfected HeLa cells. Pictures were taken with the Leica MZ 
16F microscope (Leica) with 80x magnification (picture size 1781 µm x 1331 µm). (1) HeLa cells, 
cotransfected with shBtz (plasmid #283) + WT, expressing EGFP. Expression levels of EGFP differ from 
cell to cell as can be seen here. Picture shows typically transfection efficiency for conventional HeLa 
cells. (2) Corresponding phase contrast picture to check the cells’ morphologies and their physiological 
status. 
UT, untransfected; WT, TCR-ß wt RNA without PTC; PTC, TCR-ß RNA with PTC; #100, empty 
pSUPERIOR plasmid; #283, shBtz plasmid; #291, sheIF4AIII plasmid; α, anti. 
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2.2. Establishment of the NMD assay in conventional 
HeLa cells using TCR-ß reporter constructs 
Once effective shRNA plasmids targeting chosen candidates for the NMD assay were 
designed and tested (see Methods section and 1 Creation and testing of shRNAs for 
NMD assay candidates in the Results section), they were used to investigate the role of 
the respective candidate in NMD. It is already known that if an essential component of 
the NMD machinery is lacking, the process is impaired (Sun, X. et al. 1998; Ferraiuolo, 
M. A. et al. 2004; Palacios, I. M. et al. 2004). 
Upon knockdown of the respective candidate in conventional HeLa cells, the amounts 
of different TCR-ß mRNA reporter constructs (Carter, M. S. et al. 1995; Li, S. et al. 
1997) are monitored. If a candidate protein is part of the NMD machinery, it will lead to 
an accumulation of TCR-ß mRNAs containing a PTC and therefore to an impairment of 
the NMD process. 
Conventional HeLa cells were therefore cotransfected with the shRNA plasmid 
targeting an NMD candidate and a plasmid for the expression of a wt TCR-ß construct 
without PTC (WT) or a TCR-ß construct with a PTC (PTC). RNA and protein were 
isolated with Trizol® Reagent (Invitrogen) from the samples 72 h after transfection. 
Protein downregulation of the NMD candidate was confirmed by Western Blot. The 
RNA was transcribed into cDNA and semiquantitative PCRs for the TCR-ß pre-mRNA 
(200 nt fragment) and mRNA (150 nt fragment) were performed in different PCR tubes. 
The PCR products were then checked and analysed on a 2% agarose gel. 
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2.2.1. Optimisation of semiquantitative PCR for TCR-ß pre-
mRNA in HeLa cells  
The following parameters had to be set up for the NMD assay. Foremost, the pre-
mRNA product was found to be more sensitive when amplified by PCR. In one of the 
first experiments to set up the PCR conditions, the amplification of the TCR-ß mRNA 
cDNA worked, whereas the TCR-ß pre-mRNA product could not be amplified (Figure 
3-9A). Two parameters were tested to detect the TCR-ß pre-mRNA PCR product: the 
amount of the template cDNA used for the PCR to optimize the sensitivity of the PCR 
reaction and the annealing temperature to increase the specificity of the PCR reaction 
and product. 
Different cDNA template amounts (0.25 - 1.0 μg) were tested for the PCR, but did not 
permit the detection of the expected pre-mRNA product (data not shown).  
Bioinformatical analyses (using internet tools, e.g. Primer3) revealed that the TCR-ß 
pre-mRNA primer forms secondary structures. To dissolve those, different temperatures 
were tested to optimize the annealing of the primer to the template cDNA: 55°C, 58°C, 
60°C and 62°C (data not shown with the exception of 60°C in Figure 3-9B). But only 
an annealing temperature of 60°C restored the successful amplification of the TCR-ß 
pre-mRNA, with the exception of the #291 samples (sheIF4AIII plasmid, positive 
control) (see Discussion section) in this particular experiment shown in Figure 3-9B. 
The untransfected HeLa cell control did not give a TCR-ß PCR product as expected. 
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Figure 3-9: Optimisation of semiquantitative PCR for TCR-ß pre-mRNA in HeLa cells. 
PCRs were performed on cDNA templates of HeLa cells, cotransfected with the constructs indicated 
above each lane, to amplify either TCR-ß pre-mRNA (200 bp) or TCR-ß mRNA (150 bp) products. 30 µl 
of each PCR reaction including 6x Loading Dye (Fermentas) were separated on a 2% agarose gel in 
parallel with 15 µl of the GeneRuler™ 100 bp DNA Ladder (Fermentas). The untransfected HeLa cell 
sample (UT) served as negative control. 
(A) No TCR-ß pre-mRNA amplification, but TCR-ß mRNA amplification. PCR for TCR-ß pre-
mRNA on cDNA did not work. Subsequent tests using different cDNA template amounts (0.25 - 1.0 µg) 
for PCR did not yield the expected pre-mRNA products (data not shown). (B) Increase of annealing 
temperature for TCR-ß pre-mRNA primers. The annealing temperature for the TCR-ß pre-mRNA 
primers was changed to 60°C. This successfully restored amplification of the TCR-ß pre-mRNA products 
(with exception of the sheIF4AIII samples (#291)). Tested cDNA samples are the same as in (A). 
UT, untransfected; WT, TCR-ß wt RNA without PTC; PTC, TCR-ß RNA with PTC; #100, empty 
pSUPERIOR plasmid; #283, shBtz plasmid; #291, sheIF4AIII plasmid. 
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2.2.2. Test of different RNA isolation kits 
The quality of the RNA is crucial for the detection and quantification of the TCR-ß 
products by PCR. Therefore, different RNA isolation kits were tested as shown in 
Figure 3-10A and B. After RNA isolation, all samples were reverse transcribed using 
the M-MLV reverse transcriptase (H-) (Promega). The generated cDNA was then used 
to amplify TCR-ß PCR products which were analysed on a 2% agarose gel. 
Although the RNeasy Midi Kit (Qiagen) is a phenol/chloroform-free RNA isolation 
procedure with a high degree of RNA stabilisation, it did not work well for the RNA 
isolation of our TCR-ß construct. Just a faint band of one pre-mRNA sample (#283 + 
WT) was visible on the gel picture (Figure 3-10A). But as the kit is designed to enrich 
RNAs >200 nt using a silica-gel membrane step, the TCR-ß RNAs were possibly 
excluded by size. So only in a single case, a faint band of the TCR-ß product could be 
detected. 
The mirVana™ miRNA Isolation Kit (Ambion) combines organic extraction (acid-
phenol/chloroform) and solid-phase extraction for RNA isolation over a broad size 
range. The purification was done for total RNA, which should also be very effective for 
small RNAs. A final purification step to enrich in small RNAs was not performed, 
because it would have excluded our 200 nt samples.  
With the mirVana™ miRNA Isolation Kit, isolation of the desired TCR-ß RNA worked 
really well as shown in Figure 3-10B. The intensities of the bands were proportional to 
the used template amounts, which allowed quantification of the results (data not 
shown). 
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Figure 3-10: Test of different RNA isolation kits. 
PCRs were performed on cDNA templates of HeLa cells, cotransfected with the constructs indicated 
above each lane, to amplify either TCR-ß pre-mRNA (200 bp) or TCR-ß mRNA (150 bp) products. PCR 
products amplified from cDNA, were separated and analysed on a 2% agarose gel as described in Figure 
3-9. RT-PCR was performed using the M-MLV Reverse Transcriptase (H-) (Promega) in all experiments.  
(A) RNeasy Midi Kit – Qiagen. Just a faint band of one pre-mRNA sample (#283 + WT) was seen once 
when using the RNeasy Midi Kit (Qiagen). (B) mirVana™ miRNA Isolation Kit – Ambion. In all 
cases, amplification of the TCR-ß products was successful with the mirVana™ miRNA Isolation Kit 
(Ambion). Intensity of the bands was also proportional to the used template amounts. To confirm 
reproducibility, experiments were repeated yielding comparable results.  
WT, TCR-ß wt RNA without PTC; PTC, TCR-ß RNA with PTC; #283, shBtz plasmid.  
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2.2.3. Optimisation of template amounts and internal standards 
for normalisation 
For further fine-tuning of the experimental setup, different template amounts were 
tested to find the quantitative and sensitive range of the PCR reaction (Figure 3-11). 
TCR-ß pre-mRNA was chosen for amplification, as it was more sensitive to changes in 
the experimental conditions. 0.25 -1.25 µg cDNA template amounts were tested. The 
same cDNA samples were already previously used to amplify TCR-ß cDNA 
successfully (see Figure 3-10). The PCR of TCR-ß pre-mRNA worked for all used 
conditions. However, the intensities of the PCR bands were not at all or only poorly 
correlated to the template amounts. There was just one exception. Correlation between 
template amount and the intensity of the band was observed for the sample 
cotransfected with shBtz and the wt TCR-ß construct where 1.25µg were used as 
template for PCR (sample #283 + WT 1.25 µg). 
So no obvious conclusion could be drawn concerning the quantitative PCR range and 
the precision of the semiquantitative PCR. Due to this reason, the integration of a 
housekeeping gene such as tubulin was tested as an internal PCR standard (last lane of 
each sample). GAPDH was also used to normalize the signal intensity (data not shown). 
This allows the quantification of the samples even in semiquantitative PCR reactions. 
 
Figure 3-11: Optimisation of template amounts and internal standards for normalisation. 
PCRs were performed on cDNA templates of HeLa cells, cotransfected with the constructs indicated 
above the gel picture, to amplify TCR-ß pre-mRNA (200 bp). The same cDNA samples were already 
successfully used before to amplify TCR-ß products. PCR products amplified from cDNA were separated 
and analysed on a 2% agarose gel as described in Figure 3-9. PCR of TCR-ß pre-mRNA worked for all 
conditions. In the last lane of each sample tubulin was also amplified as internal standard.  
WT, TCR-ß wt RNA without PTC; PTC, TCR-ß RNA with PTC; #283, shBtz plasmid. 
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2.2.4. Optimisation of RT-PCR conditions  
Since the integration of an internal standard was successful, different RT-PCR 
conditions were now tested to increase the sensitivity of the assay. Within the reverse 
transcriptase reaction, it is possible to enrich your target cDNA by using a specific 
primer instead of random primers, which were used in the reactions so far. RNA that 
was isolated with the mirVana™ miRNA Isolation Kit (Ambion), was in parallel 
reverse transcribed using the M-MLV reverse trancriptase (H-) (Promega) either using 
Random Primers (Promega) or the specific TCR-ß reverse primer. The resulting PCR 
products were then analysed on 2% agarose gels (Figure 3-12). Tubulin could still be 
amplified in the specific TCR-ß reverse primer reactions (see Discussion section). So as 
a next step, the bands on the gels could then be quantified to establish the normalisation 
of the PCR results via tubulin. 
 
 
.
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The bands on the gels were quantified using the Quantity One software (Bio-Rad)  
(Table 3-1A and B). The measured values of the samples were normalised to the 
tubulin values. mRNAs with a PTC should be degraded in the negative control samples 
(#100), where NMD is intact, whereas incorrect RNAs should accumulate in the 
eIF4AIII knockdown samples (#291, positive control), where NMD is impaired. These 
expected results could not be experimentally verified, which might also indicate 
insufficient detection sensitivity of the semiquantitative PCR. But as the total RNA was 
isolated using the mirVana™ miRNA Isolation Kit, protein could not be isolated in 
parallel to analyse the protein downregulation upon transfection with the respective 
shRNA via Western Blot. So it was not possible to confirm whether the knockdown of 
the controls was sufficient in this experiment. Possibly, eIF4AIII was simply not 
sufficiently downregulated (#291 samples), which explains the obtained results 
concerning the NMD process. 
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2.2.5. Variability of cotransfections 
Cotransfections are usually performed to introduce 2 or more plasmids into HeLa cells. 
In theory, both plasmids should be equally taken up, if transfection worked. But in some 
of the experiments for the NMD assay, problems with cotransfection of the TCR-ß 
construct and the shRNA plasmid occurred in conventional HeLa cells (Figure 3-13). 
According to the PCR results in Figure 3-13, cells were only transfected with the 
shRNA plasmid, but not the TCR-ß plasmid. Since all shRNA plasmids also express 
EGFP, transfected cells were always checked for EGFP expression under the 
microscope and pictures were taken to monitor transfection efficiencies (data not 
shown). In contrast, expression of the TCR-ß plasmid could only be verified by PCR. 
Therefore, we chose HeLa cell lines with stable integrated NMD reporter constructs (in 
our case ß-globin and TCR-ß) for the subsequent experiments. 
 
Figure 3-13: Variability of cotransfections. 
RNA isolation was done using Trizol® Reagent (Invitrogen) and RT-PCR was performed to generate 
cDNA, using Random Primers and reagents from Promega. PCR products amplified from cDNA were 
separated and analysed on a 2% agarose gel as described in Figure 3-9. TCR-ß pre-mRNA (200 bp) could 
be amplified in the first 2 samples, but not in the last 2 ones, indicating that the WT and PTC plasmids 
were not cotransfected together with plasmid #100.  
WT, TCR-ß wt RNA without PTC; PTC, TCR-ß RNA with PTC; #283, shBtz plasmid; #100, empty 
pSUPERIOR plasmid. 
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2.3. Cell lines stably expressing ß-Globin & real-time 
PCR 
The variability in the amount and quality of the isolated total RNA, the inconsistency in 
the cotransfection efficiency and the fact that a conventional PCR is only 
semiquantitative (Ferre, F. 1992; Kubista, M. et al. 2006; Blow, N. 2007), led us to set 
up quantitative real-time PCR. In this case, total RNA and protein isolation using the 
Trizol® Reagent (Invitrogen) is state-of-the-art (see http://www.invitrogen.com, e.g. 
(Albertini, V. et al. 2006)), since Trizol® does not interfere with the reaction. 
To overcome the inconsistency of the cotransfection efficiencies in the conventional 
HeLa cells, 4 stable HeLa cell lines expressing NMD mRNA targets (ß-globin or TCR-
ß) with or without PTC were used for the real-time PCR experiments, which were a 
generous gift from Dr. Oliver Mühlemann (Institute of Cell Biology, University of 
Bern, Switzerland).  
 
In the remainder, the following two ß-Globin cell lines were used to investigate the role 
of the candidates in NMD by real-time PCR: wt ß-Globin HeLa cells without a PTC and 
NS39 ß-Globin HeLa cells containing a PTC (Thermann, R. et al. 1998). Two HeLa cell 
lines with a TCR-ß construct were also tested for the NMD assay: HeLa 290F without a 
PTC and HeLa 593C without a PTC (Muhlemann, O. et al. 2001).  
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2.3.1. Analysis of NMD assay candidates in TCR-ß and ß-Globin 
HeLa cell lines 
The expression levels oft the candidate proteins and the NMD assay controls Btz and 
eIF4AIII were analysed by Western Blots, shown in Figure 3-14. Total protein was 
isolated with Trizol® Reagent from stably transfected ß-Globin and TCR-ß HeLa cell 
lines. The protein lysates from the cell lines were compared to a protein sample from 
conventional HeLa cells. Same volumes of the protein samples were loaded for Western 
Blots to yield comparable protein amounts. The first Western Blot was probed for Btz, 
DDX5, Tubulin, RBM4 and NPM1 (Figure 3-14A). On the second Western Blot, the 
expression levels of U5-116 kDa, Tubulin and eIF4AIII were analysed (Figure 3-14B). 
RBMX was also tested, but the antibody recognised a protein double band of a different 
size (<35 kDa, marked by an asterisk) than the expected 43 kDa of RBMX. The visible 
double band at <35 kDa, after the incubation with RBMX antibody, was even stronger 
for the 4 cell lines (see Discussion section).  
 
According to the normalisation to the Tubulin signal, Btz was stronger expressed in the 
TCR-ß cell lines and much stronger expressed in the ß-Globin cell lines, compared to wt 
conventional HeLa cells. The expression levels observed for DDX5, U5-116 kDa as 
well as for eIF4AIII were approximately the same in all tested cell lines. RBM4 proteins 
were nearly equally expressed in the conventional HeLa cells and the ß-Globin cell 
lines, but a bit reduced in the TCR-ß cell lines. The strong expression of NPM1 in the 
stable cell lines, compared to conventional HeLa cells, was very surprising. The NPM1 
signals were so prominent that the phosphorylated and the unphosphorylated form of 
NPM1 (Okuda, M. et al. 2000) could no longer be distinguished.  
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Figure 3-14: Analysis of NMD assay candidates in TCR-ß and ß-Globin HeLa cell lines. 
Protein isolations with Trizol® Reagent (Invitrogen) were separated on 10% SDS-PA gels for Western 
Blots. Protein expression of conventional HeLa cells was compared to protein expression of the stable 
HeLa cell lines. PageRuler™ Prestained Protein Ladder (Fermentas) was used to determine the molecular 
weight on the left (MW), where the size of the marker is depicted. αTubulin antibody was applied as 
loading control. 
(A) Western Blot was probed for Btz (115 kDa), DDX5 (68 kDa), Tubulin (55 kDa), RBM4 (43 kDa) and 
NPM1 (38 kDa). NPM1 displayed the characteristic double bands, described in Figure 3-2. 
(B) Western Blot was probed for U5-116 kDa (116 kDa), Tubulin and eIF4AIII (48 kDa). RBMX (43 
kDa) was also tested, but antibody recognised a double band of different size <35 kDa (*). 
MW, molecular weight marker (PageRuler™ Prestained Protein Ladder - Fermentas); HeLa, conventional 
HeLa cell sample; TCR-ß, stable TCR-ß HeLa cell line; ß-Globin, stable ß-Globin HeLa cell line; PTC, 
premature termination codon; PTC-, without PTC; PTC+, with PTC; α, anti. 
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2.3.2. NPM1 downregulation in wt ß-Globin HeLa cells 
The designed shRNA plasmids that had already been tested in conventional HeLa cells, 
were tested for their efficiency in downregulating the corresponding protein in the 
stable cell lines. 
 
72 h after transfection, downregulation of NPM1 in the stable cell lines was not 
sufficient (data not shown). Since the shRNA plasmids for NPM1 (#312 and #317) were 
very efficient in the conventional HeLa cells, I decided to examine the protein turnover 
and downregulation of the respective protein in the stable cell lines (Figure 3-15).  
Wt ß-Globin HeLa cells were transfected with a shNPM1 plasmid (#317) and 
downregulation was allowed to take place for 4 or 5 days. Protein lysates of transfected 
cells were then analysed by Western Blot and compared to an untransfected control 
sample (Figure 3-15A). The Western Blot was probed for Btz, Tubulin, NPM1 and 
EGFP. The EGFP signals on the Western Blot confirmed the successful transfection 
with the shNPM1 plasmid (#317).  
Quantification of the Western Blot revealed a slight downregulation of NPM1 after 5 
days to 68.94% (Figure 3-15B). Compared to the 17.94% NPM1 expression obtained 
with the same plasmid in conventional HeLa cell after 72 h of downregulation, the 
achieved effect was quite marginal. The expression level of Btz was not influenced by 
the shNPM1 plasmid, as expected. 
Afterwards, immunocytochemistry was performed in wt ß-Globin HeLa cells to 
investigate, whether the NPM1 downregulation after 5 days was visible in single cells 
(Figure 3-16). The wt ß-Globin HeLa cells were transfected with the shNPM1 plasmid 
(#317) and strongly expressed EGFP. The observed transfection efficiencies in the wt ß-
Globin HeLa cells were lower than the usually obtained transfection rates in 
conventional HeLa cells (data not shown). The nuclei were intact and the morphology 
of the cells was normal, which indicated that the cells were not stressed and alive. The 
antibody staining for NPM1 (Yung, B. Y. et al. 1990; Iggo, R. D. et al. 1991; Bocker, T. et al. 
1995; Wu, M. H. et al. 1995; Nozawa, Y. et al. 1996; Zatsepina, O. V. et al. 1997; Cordell, J. L. 
et al. 1999), to visualize downregulation in transfected cells, is shown in red. The 
transfected cells were clearly depleted of NPM1 and also the speckles of NPM1 were 
reduced or absent in the nuclei. Furthermore, the puncta of NPM1 in the untransfected 
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cells were less prominent than those in conventional HeLa cells (Figure 3-3C), but that 
in general the nuclear area was more intensely red, which might indicate the higher 
expression level of NPM1 in the ß-Globin cells. As the NPM1 downregulation was 
quite low with just 31.06% reduction on the Western Blot, downregulation judged by 
immunostaining also seemed to be a little weaker as for the conventional HeLa cells 
(Figure 3-3C). This is easy to see in the white squares which indicate a 3x 
magnification of one cell area. 
Therefore, the immunocytochemistry experiment confirmed that NPM1 can also be 
downregulated in stable HeLa cell lines. In contrast to the obvious NPM1 knockdown 
visualized by immunostaining, no significant downregulation was observed via Western 
Blot. This might be due to the observed lower transfection efficiency in the stable HeLa 
cells compared to the wt cells (see Discussion section). 
Antibiotic selection has been used previously in NMD assay experiments (e.g. (Chan, 
W. K. et al. 2007; Stalder, L. et al. 2007)). Via selection, low transfection efficiencies in 
the stable cell lines can be compensated, because only cells containing the desired 
plasmids survive the procedure. Therefore, it is easier to monitor the effect of the 
knockdown of a candidate protein, because there will be less background signal of 
untransfected cells. Hence, as a next step neomycin selection was performed on the ß-
Globin cell lines, as all the shRNA plasmids had a neomycin resistance gene.  
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Figure 3-15: Time course of NPM1 downregulation in wt ß-Globin HeLa cells.  
(A) Western Blots. Samples of wt ß-Globin HeLa cells were transfected with the shNPM1 plasmid 
(#317) and downregulation was allowed to take place for 4 or 5 days (not 3 days as in previous 
experiments). Protein lysates of an untreated and two transfected (#317) samples were then separated on a 
10% SDS-PA gel for Western Blot. PageRuler™ Prestained Protein Ladder (Fermentas) was used to 
determine the molecular weight (MW).The size of the marker is depicted on the left. EGFP signals show 
successful transfection with the shNPM1 plasmid (#317). Western Blot was probed for Btz (115 kDa), 
Tubulin (55 kDa), NPM1 (38 kDa) and EGFP (26 kDa). (B) Quantification of downregulation. 
Quantification was done using the Odyssey® Application Software 2.1 (LI-COR® Biosciences). 
Expression levels of NPM1 samples were normalised to Tubulin and compared to the UT sample 
(=100%). Downregulation of NPM1 for 5 days resulted in a reduced expression level of 68.94%. 
MW, molecular weight marker (PageRuler™ Prestained Protein Ladder - Fermentas); UT, untransfected 
wt ß-Globin HeLa cell sample; 4 days, 4 days of transfection and downregulation with shNPM1 #317; 5 
days, 5 days of transfection and downregulation with shNPM1 #317; α, anti. 
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Figure 3-16: 5 days of NPM1 downregulation in wt ß-Globin HeLa cells. 
Wt ß-Globin HeLa cells were transfected and immunostained as described in the Methods section to 
visualise the downregulation of NPM1 visible in fixed cells. 
(1) HeLa cells transfected with the shNPM1 plasmid (#317) expressing EGFP are marked with *. 
(2) DAPI staining of the DNA to visualise nuclei. (3) Antibody staining for NPM1 to visualise 
downregulation in transfected cells. Transfected HeLa cells are clearly depleted of NPM1: the puncta of 
NPM1 in the nuclei are reduced or abolished. The inset on the left indicates a 3fold magnification of the 
selected cell area. (4) Corresponding phase contrast picture to investigate the cells’ morphologies and 
their physiological status. 
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2.3.3. Neomycin selection to enrich transfected cells 
As downregulation for 3 - 5 days was not sufficient on Western Blot to considerably 
downregulate the candidate proteins to be tested in the NMD assay (Figures 3-15, 3-16 
and data not shown), neomycin selection was performed to enrich for transfected ß-
Globin HeLa cells (Figure 3-17). Transfections with the respective shRNA plasmids 
were done as usual and were followed by a neomycin selection procedure (see Methods 
section and the pSUPERIOR.neo+gfp vector manual (OligoEngine)). The final 
neomycin concentration of 600 µg/ml was identified to be sufficient for selection within 
7 days. 
First, the empty pSUPERIOR.neo+gfp vector, shBtz (plasmid #283), shNPM1 (plasmid 
#312 and #317), shDDX5 (plasmid #339) and shU5-116 kDa (plasmid #342), which 
were tested successfully in conventional HeLa cells, were transfected into wt and NS39 
ß-Globin HeLa cells. After transfection, neomycin selection was performed as described 
and total RNA and proteins were then isolated using Trizol® Reagent. Before samples 
were analysed by real-time PCR, Western Blots were performed (data not shown) to 
determine the knockdown efficiency of the respective protein. Quantification of the 
downregulation of the respective candidate proteins by Western Blots (Figure 3-17A) 
revealed that the shBtz (expression level of 16.74%), the shDDX5 (expression level of 
84.99%) and the shU5-116 kDa (expression level of 31.19%) downregulated their 
corresponding protein in the NS39 ß-Globin HeLa cells. In the wt ß-Globin HeLa cells, 
only the shBtz showed a reduction in Btz protein expression of 53.88%. The two 
shNPM1 plasmids (#312 and #317) did not affect the expression level of NPM1 in both 
cell lines. 
Figure 3-17B shows examples of NS39 ß-Globin HeLa cells transfected with shBtz 
(plasmid #283) after 7 days of neomycin selection, to prove the efficiency of the 
selection procedure. The EGFP picture shows a typical example for usually obtained 
transfection efficiencies. The combined EGFP and phase contrast picture demonstrates 
that the transfected cells survived the selection. In contrast, untransfected cells rounded 
up, died and swam around in the medium. 
Pictures were taken for all samples during the experiments (data not shown) to monitor 
the efficiencies of the neomycin selection. 
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Figure 3-17: Neomycin selection to enrich HeLa cells. 
(A) Quantification of downregulation of NMD assay candidates on Western Blots after neomycin 
selection. Quantification was done using the Odyssey® Application Software 2.1 (see manufacturer’s 
manual). Protein levels of samples are always compared to an untransfected control (=100%) and 
normalised to Tubulin. The following three shRA plasmids: shBtz, shDDX5 and shU5-116 kDa 
downregulated their corresponding proteins in NS39 ß-Globin HeLa cells. (B) Pictures of HeLa cells 
after transfection and neomycin selection. Pictures were taken with the Leica MZ 16F microscope 
(Leica) and an 80x magnification (picture size 1781 µm x 1331 µm). (1) NS39 ß-Globin HeLa cells 
transfected with shBtz (plasmid #283) expressing EGFP. (2) EGFP and phase contrast picture of NS39 ß-
Globin HeLa cells transfected with shBtz (plasmid #283). Transfected cells survived the selection, 
whereas untransfected cells were rounded, died and swam around in the medium. 
UT, untransfected; #283, shBtz plasmid; #339, shDDX5 plasmid; #342, shU5-116 kDa plasmid. 
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2.3.4. Establishment of the real-time PCR  
In parallel to the tests of the shRNA plasmids in the stable ß-Globin cell lines, the 
optimal conditions for the real-time PCR were determined in these cells. The following 
parameters were optimised: template amounts (tested from 200 - 800 ng), primer 
concentrations and the setup for the dilution series. In addition, the real-time PCR cycle 
scheme was also fine tuned. The establishment was done for the stable ß-Globin cell 
lines which should be investigated using specific ß-globin primers. GAPDH and tubulin 
primers were utilised for normalisation. 
One important parameter for all PCRs is to determine the optimal annealing temperature 
of all used primer pairs (Figure 3-18A and B). First, the primers were analysed for 
secondary structures with different internet tools (e.g. Primer3). Secondly, temperature 
gradient PCRs were performed as described in the Methods section, to find the best 
annealing temperature for all primers. For this purpose, 400 nM of each primer (800 nM 
per primer pair) was tested on 0.5 μg total cDNA from untreated wt ß-Globin HeLa 
cells. Each primer pair was analysed separately in different PCR tubes, but the reactions 
were run at the same time using the same PCR machine and the same PCR program. 
The quality of the resulting PCR products was analysed via agarose gel electrophoreses. 
Figure 3-18A shows the results of the temperature gradient from 50°C - 70°C for ß-
globin (PCR product size: 277 bp), GAPDH (PCR product size: 104 bp) and tubulin 
(PCR product: size 150 bp) primers. A secondary product of ~450 bp at 54.0°C - 68.6°C 
was amplified by the tubulin primers (Figure 3-18A). Single PCR products with the 
expected size were obtained using the ß-globin or GAPDH primers, respectively. 
In Figure 3-18B, a temperature gradient from 50°C - 58°C for ß-globin (PCR product 
size: 277 bp) primers was tested, to narrow down the temperature range for the 
annealing. The detected PCR product of ß-globin was specific over the whole range. 
The same gradient was also done for the tubulin primers (data not shown), showing 
their specificity for the same temperature range. According to the data, an annealing 
temperature of 55°C was used in all following real-time PCR experiments. 
Beside the quality also the quantity of the primers is a very important parameter for 
real-time PCR. Primer concentrations were optimised using total cDNA from untreated 
wt ß-Globin HeLa cells (Figure 3-19). Once 200 ng cDNA were identified to serve as 
best template amount (data not shown), 200 nM, 250 nM, 300 nM, 350 nM and 400 nM 
Ingrid Kieweg Results 
__________________________________________________________________________________________________________________________________________________________________________ 
 108 / 148 
primer concentration were tested for the housekeeping genes GAPDH and tubulin.  
For ß-globin, only 300 nM and 350 nM were examined. The PCRs were performed 
using the real-time PCR program, described in the Methods section. Afterwards, the 
PCR products were checked for their quality and purity on 2% agarose gels.  
The results of the gel pictures were compared to real-time PCR parameter results 
(efficiency, R^2, slope). In addition, a concentration of 100 nM per primer was also 
tested with nearly the same results, efficiency and quality as 200 nM primer 
concentration (data not shown). Based on these results, the optimal real-time PCR 
conditions were determined for all three genes, which yielded similar real-time PCR 
parameter results, especially the efficiencies very close to each other. 
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Figure 3-18: Optimisation of annealing temperature for real-time PCR primers. 
18 µl of PCR reactions including 6x Loading Dye (Fermentas) were separated on a 2% agarose gel in 
parallel with 15 µl of the GeneRuler™ 100 bp DNA Ladder (Fermentas). Primers (400 nM each) were 
tested on 0.5 µg total cDNA from untreated wt ß-Globin HeLa cells. PCR products were analysed for 
quality and purity on the gel. (A) Temperature gradient 50°C - 70°C. Temperature gradient from 50°C 
- 70°C for ß-globin (PCR product size: 277 bp), GAPDH (PCR product size: 104 bp) and tubulin (PCR 
product: size 150 bp) primers. The tubulin primers give also a secondary product of ~450 bp at 54.0°C - 
68.6°C, marked with a white *. (B) Temperature gradient 50°C - 58°C. Temperature gradient from 
50°C - 58°C for ß-globin (PCR product size: 277 bp) primers to narrow down the temperature range. PCR 
product is specific over the whole range. The same gradient was also done for tubulin primers (data not 
shown) showing their specificity for the same temperature range. 55°C was subsequently used for real-
time PCR. 
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2.3.5. Real-time PCR of ß-Globin HeLa cell lines after neomycin 
selection 
First, the efficiencies of protein downregulation with the shRNA plasmids after 
neomycin selection were tested in the ß-Globin cell lines (Figure 3-17A). Secondly, the 
downregulated samples after neomycin selection were now tested under the optimised 
real-time PCR conditions for their effects on the NMD process. In detail, they were 
analysed for their efficiency of decay of the ß-globin constructs and therefore on the 
expression level of these constructs (Figure 3-20). 
Real-time PCR was performed as described in 2.3.4 and the Methods section. 300 nM ß-
globin primer as well as 400 nM GAPDH and tubulin primer were used respectively per 
reaction. All samples were tested in triplicates. The obtained real-time data was 
analysed using the iQ5 Optical System Software (Version 2.0, Bio-Rad) and the ΔΔCt 
method. Finally, all shRNA samples were normalised to untransfected cells (UT sample 
with Normalised Fold Expression = 1). It is important to note the different scaling of the 
diagrams, which were drawn using the iQ5 Optical System Software. 
 
Figure 3-20A displays the real-time PCR results for the wt ß-Globin HeLa cell line. 
The parameters of this reaction were E = 104.7%, R^2 = 0.989 and slope = -3.215. The 
depletion of Btz (plasmid #283) down to 46.12% residual protein expression led to a ~ 
9fold increase of wt ß-globin expression. But also the transfection with the empty 
pSUPERIOR.neo+gfp vector resulted in a ~ 6fold increase of expression (see 
Discussion section). 
The results for the NS39 ß-Globin cell line are shown in Figure 3-20B. E = 106.7%, 
R^2 = 0.964 and slope = -3.171 were the real-time parameters for this PCR reaction. 
The reduction of U5-116 kDa (plasmid #342) to 31.19% protein expression had nearly 
the same effect as the depletion of Btz (plasmid #283) to 16.74% protein expression 
with a ~ 10fold increase of NS39 ß-globin expression. It was surprising that the increase 
in expression of ß-globin was nearly the same for the wt and the NS39 cell line, if Btz 
had been knocked down.  
Although DDX5 is only reduced by 15.01%, it led to a drastic > 40fold increase of 
NS39 ß-globin. This indicated that the NMD process was strongly impaired in DDX5 
depleted cells. But as the knockdown of DDX5 with plasmid #339 did not work in the 
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wt ß-Globin cell line, which would have been an important control, no firm conclusion 
can be drawn from this real-time data set yet. 
 
 
Figure 3-20: Real-time PCR of ß-Globin HeLa cell lines after neomycin selection. 
Real-time PCR was performed using 200 ng cDNA (RNA isolation with Trizol® Reagent) as template. 
Samples were tested for ß-globin cDNA levels. GAPDH and tubulin were used as internal standards for 
normalisation. 300 nM ß-globin primer and 400 nM GAPDH and tubulin primers were used per reaction. 
Samples were tested in triplicates. Real-time data was analysed using the iQ5 Optical System Software 
(Version 2.0, Bio-Rad) and the ΔΔCt method. ShRNA samples were normalised to UT (Normalised Fold 
Expression = 1). Note the different scaling of the diagrams. (A) wt ß-Gobin HeLa cells. E = 104.7%; 
R^2 = 0.989; slope = -3.215; The depletion of Btz (plasmid #283) leads to a ~ 9x increase of wt ß-globin 
expression, but also the transfection with the empty pSUPERIOR.neo+gfp vector results in a ~ 6x 
increase of expression. (B) NS39 ß-Gobin HeLa cells. E = 106.7%; R^2 = 0.964; slope = -3.171; The 
reduction of U5-116 kDa (plasmid #342) shows nearly the same effect as the depletion of Btz (plasmid 
#283) with a ~ 10x increase of NS39 ß-globin expression. The knockdown of DDX5 (plasmid # 339) 
even leads to a > 40x increase of NS39 ß-globin expression. This indicates that NMD is impaired under 
these conditions.  
UT, untransfected; #100, empty pSUPERIOR vector; #283, shBtz plasmid; #339, shDDX5 plasmid; 
#342, shU5-116 kDa plasmid. 
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3. TEST OF DESIGNED shRNA PLASMIDS IN E17 
RAT HIPPOCAMPAL NEURONS 
 
The next step was to adapt the NMD assay, which was established in HeLa cells, for 
hippocampal neurons. This would allow us to identify the NMD machinery in neurons, 
which has not been investigated so far. 
All designed shRNA plasmids which I had created for the NMD assay and also other 
projects in the laboratory and which worked in human HeLa cells were now tested in 
embryonic  
day 17 (E17) rat hippocampal neurons. This should also be a first effort to start an NMD 
assay in neurons. Neurons were nucleofected with the Nucleoector II (Amaxa) (see 
Methods section). The O-003 programme was used and 10 μg and 20 μg plasmid DNA, 
respectively, were tested for their transfection efficiencies. 
Figure 3-21A shows the quantification of the downregulation on Western Blots. This 
was achieved by using the Odyssey® Application Software 2.1 (see manufacturer’s 
manual). All shRNA samples were compared to a control (=100% protein expression). 
Untransfected or not downregulated samples served as controls. Only the shDDX6 
(plasmid #300) downregulated its corresponding protein to 52.45% protein expression 
as well as the shKif3A (plasmid #323) which downregulated the Kif3A protein to 
80.23%.  
The shNPM1 (#312 and #317) and shDDX5 (# 399) plasmids were also tested, but did 
not downregulate their corresponding proteins (data not shown). Interestingly, the 
NPM1 protein was not even detectable on Western Blots (see Discussion section).  
Figure 3-21B shows the maximal obtained transfection efficiency upon nucleofection 
with 20 μg plasmid DNA. In this case, the neurons expressing EGFP were transfected 
with shDDX5 (plasmid #339). 
Although all tested shRNA plasmids were designed to target rat and human sequences, 
none of the plasmids working in HeLa cells displayed downregulation of the respective 
protein in rat hippocampal neurons. So further shRNA plasmids have to be designed 
and tested in order to start an NMD assay also in rat neurons. 
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Figure 3-21: Test of shRNA plasmids in rat hippocampal neurons. 
(A) Quantification of downregulation on Western Blots. Rat embryonic day 17 (E17) neurons were 
nucleofected with the Nucleoector II (Amaxa). The O-003 programme was used and 10 µg and 20 µg 
plasmid DNA were tested for their transfection efficiency. Quantification was done using the Odyssey® 
Application Software 2.1 (see manufacturer’s manual). Protein levels of samples are compared to a 
control (=100%) and normalised to Tubulin. ShNPM1 plasmids (# 312 and #317) and shDDX5 plasmid 
(# 339) were also tested, but did not downregulate their corresponding proteins (data not shown). 
(B) Picture of nucleofected E17 rat hippocampal neurons. For the testing of five generated shRNA 
plasmids, the maximal obtained transfection efficiency upon nucleofection with 20 µg plasmid DNA is 
shown. (1) Transfected rat hippocampal neuron expressing EGFP marked with *. (2) Phase contrast 
picture. 
Control, untransfected or not downregulated samples; #300, shDDX6 plasmid; #323, shKif3A plasmid. 
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DISCUSSION 
 
 
The intention of this diploma thesis was to establish an NMD assay in order to 
investigate the role of putative players in the NMD process. Therefore, shRNA plasmids 
were created against selected protein candidates to study their function in NMD. HeLa 
cells were then depleted of these protein candidates and the effect of the protein 
knockdown on the NMD process was monitored. 
 
1. TRANSFECTION OF shRNA PLASMIDS 
 
For the design of the shRNAs, the selection of the shRNA sequence by hand with the 
computer program Lasergene from DNASTAR (Version 7.1.0 (44)) was found to be as 
successful as the design with the used tool “Stealth™ RNAi“ of the “BLOCK-iT™ 
RNAi Designer” from Invitrogen. 
 
Although all shRNAs were designed specifically for their respective target, not all of 
them were successfully downregulating their corresponding protein. It remains unclear, 
why a particular sequence worked as shRNA, whereas others failed to do so. Some of 
the used and previously published criteria to increase the success of the shRNA design 
are mentioned in the Methods section. For each candidate protein, several shRNA 
plasmids had to be generated and tested to identify at least one that was working. 
Interestingly, also the sequences of the shRBM4 plasmids #343 and 344 which were 
taken from a publication where they were introduced as 2’-O-methyl 
oligoribonucleotides into HeLa cells did not downregulate the respective protein. As the 
same sequence was used, it may also make a difference whether a plasmid or an oligo is 
used for transfection and protein knockdown.  
The presence of 2'-O-methylation protects the oligos against intracellular nuclease 
digestion and increases their stability against alkaline hydrolysis (Sproat, B. S. et al. 
1989). The 2’-O-alkylation also increases the affinity for the target, due to a decrease of 
non-specific binding because of optimised thermodynamics and reduced steric 
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hindrance (Iribarren, A. M. et al. 1990). Therefore, oligonucleotides might be more 
successful in downregulation of their target protein. 
Also the secondary structures of the target mRNA is important for the successful 
downregulation via siRNA. The 3-dimensional structure of the target influences its 
accessibility for the siRNA. So the successful binding of the siRNA to its target is 
crucial and obligatory for the protein knockdown. 
Furthermore, I observed that impurities of the plasmid DNA interfere with a successful 
transfection (data not shown and (Zeitelhofer, M. et al. 2008)). Maybe, because they 
encumber the formation of lipid vesicles around the DNA at all or they just hinder the 
formation of vesicles of the right size which are taken up by the cell.  
 
Variability of the cotransfection was also observed (see Figure 3-13). In theory, two or 
more plasmids can be taken up by a single cell during the transfection. I tried to 
cotransfect conventional HeLa cells using a plasmid with a TCR-ß construct and an 
additional shRNA plasmid, and observed that cotransfections did not always work. As 
all shRNA plasmids had an EGFP gene, successful transfections of the shRNA plasmids 
were monitored by microscopy and Western blotting. The semiquantitative PCRs 
analysed via agarose gel electrophoreses revealed that the TCR-ß construct was not 
always present in the cells. But as only 100 ng of TCR-ß DNA (Dr. Corinna Giorgi - 
personal correspondence) compared to 7.5 µg of shRNA plasmid DNA were 
transfected, it is quite obvious that the cotransfection of the two plasmids often did not 
work due to the present DNA amounts. More than 100 ng of the TCR-ß DNA should 
not be transfected or otherwise the NMD process could be overloaded, as it is just an 
“emergency mechanism” to get rid of incorrect RNAs. 
 
Polyethylenimine (PEI) (see Material section) was also tested as an alternative to the 
FuGENE® HD Transfection Reagent (Roche) for the transfection of HeLa cells. The 
cationic polymer PEI was chosen, because it is gentle and efficient for gene transfer into 
a variety of cell types, especially HeLa cells ((Boussif, O. et al. 1995) and 
http://www.sigmaaldrich.com). A PEI:DNA ratio of 3:1 [µl:µg] was used. The PEI was 
found to have a cytotoxic activity on the cells which were dying shortly after 
transfection. This observed circumstance concerning cytotoxicity of PEI was confirmed 
by a literature search (Boussif, O. et al. 1995; Neu, M. et al. 2005; Hunter, A. C. 2006). 
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2. DOWNREGULATION AND DETECTION OF 
SELECTED PROTEIN CANDIDATES 
 
The protein candidates for the NMD assay and their knockdown with the respective 
shRNAs were detected via Western Blots and immunocytochemistry. Specificity of the 
observed protein expression and localisation patterns was verified via literature search 
wherever possible. The outcome of the experiments, concerning the verifiability of the 
expression and/or depletion of a protein and the subcellular localisation of the protein 
candidates, is discussed below. 
 
2.1. DDX5 detection with immunocytochemistry 
Whereas DDX5 downregulation was confirmed via Western Blot, it was not visible in 
the performed immunostainings (Figure 3-4C), although the same antibody was used as 
for the Western Blot analysis. It is possible and often encountered that antibodies 
working well on Western Blots do not work for immunocytochemistry and vice versa 
(Harlow E. and Lane D.; Antibodies: A Laboratory Manual; Cold Spring Habor 
Laboratory; Cold Spring Habor; 1988 and Harlow E. and Lane D.; Using Antibodies: A 
Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Habor; 1999). 
Different explanations for this are possible. 
Maybe this is due to the reduced accessibility of the epitope for the antibody in fixed 
specimens on coverslips. Therefore, the antibodies can not find their target as easily and 
quickly as on a Western Blot where the denatured proteins are presented on a 
membrane. 
Also the fixation method has an influence of the later accessibility of the epitopes. The 
chemicals used for fixation (4% PFA) may interfere with the accessibility or integrity of 
the epitopes. 
Another explanation could be that the used antibody is not specific therefore yielding 
ambiguous staining patterns. The members of the DEAD-box (DDX) family are highly 
conserved (e.g. (Luking, A. et al. 1998; Fuller-Pace, F. V. 2006; Linder, P. 2006)). 
Thus, it is possible that the used, particular antibody is also recognizing other members 
of this family. In addition to DDX5, the DDX5 antibody also recognises a second 
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protein band on the Western Blot (data not shown). This might be a either DDX3 or 
DDX17, which are highly related to DDX5 (Luking, A. et al. 1998; Abdelhaleem, M. 
2005; Barbosa-Morais, N. L. et al. 2006; Fuller-Pace, F. V. 2006). The latter two RNA 
helicases share 90% amino acid identity across the conserved core (Ogilvie, V. C. et al. 
2003) and exist as a heterodimer in the cell (Lamm, G. M. et al. 1996). Due to these 
facts, the used antibody can maybe not distinguish between these two or respectively 
three proteins.  
In summary, DDX5 was clearly reduced on the Western Blot, according to the band of 
the right molecular weight, but the downregulation of the protein was maybe not visible 
in the immunostaining, because the antibody did not only recognise DDX5 but possibly 
also DDX17 and/or DDX3. 
 
2.2. U5-116 kDa detection with immunocytochemistry 
Only one paper reported the subcellular localisation of U5-116 kDa in HeLa cells, 
showing a staining pattern with a predominantly nuclear localisation of U5-116 kDa, 
where the nucleoli and the cytoplasm were largely unstained (Fabrizio, P. et al. 1997).  
In contrast, the performed immunostainings for this thesis displayed a slightly aberrant 
staining pattern where the protein is equally distributed in the cell, with a slightly higher 
concentration in the nucleus (Figure 3-5C). Upon downregulation, U5-116 kDa seemed 
to be reduced in the cell periphery but unchanged in the nucleus. Interestingly, the used 
antibody is the same as in Fabrizio et al. (1997). 
U5-116 kDa shows a high degree of homology with the ribosomal elongation factor 
EF-2 (Fabrizio, P. et al. 1997). Thus, a possible explanation for the obtained staining 
pattern in this thesis is that the antibody recognises both proteins - U5-116 kDa and 
EF-2. But the specificity of the antibody was already confirmed in the mentioned 
publication (Fabrizio, P. et al. 1997) 
 EF-2 has a molecular weight of approximately 95 kDa on a Western Blot  
(e.g. (Carroll, M. et al. 2004; Devost, D. et al. 2005)). A band of the size for EF-2 was 
visible after incubation with the U5-116 kDa antibody (data not shown). But it is also 
possible that the observed bands on the Western Blots are just degradation products. 
The additional band is not present on the Western Blots made from HeLa lysates by 
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Fabrizio et al. with the same antibody (Fabrizio, P. et al. 1997). Therefore, I conclude 
that the bands on my Western Blots are rather degradation products than isoforms or 
related proteins. 
 
2.3. RBMX and RBM4 detection on Western Blots 
RBMX and in some experiments RBM4 were not detectable via Western Blot. It is 
already known that both proteins mainly localise in the nucleus (Elliott, D. J. 2004; 
Markus, M. A. and Morris, B. J. 2006). 
 
RBMX (~43 kDa) could not be detected in conventional HeLa cells via Western Blot by 
the used commercial antibody (see Material section), even if high protein amounts were 
tested (Figure 3-6A). The protein candidate could also not be detected in the TCR- ß 
and ß-Globin HeLa cell lines (see Figure 3-14), but the antibody recognised a double 
band of a different size (<35 kDa) (see Figure 3-14B and 2.2.1 in the Results section). 
Therefore, the shRBMX plasmids could not be tested for their downregulation of 
RBMX in HeLa cells by Western blotting.  
Interestingly the same antibody used for Western Blots gave a reproducible staining 
pattern for RBMX in the immunocytochemistry. This indicates that the RBMX antibody 
did not work for Western Blots but for immunocytochemistry. In this case, as well as 
for the DDX5 antibody, the used antibodies did not work equally well for Western Blot 
and immunofluorescence. In contrast, the DDX5 antibody seemed to work for Western 
blotting but not for immunostaining. 
The used RBMX antibody recognised a protein double band (< 35 kDa) on the Western 
Blot from the stable HeLa cell lines and gave a reproducible pattern in the 
immunostaining of conventional HeLa cells. One explanation of these findings is that 
different isoforms of RBMX exist which are recognised by the commercial antibody. 
This would confirm the specificity of the used RBMX antibody. 
This assumption is attenuated by the fact that no RBMX signal was detected on Western 
Blots made from conventional HeLa cells. Thus, if there are different RBMX isoforms, 
which lead to a specific immunostaining pattern of conventional HeLa cells, their signal 
should also be detectable via Western Blot. This, however, is not the case. 
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Another explanation is that RBMX may be very instable when isolated. If the protein 
was then also expressed at a higher level in the stable compared to the conventional 
HeLa cells, this could explain the signal (< 35 kDa) on the Western Blot from the stable 
cell lines (Figure 3-14). This would also illustrate why RBMX is still detectable by 
immunofluorescence, under the assumption that RBMX is not degraded or altered upon 
fixation. 
If the staining pattern for RBMX was specific, it indicated that most RBMX protein was 
concentrated in the nuclei and just a minor portion of the protein was present in the cell 
periphery. This could confirm that the RBMX concentration in the cell lysate from the 
cytoplasm was simply to low for detection by Western Blot, because the buffer used to 
lyse the conventional HeLa cells in this diploma project was not strong enough to break 
up the nuclei as well.  
This assumption was strengthened by the protein isolations from the stable HeLa cell 
lines (Figure 3-14) which were performed with Trizol® Reagent that is potent enough to 
break up the nuclei. Nevertheless, the protein was still not detectable on the Western 
Blot. This indicates that the RBMX protein is not or just at a minor level expressed in 
HeLa cells, which can not be confirmed via literature, because nothing has been 
published about the expression of RBMX in HeLa cells or different tissues yet. There is 
just one publication ascertaining that RBMX is ubiquitously expressed in humans 
(Lingenfelter, P. A. et al. 2001). On the Western Blots of the stable HeLa cells, a double 
band <35 kDa was recognised by the used antibody. These bands can again represent 
RBMX isoforms.  
Another possible explanation is that as the RBMX protein is a member of the RNA-
binding motif (RBM) family and these proteins have highly conserved domains. So the 
used RBMX antibody is maybe not selective enough and recognises also other protein 
family members. 
 
In some experiments, RBM4 was also not detectable via Western Blot in HeLa cells  
(Figure 3-7B). A literature search revealed that RBM4 is mainly localised in the 
nucleus in a cell (Markus, M. A. and Morris, B. J. 2006). The used lysis buffer did not 
break up the nuclei. Therefore, the protein concentration in the cytoplasm might simply 
be too low to detect it via Western Blot in some cases, depending on distinct factors 
such as stress, expression level and distribution of RBM4. This hypothesis was 
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confirmed by experiments with proteins which were isolated from stable HeLa cell lines 
(Figure 3-14) using Trizol® Reagent that broke up nuclei. In this experiment, RBM4 
signals were detectable on the Western Blots. 
 
 
3. OPTIMISATION OF RNA ISOLATION & PCR 
SETUPS 
 
The used RNA isolation kits and procedures (see Figure 3-10) had a significant impact 
on the obtained quality and quantity of RNA. Furthermore, this was also a crucial factor 
for the reproducibility of the semiquantitative PCR for the respective cDNA. 
 
Variability in the amplification of the TCR-ß pre-mRNA was a significant problem at 
the beginning of this diploma thesis (Figure 3-9A). Bioinformatical analyses revealed 
that the TCR-ß pre-mRNA primer may actually form secondary structures. So 
optimisation of the semiquantitative PCR of the TCR-ß pre-mRNA construct was 
necessary to permit the PCR product. Finally, an increase of the annealing temperature 
to 60°C restored the successful amplification of the TCR-ß pre-mRNA product 
(Figure 3-9B), with the exception of the eIF4AIII depleted samples (#291) in this 
particular experiment. Maybe the #291 samples were degraded or contaminated with a 
PCR inhibitor during the troubleshooting, as the tested #291 samples in Figure 3-9A 
and B were the same. This can be possible, because the wt and PTC TCR-ß samples, 
cotransfected with the same shRNA plasmid (#291 in this case) were always treated in 
parallel. So contaminations could be spread between these two samples. 
Finally, 60°C annealing temperature for the TCR-ß pre-mRNA primer were stringent 
enough to reduce secondary structures and still allowed annealing of the primer to the 
cDNA. Therefore, 60°C annealing temperature enabled successful amplification of the 
TCR-ß pre-mRNA product. 
 
The reverse transcription PCR was also optimised for the NMD assay to increase the 
sensitivity of the analysis (Figure 3-12 and Table 3-1). Therefore, RT-PCR with 
Random Primers and the specific TCR-ß reverse primer, to enrich the target cDNA, 
were compared. In addition, tubulin was tested as an internal PCR standard for 
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normalisation of the PCR results.  
 The RT-PCR using specific primers lead to an enrichment of the target cDNA, 
but interestingly tubulin could still be amplified from the cDNA after the specific TCR-
ß reverse primer reaction. Two explanations are possible for the successful 
amplification of tubulin. First, the specific TCR-ß reverse primer binds to the RNA and 
the RNA is reverse transcribed. So the RNA coding for tubulin is also amplified, as it is 
on the same RNA to which the primer bound. Reverse transcription is made in one 
direction from the primer to the end of the RNA, thereby also amplifying the tubulin 
sequence. Secondly, it is also possible that the tubulin primers are not specific and by 
chance create a PCR fragment of the expected size. 
 
 
4. COMPARISON OF CONVENTIONAL & STABLE 
HELA CELLS 
 
Since variability of cotransfection was observed in conventional HeLa cells, HeLa cell 
lines with stable NMD reporter constructs were used for the real-time PCR experiments. 
The shRNA plasmids of the candidate proteins working in conventional HeLa cells 
were tested for their efficiency of protein knockdown in the stable cell lines. Thereby, 
the following differences between conventional and stable HeLa cell lines were 
observed. 
 
In general, the observed transfection efficiencies with stable HeLa cell lines were much 
lower than with conventional HeLa cells. Although transfections were exactly 
performed the same way in all HeLa cell lines, transfection efficiencies, even using the 
same maxiprep DNA, were lower in the stable cell lines. In addition, the obtained 
transfection efficiencies were in general lower for the wt ß-Globin cells compared to the 
NS39 ß-Globin cells (data not shown). We observed that the stable cell lines were 
growing faster than conventional HeLa cells. So less stable HeLa cells than 
conventional cells were plated for transfection, to have a similar confluence of all HeLa 
cells, when they were transfected. 
It was also surprising that plasmids working in conventional HeLa cells, downregulated 
the respective protein less or they did not even downregulate the protein candidate at all 
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in the stable cell lines (Figure 3-15 and 3-16 and data not shown). This was very 
astonishing, as all cell lines were HeLa cells with just one difference: some expressed a 
stable construct and the others not.  
These findings indicate that there are differences in the expression pattern and also 
transfection of conventional and stable HeLa cells. As HeLa cells are cancer cell lines, 
even distinct conventional HeLa cell batches might have different genetic backgrounds 
due to spontaneous mutations. This might explain their different features and reactions 
to the introduction of transgenes. 
 
 
5. NEOMYCIN SELECTION  
 
Since the shRNA plasmids working in conventional HeLa cells (Figure 3-2 – 3-5) did 
not sufficiently downregulate their respective protein in the stable HeLa cell lines even 
after 5 days (Figure 3-15 and 3-16 and data not shown), neomycin selection was 
performed to enrich for successfully transfected cells (see 2.3.3 Neomycin selection to 
enrich transfected cells in the Results section).  
 
It was surprising that even 7 days of neomycin selection did not sufficiently knockdown 
the protein candidates (Figure 3-17 and data not shown). Unfortunately, only the 
downregulation of Btz worked in the wt ß-Globin cell line. In the NS39 ß-Globin cell 
line, Btz, DDX5 and U5-116 kDa were downregulated, but still to a minor extent than 
observed in conventional HeLa cells. 
 
The antibiotics neomycin and geneticin (G418) are usually really effective tools for 
selection (e.g. (Muhlemann, O. et al. 2001)). Although selection seemed to work 
according to the taken pictures of the cell samples (Figure 3-17), not all protein 
candidates were depleted in both cell lines or were reduced at all. This finding is also 
discussed in 4 Comparison of conventional & stable HeLa cells in this section. 
 
Interestingly, NPM1 was even upregulated after neomycin selection compared to the 
control (data not shown), when tested via Western Blot. Neomycin as well as geneticin 
block protein synthesis and therefore also interfere with cell growth.  
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The phenomenon of translational upregulation upon introduction of miRNAs in growth-
arrested cells was recently published (Vasudevan, S. et al. 2007). As there is no 
structural differences in siRNAs and miRNAs (Rana, T. M. 2007), they could possibly 
both mediate translational activation as well. 
 
 
6. PRELIMINARY NMD ASSAY RESULTS 
 
Real-time PCR was then performed for the samples where the respective protein was 
sufficiently downregulated after neomycin selection (Figure 3-20).These samples were 
the shBtz (#283) and the empty pSUPERIOR sample (#100) for the wt ß-Globin cell 
line as well as the shBtz (#283), the shDDX5 (#339), the shU5-116 kDa (#342) and the 
empty pSUPERIOR sample (#100) for the NS39 ß-Globin cell line. The PCR results 
were normalised to the ß-globin levels in untreated controls. The reduction of U5-116 
kDa protein expression had nearly the same effect as the depletion of Btz protein 
expression with a ~ 10fold increase of NS39 ß-globin expression, although U5-116 kDa 
was twice as highly expressed as Btz. This preliminary data indicates that U5-116 kDa 
probably plays an important role in NMD if it has such an impressive effect on the ß-
globin construct amount compared to Btz.  
 It was surprising that the fold increase in ß-globin expression was nearly the 
same for the wt and the NS39 cell line, if Btz had been knocked down, because the 
downregulation efficiency varied from 46.12% residual protein expression in the wt to 
16.74% residual protein expression in the NS39 ß-Globin cell line. I would have 
expected that the fold increase in expression is higher than ~ 10 in the NS39 cells, if you 
take away Btz protein to a higher extent and thereby impair NMD. This in turn should 
lead to an accumulation of aberrant NS39 ß-globin mRNA. 
The DDX5 protein seemed to have the strongest effect on NMD in the first, preliminary 
real-time experiment performed in this thesis. Even a minor depletion of DDX5 by 
15.01% resulted in > 40fold increase of NS39 ß-globin. In DDX5 depleted NS39 cells, 
ß-globin accumulates and is no longer degraded. This indicates that NMD is impaired as 
well as that DDX5 possibly plays a role in NMD. Unfortunately, the knockdown of 
DDX5 with plasmid #339 did not work in the wt ß-Globin cell line. This will be an 
essential control to perform. Therefore, no firm conclusion can yet be drawn from this 
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preliminary real-time data about the role of DDX5 in the NMD process. 
 
Interestingly, also the transfection with the empty pSUPERIOR.neo+gfp vector (#100), 
which served as negative control, resulted in a ~ 6fold increase in the wt and a ~ 3fold 
increase of ß-globin expression in the NS39 ß-Globin HeLa cells. Literature search for 
evaluation of the experiments showed that some aminoglycoside antibiotics can also 
interfere with and block NMD to a certain extent under not fully understand conditions 
(reviewed in (Holbrook, J. A. et al. 2004; Behm-Ansmant, I., Kashima, I. et al. 2007)). 
Therefore, it might be better to normalise the real-time PCR results to the samples 
transfected with the empty pSUPERIOR.neo+gfp vector (#100) instead of the untreated 
samples (UT). As all samples were treated the same with geneticin for antibiotic 
selection, the normalisation of the results to the empty pSUPERIOR.neo+gfp vector 
samples statistically eliminates the possible inhibiting effect of the antibiotic selection 
on NMD and visualises the specific effect of the tested candidate. Normalised to the 
pSUPERIOR.neo+gfp vector sample (#100), the treatment of the wt ß-Globin cells with 
the shBtz led to a 1.42fold increase of wt ß-globin expression. In NS39 ß-Globin cells, 
the depletion of Btz results in 3.15x increase, the reduction of DDX5 in a 12.88fold 
increase and the depletion of U5-116 kDa in a 2.99fold increase of NS39 ß-globin level 
normalised to the negative control sample (#100). Upon this normalisation, the different 
reductions of Btz in the wt and the NS39 ß-Globin cell line would negatively correlate 
with the change in expression of ß-globin, which was not the case when the samples 
were normalised to the untreated control. 
 
 
7. CONCLUSIONS & PROSPECTS 
 
The goal was to establish the NMD assay first in HeLa cells, because this was fast and 
experimentally easy to set up. In a second step, which would follow now this diploma 
thesis, the assay can then be modified and adapted for primary rat hippocampal neurons. 
Therefore, the shRNAs were designed to target human and rat sequences whenever 
possible.  
As HeLa cells are cancer cells which have been cultivated for a long time, the use of 
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primary, non-mutated rat hippocampal neurons might be even more physiological for 
the investigation of NMD. 
All designed shRNA plasmids for the NMD assay and also other projects in the 
laboratory were tested by Dr. Daniela Karra and myself in embryonic day 17 rat 
hippocampal neurons (data not shown and Figure 3-21). Figure 3-21 shows successful 
downregulation of DDX6 (plasmid #300) and Kif3A (plasmid #323). Unfortunately, 
none of the shRNA plasmids for candidates of the NMD assay depleted the respective 
protein. 
Interestingly, the NPM1 protein, which was a promising candidate in HeLa cells, was 
not even detectable via Western Blots made from neuronal lysates after nucleofection, 
although the used antibody also recognises rat NPM1 (according to the manufacturer). 
NPM1 is a predominantly nucleolar protein (Feuerstein, N. et al. 1987; Schmidt-
Zachmann, M. S. et al. 1987), also in neurons (Kalita, K. et al. 2008). Even the use of a 
more concentrated lysis buffer, e.g. the 2x Laemmli Buffer, which usually lyses the 
nuclei, did not result in NPM1 signals on the blots. This might indicate that it is just 
expressed at a very low level in E17 rat hippocampal neurons. The assumption can not 
be confirmed via literature, because nothing is published yet about NPM1 expression in 
E17 rat hippocampal or young neurons. 
So, unfortunately none of the shRNA plasmids of the candidates for the NMD assay 
could downregulate its corresponding protein in rat hippocampal neurons. As the 
shRNA sequences were designed to recognise human and rat protein isoforms, it is 
unclear why some worked in HeLa cells but not in rat neurons. Different facts and 
assumptions might explain this finding. 
In general, it is a demanding issue to reach transfection efficiencies in neurons which 
are high enough to visualise genetic alterations via Western blotting. So the obtained 
transfection rates in these experiments, which were monitored via EGFP expression, 
were maybe too low to detect downregulation on the Western Blot.  
HeLa cells are differentiated, genetically instable cancer cells, whereas the used E17 rat 
hippocampal neurons are undifferentiated, primary and non-mutated cells. This could 
also influence the effect of a given shRNA plasmid in these two cell types. However, 
we do not have detailed knowledge about the pathway(s) leading to the uptake of the 
DNA into the nucleus. So we can only speculate that there are some differences, like 
different required factors or distinct pathways that influence the uptake, intracellular 
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processing and effect of the shRNA plasmids.  
In general, neurons are more sensitive to any kind of stress than other cell types. This is 
also a reason why high transfection efficiencies are difficult to reach in neurons. For 
protection and maintenance of their intracellular composition, neurons may synthesise 
higher concentrations or a different subset of nucleases compared to HeLa cells. 
Therefore, in some cases introduced DNA would simply be degraded, before it can 
mediate its action.  
So in order to start the NMD assay also in hippocampal neurons, further shRNA 
plasmids have to be designed and tested for their downregulation of the protein 
candidates in neurons.  
 
 
8. ARRIVAL AT HYPOTHESIS 
 
Btz as an essential component of the EJC plays a central and crucial role in NMD 
(Palacios, I. M. et al. 2004) and is upregulated in most cancer cell lines (e.g. (Degot, S. 
et al. 2002)). These are interesting facts which might indicate that cancer cells try to 
overcome its derailing metabolism and the production of aberrant transcripts by 
upregulation of decay factors like Btz. This might bring transient help to clean the cell 
from abnormal or harmful transcripts and proteins. But at a certain point, this rescue 
attempt fails. The decay pathways are then overloaded with aberrant substrates and 
can’t get rid of it as fast as required anymore. Harmful or non-functional proteins 
accumulate and mediate their action which further destabilises the cell and interferes or 
blocks important processes. This might then results in the cell’s death, if essential 
reactions necessary for survival are encumbered.  
But one principal question remains: Why do the decay pathways fail to clear up the cell 
before the mutations causing the production of the aberrant transcripts are repaired? Of 
course, this is clearly depending on the severity and quantity of mutations in the cell’s 
genome. But let me speculate about another essential factor which might influence the 
time course of the cell’s decline. Phosphorylation, for example, like other modifications 
of executive factors in the decay pathways seems to be crucial for the initiation and 
successful completion of the degradation, especially in NMD (e.g. (Chang, Y. F. et al. 
2007)). Modifications on molecules are also necessary to elicit or upregulate the 
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expression of the executive factors in the beginning. These regulatory modifications 
require a sufficient supply of the cell with micronutrients. The uptake and especially the 
distribution of micronutrients are for sure impaired in a cell, where normal metabolism 
and transport is overloaded and blocked by non-functional transcripts and proteins. The 
depletion of micronutrient storages and the restriction of the supply with nutrients might 
be an important factor for the collapse of the cell’s decay and metabolism leading to cell 
death in the end. This interesting model explaining the role of decay pathways like 
NMD in diseases (e.g. cancer) is supported by a recently published paper. In this 
publication, the MAPK pathway is linked to the expression and function of essential 
decay factors in fibroblast-like cells (Ha, J. E. et al. 2008). After stimulation of the cells 
with granulocyte-macrophage colony-stimulating factor (GM-CSF), the mitogen-
activated protein kinase (MAPK) pathway is activated and especially the subfamilies 
p38 and JNK are dramatically phosphorylated. These events lead to the upregulation of 
Btz via transcriptional and post-translational control. Finally, Btz initiates or 
upregulates the expression of anti-apoptotic factors promoting cell survival. Thereby, 
this publication also points out the importance and essential functions of modification, 
especially phosphorylation, of signal and effector molecules. To maintain and support 
these cellular processes a sufficient supply with micronutrients is obligatory. 
Another recently published minireview discusses the role of the EJC in translational 
activation and repression (Le Hir, H. et al. 2008), thereby also underscoring the 
important role of phosphorlyation in these signalling pathways. 
However, RNA decay is for sure a very important and central issue in cells. It is a 
quality control for its metabolism and prevents the development of many diseases. So it 
is a rewarding research topic for the future to investigate the interactions and key 
players in RNA decay, especially in NMD, in detail. 
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APPENDIX I: ZUSAMMENFASSUNG 
 
„Nonsense-mediated mRNA decay“ (NMD) ist ein Mechanismus zur Regulierung der 
Genexpression auf post-transkriptioneller Ebene in Eukaryonten. Neben der Quantitäts- 
dient NMD auch der Qualitätskontrolle von Transkripten. Letztere Funktion umfasst die 
Beseitigung fehlerhafter RNAs mit einem verfrühten Stop-Codon, auch „Premature 
termination codon“ (PTC) genannt. Andernfalls würden diese RNAs zur Bildung 
verkürzter Proteine mit möglicherweise für die Zelle gefährlichen Funktionen führen, 
wie es bei Krankheiten, wie z. B. Krebs, oft der Fall ist.  
In meiner Diplomarbeit untersuchte ich ausgewählte Proteine näher auf ihre Rolle in 
NMD. Zu diesem Zweck etablierte ich einen funktionellen Assay in verschiedenen 
HeLa-Zelllinien. NMD ist nicht voll funktionsfähig, wenn bestimmte NMD-
Komponenten – wie z. B. Barentsz (Btz) oder eIF4AIII – fehlen. Es kommt zur 
Anhäufung fehlerhafter, PTC-enthaltender Transkripte, da jene nicht länger durch NMD 
abgebaut werden. Deshalb dienten diese beiden Proteine als Positivkontrollen für die 
Etablierung des Assays. Es galt im Folgenden, den Einfluss von fünf potentiellen 
Protein-Protein-Interaktoren des RNA-Bindeproteins Btz auf NMD zu testen: 
Nucleophosmin 1 (NPM1), DEAD-Box-Polypeptide 5 (DDX5), U5-116 kDa, RNA-
Binding-Motif-Protein - X-linked (RBMX) und RNA-Binding-Motif-Protein 4 
(RBM4). Ich stellte gegen diese Proteine gerichtete „Short hairpin RNA (shRNA)“-
Plasmide her und testete sie. Danach verminderte ich die Expressionslevels der 
entsprechenden Proteine in HeLa-Zellen mittels ihrer shRNA-Plasmide und überprüfte, 
ob dies zur Akkumulierung von PTC-enthaltenden NMD-Reporter-Konstrukten führt, 
wie im Fall des Btz-Knockdowns. Hierfür wurden die Expressionslevels und somit der 
Abbau von eigens eingebrachten T-Zellrezeptor-ß (TCR-ß) - und ß-Globin-NMD-
Reporter-Konstrukten mit und ohne PTC über semiquantitative und Real-time-PCR 
verglichen. Zusätzlich wurde eine Neomycin/G418-Selektion durchgeführt, um 
erfolgreich transfizierte Zellen anzureichern. Die ersten Real-time-PCR-Daten lassen 
auf eine wichtige Rolle von DDX5 und U5-116 kDa in NMD schließen, da ihre 
Reduktion zur Anhäufung PTC-enthaltender Transkripte führte. Für NPM1, RBMX und 
RBM4 konnten noch keine Aussagen getroffen werden, weil die entsprechenden 
shRNA-Plasmide in den verwendeten stabilen HeLa-Zelllinien keine Reduktion 
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entsprechender Proteinslevels bewirkten. Weitere Experimente zur Untersuchung dieser 
Proteine sind daher notwendig.  
Zusammenfassend lässt sich festhalten, dass es mir in meiner Diplomarbeit gelungen ist, 
mit den potentiellen Btz-Interaktoren DDX5 und U5-116 kDa zwei weitere Proteine zu 
identifizieren, die eine Rolle in NMD spielen. 
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